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Abstract
Since the introduction of glucocorticoids (GCs) in the treatment of rheumatoid
arthritis in 1949, GC therapy has been associated with a number of adverse effects.
Long-term use of GCs can result in growth retardation during childhood due to their
actions on growth plate chondrocytes, although the exact mechanisms involved are
unclear. The work of this thesis has investigated the cellular and molecular
mechanisms involved in mediating GC effects at the growth plate.
Affymetrix microarray has been used to identify and characterise the expression of
lipocalin 2, a novel GC-responsive chondrocyte gene which may contribute to GC-
induced growth retardation in the growth plate. In vitro and in vivo studies have also
been used to examine the role of the cell cycle regulator, p21
WAF1/CIP1 in GC-induced
growth retardation. Finally, the growth plate sparing effects of a novel GC receptor
modulator, AL-438, have also been identified. AL438, has reduced effects on bone
growth compared to Dex, but maintains similar anti-inflammatory efficacy.
This work has not only determined novel mechanisms of GC-induced growth
retardation, but has also advanced the search for novel GC receptor modulators with
reduced adverse effects.Declaration
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Preface
Since the introduction of glucocorticoids (GCs) in the treatment of rheumatoid
arthritis in 1949, their therapeutic applications have broadened to encompass a large
number of non-endocrine and endocrine diseases (Hench et al., 1949). However,
despite the intense efforts made by science and industry to maximise the efficacy and
minimise the side effects of GCs, adverse reactions are still common. Impairment of
childhood growth with long-term GC treatment was described nearly 50 years ago;
however the mechanisms by which GCs cause this growth retardation are still
unknown. With 5-10% of children requiring GC treatment at some point during
childhood, it is vital that we gain a better understanding of these mechanisms to aid
the development of new GCs with reduced side effects.
1.1 Skeletal Growth
Growth takes place at the epiphyseal growth plate of long bones by a finely balanced
cycle of cartilage growth, matrix formation and calcification. This sequence of
cellular events is known as endochondral ossification. An individual's skeletal growth
rate and adult limb bone length are influenced by many factors including circulating
hormones, nutritional intake, mechanical influences and disease, and growth
disturbances result when there is disruption of the normal cellular activity of growth
plate chondrocytes and/or the cells of bone. There is an increasing body of evidence
to demonstrate that factors produced locally in bone and cartilage, or trapped within
hard tissue matrix, may play a critical role in regulating normal and pathological
skeletal growth and remodelling.Chapter 1 Introduction and Literature Review
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1.2 The Structure and Composition of Bone Tissue
1.2.1 Cortical Bone
Two types of bone structure exist; cortical (compact) and trabecular (spongy) bones
(Figure 1.1A). Cortical bone makes up approximately 80% of the total skeletal mass
(Sambrook et al, 1993), and contains few spaces. It forms the external layer of all
bones in the body and the majority of the diaphyses of long bones, and provides
protection and support by helping the long bones resist the stress of weight placed
upon them (Skedros et al, 1996). Cortical bone is composed of concentric rings of
bone tissue known as osteons (Figure 1.1B). Blood vessels, lymphatic vessels, and
nerves from the periosteum penetrate the cortical bone through perforating
(Volkmann’s) canals. The blood vessels and nerves of these canals connect with
those of the medullary cavity, periosteum, and central (Haversian) canals of the
osteon (Havers, 1961). The central canals run longitudinally through the bone, and
around the canals are concentric lamellae – rings of hard, calcified matrix. Between
the lamellae are small spaces, or lacunae, which contain osteocytes. Radiating in all
directions from the lacunae are minute canals known as canaliculi, which are filled
with extracellular fluid. Inside these canaliculi are slender finger-like processes of
osteocytes. The canaliculi connect lacunae with one another and, eventually, with the
central canals. Thus, there is an intricate branching network of canals which provide
a route for nutrients and oxygen to reach the osteocytes and for wastes to diffuse
away. Osteocytes from neighbouring lacunae form gap junctions with one another,
facilitating easy movement of materials from cell to cell. Each central canal, with its
surrounding lamellae, lacunae, osteocytes and canaliculi, forms an osteon (Haversian
System). Cortical bone tissue is the only connective tissue containing a basic
structural unit – the osteon – associated with it.Chapter 1 Introduction and Literature Review
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Figure 1.1 Structure and components of long bone. (A) Long bones are longer than
they are wide, consisting of a long shaft (the diaphysis) plus two articular (joint)
surfaces, called epiphyses. They are comprised mostly of compact bone, but are
generally thick enough to contain considerable spongy bone and marrow in the hollow
centre (the medullary cavity). Most bones of the limbs (including the three bones of
the fingers) are long bones, except for the kneecap (patella), and the carpal,
metacarpal, tarsal and metatarsal bones of the wrist and ankle
(training.seer.cancer.gov) (B) A 3D representation of the structure and organisation of
trabecular and compact bone (www.iofbonehealth.org).
1.2.2 Trabecular Bone
In contrast to cortical bone, trabecular (cancellous) bone does not contain true
osteons, but instead consists of lamellae arranged in an irregular latticework of thin
columns of bone called trabeculae. The macroscopic spaces between the trabeculae of
some bones are filled with red bone marrow, which produces blood cells. Within the
trabeculae are osteocytes that lie in lacunae, and radiating from the lacunae are
canaliculi. Blood vessels from the periosteum penetrate through to the trabecular
bone, and osteocytes in the trabeculae receive nourishment directly from the blood
circulating through the marrow cavities. Osteons are not necessary in spongy bone as
osteocytes are not deeply buried as they are in cortical bone, and so have access toChapter 1 Introduction and Literature Review
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nutrients directly from the blood. Trabecular bone constitutes the majority of bone
tissue of short, flat and irregularly shaped bones and most of the epiphyses of long
bones. Trabecular bone tissue in the ribs, sternum, vertebrae and in the ends of some
long bones is the only site of red bone marrow storage, and hence haemopoiesis in
adults.
1.2.3 Osteoblasts
Osteoblasts are bone-forming cells that are derived from multipotent mesenchymal
stem cells (stromal stem cells), are cuboidal in shape and are localised mainly to the
bone surface. The gene expression profile of the osteoblast is very similar to that of a
fibroblast with very few bone specific transcripts being produced. The main
difference in cell function is that osteoblasts have the ability to form an extracellular
matrix (osteoid) which they can subsequently mineralise (Ducy et al, 2000). The un-
mineralised matrix is formed mainly from collagen type 1 (approximately 94%) which
is laid down early in bone formation, with the remainder being taken up with
embedded proteins such as osteocalcin, osteonectin, osteopontin and bone sialoprotein
(Sommerfeldt and Rubin, 2001). This stage of matrix production is under strict
control of growth factors such as fibroblast growth factor (FGF) and insulin like
growth factor-I (IGF-I) (McCarthy et al, 1989; Hurley and Florkiewicz, 1996).
During intramembranous ossification, mesenchymal cells differentiate into osteoblasts
and bone is formed without replacing a cartilaginous model, whereas during
endochondral ossification the cartilage template matrix is calcified and osteoblasts are
recruited to deposit woven bone (and later lamellar bone) on the surface of the
mineralised matrix residues. Following bone formation, osteoblasts can have one of
four different fates: (1) they can become embedded in the bone as osteocytes, (2)Chapter 1 Introduction and Literature Review
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transform into inactive osteoblasts and become bone lining cells, (3) undergo
apoptosis, or (4) transdifferentiate into cells that deposit chondroid or chondroid bone
(Noble et al., 1997; Jilka et al., 1998;). Once embedded into the bone matrix the
former osteoblasts, now osteocytes, cease their activity.
1.2.4 Osteocytes
Osteocytes are mature bone cells that are derived from osteoblasts, and are by far the
most abundant cellular component of mammalian bones, making up 95% of all bone
cells (Parfitt., 1990; Marotti et al., 1996). An important role of osteocytes and their
network of cell processes are to function as strain and stress sensors, signals that are
vital for maintaining bone structure (Burger et al., 2003). Osteocytes communicate
with one another and with osteoblasts at the bone surface via a meshwork of cell
processes that run through canaliculi in the bone matrix (Franz-Odendaal et al., 2006).
Osteocytes no longer secrete matrix minerals, but maintain daily cellular activities of
bone tissue, such as the exchange of nutrients and wastes with the blood. Another
function of osteocytes within the bone network is the ability to deposit and resorb
bone around the osteocyte lacuna in which they are housed, thus changing the shape
of the lacuna. This process, known as osteocytic osteolysis, is often not regarded as
characteristic of human osteocytes, but has been observed in many vertebrates such as
hamsters (Steinberg et al., 1981), squirrels (Haller and Zimny 1978) and rats
(Belanger 1977; Tazawa et al., 2004). It has recently been proposed that the three-
dimensional network of osteocytes provides the cellular basis for mechanosensing in
bone, leading to adaptive bone remodelling. Mechanotransduction in bone is complex
in nature, and is influenced by many modulators including PTH, prostanoids, and
extracellular Ca
2+. It has been postulated that osteocytes transduce signals ofChapter 1 Introduction and Literature Review
8
mechanical loading resulting in anabolic responses such as the expression of c-fos,
IGF-I, and osteocalcin (Mikuni-Takagaki 1999).
1.2.5 Osteoclasts
Osteoclasts are multi-nucleated cells, derived from haematopoietic stem cells, which
resorb mineralised bone at sites known as Howships lacunae (Sommerfeldt and
Rubin, 2001). This is an essential process which allows bone repair and sequestration
of calcium into the blood to maintain ion homeostasis. Bone modelling and re-
modelling are crucial events in skeletal development and repair, and are strictly
controlled by osteoclasts. Defects in these processes lead to diseases such as
hypercalcemia of malignancy and postmenopausal osteoporosis where an increase in
bone resorption is the main pathological episode (Vaananen et al, 2000). Osteoclasts
are closely related to macrophages and dendritic cells with only the final stage of
differentiation altering for each cell type. This differentiation is dependent on whether
the cell is stimulated by exposure to a particular receptor activator of nuclear-factor
kB (NF-kB) ligand i.e. osteoclast differentiation factor, macrophage colony-
stimulating factor (M-CSF) or granulocyte-macrophage colony-stimulating factor
(Vaananen et al, 2000). Osteoclasts create a cavity at the remodelling site through the
secretion of enzymes and acids such as matrix metalloproteases and tartrate resistant
acid phosphatase (TRAP). Osteoblasts are then recruited to this site where they lay
down a matrix which is subsequently mineralised.Chapter 1 Introduction and Literature Review
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1.3 Bone Growth
1.3.1 Embryonic Bone Formation
Embryonic skeletogenesis involves the sequential events of patterning, cell
differentiation, and morphogenesis to give rise to cartilage and bone. The significant
functional role of the skeletal structures, such as the scaffolding of the vertebrate
animal, requires that skeletogenesis be under stringent regulation at multiple levels.
There are two principle pathways of skeletal development: intramembranous and
endochondral (Hall et al., 1987). Intramembranous ossification involves direct
differentiation of mesenchymal cells into osteoblasts, and is seen predominantly in
craniofacial bones (Langille et al., 1994). During endochondral ossification, (such as
that seen in the long bones and vertebrae), mesenchymal cells condense, undergo
chondrogenesis and form cartilage. This cartilage subsequently matures, undergoes
hypertrophy, and is eventually replaced by bone (Caplan et al., 1994).
1.3.2 Endochondral Ossification
Endochondral ossification is the process responsible for much of the bone growth in
vertebrate skeletons, especially in long bones. As the name might suggest (endo -
within, chondro - cartilage), endochondral ossification occurs by replacement of
hyaline cartilage. Long bones of the skeleton first appear as limb buds and the earliest
observable morphological event in this process (between 10.5 and 12.5 days post-
coitum in the embryonic mouse) is the aggregation of committed, undifferentiated
mesenchymal cells into structures known as condensations. Prechondrogenic
condensation begins the process of endochondral ossification and is required for
subsequent skeletal development. Chondrocytes derive from mesenchymal cells that
migrate into presumptive skeletogenic sites from the cranial neural crest, paraxialChapter 1 Introduction and Literature Review
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mesoderm and lateral plate mesoderm. At these skeletogenic sites, the cells become
tightly packed and form cell mass condensations that prefigure the future skeletal
elements (Hall and Miyake 2000). In the centre of these condensations,
prechondrocytes emerge that turn off expression of mesenchymal and condensation
markers, and start to express collagen type 2 (Coll II) and other early cartilage
markers (Figure 1.2). Surrounding these prechondrocytes is the perichondrium, the
outer layer of which becomes a connective tissue sheath while the inner cells remain
pluripotential. This cartilage rudiment grows by interstitial and appositional growth,
and a vascular system develops to invade the perichondrium (Figure 1.3). A collar of
bone is then laid down around the mid-shaft of the bone. This ossification is a result
of the inner perichondrial cells differentiating into bone forming cells, the osteoblasts.
At the same time the osteoblasts, together with capillaries, invade the centre of the
shaft to form a primary or diaphyseal ossification centre at a site where the cartilage
cells and matrix have begun to disintegrate. Trabecular bone is then deposited on
cartilaginous remnants. The embryonic bone increases in width by appositional
growth, and the central cancellous bone core gradually becomes resorbed to form a
marrow cavity (Figure 1.3).Chapter 1 Introduction and Literature Review
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Figure 1.2 Coll II Stained Murine Embryos (A) Coll II-GFP murine embryos
The GFP fluorescent reporter is expressed in cells of cartilaginous skeleton in E14.5
(left) and E17.5 (right) mouse embryos. Fluorescence is brightest in structures
exhibiting the highest level of chondrogenesis, such as external ears and long bones of
the extremities of the younger embryo. Some structures in the older embryo, such as
most of the spine, the posterior ribs and central portions of limb bones no longer show
fluorescence as the cartilage has been replaced by bone. (B) Coll II-GFP murine
embryonic tibia Confocal optical sectioning of tibia from E17.5 embryo shows
epiphyseal cartilages and growth plates on the right and a higher magnification of the
proximal growth plate on the left. (www.shcc.org/growth_plate.htm)
In long bones, another centre of ossification appears at the growing cartilaginous
ends, known as the secondary ossification centre (Figure 1.3). This ossification does
not replace the cartilage at the articular end of the model but results in a transverse
plate of cartilage extending across the epiphysis separating the secondary ossification
centre from the diaphysis. This is known as the epiphyseal growth plate. Growth of
cartilage in the epiphyseal plate is continuous, but the plate does not become
thickened because on its diaphyseal side the cartilage matures, is calcified, resorbed
and replaced by bone. This is endochondral ossification, the mechanism responsible
for increasing the length of the bone. During growth this is a site of many complex
cellular events; namely cartilage growth, maturation, resorption and bone formation.
Disturbance of any one of these processes may be reflected in growth retardation.Chapter 1 Introduction and Literature Review
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Figure 1.3 The Process of Endochondral Ossification. Following the
development of a cartilage model of chondrocytes derived from mesenchymal cells, a
primary ossification centre is formed in the centre of the diaphysis. This leads to the
formation of the periosteum and the bone collar, and causes the chondrocytes within
the primary ossification centre to hypertrophy, secrete alkaline phosphatase (ALP),
and mineralise the matrix surrounding them. These chondrocytes then undergo
apoptosis, and, in their place, blood vessels, lymph vessels and nerves invade the
cavity they have left behind. This leads to invasion by osteoblasts, osteoclasts and
hoemopoietic cells. Osteoblasts use the calcified matrix as a scaffold and begin to
secrete osteoid, which forms the bone trabecula. The secondary ossification centre is
formed when cartilage is retained in the growth plate, located between the diaphysis
(the shaft) and the epiphysis (end) of the bone. Cartilage cells undergo the same
transformation as above. As growth progresses, the proliferation of cartilage cells in
the growth plate slows and eventually stops (http://training.seer.cancer.gov/
module_anatomy/unit3_3_bone_growth.htm).
1.4 The Growth Plate
1.4.1 Structural Organisation of the Growth Plate
The process of bone growth relies upon chondrocytes produced at the epiphyseal
growth plate, which are progressively synthesised and replaced by bone with
accompanying longitudinal (endochondral) bone growth (Farquharson 2003). The
growth plate is a thin layer of cartilage found near the ends of long bones and
vertebrae (Kronenberg et al., 2003) and it comprises of both chondrocytes and their
extracellular matrix (ECM). A characteristic of endochondral bone growth is the
precise temporal and spatial organisation of chondrocytes within the growth plateChapter 1 Introduction and Literature Review
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where they differentiate through a series of maturational stages whilst remaining in a
spatially fixed location (Hunziker et al., 1987). Histologically, the chondrocytes are
arranged in columns similar to a stack of coins that parallel the longitudinal axis of the
bone (Figure 1.4). Each column and each chondrocyte within a column are
respectively separated by longitudinal and transverse septae made up of a collagenous
and proteoglycan rich ECM. At the most proximal end of the growth plate are the
resting chondrocytes. Directly below the resting chondrocytes are the proliferating
chondrocytes, and then the pre-hypertrophic and hypertrophic chondrocytes (Figure
1.4).
Figure 1.4 The Epiphyseal Growth Plate The growth plate is located at the end of
the long bone and is contained within the epiphysis. Chondrocytes within the growth
plate proceed through stages of proliferation and differentiation, ultimately leading to
hypertrophy and calcification (www.kumc.edu/imstruction/medicine/anatomy/histo
web/bone/small/Bone002s.JPG and www.bu.edu/histology/p02401ooa.htm)
1.4.2 The Resting Zone
At the most proximal end of the growth plate, the reserve zone, or stem cell zone,
contains the resting chondrocytes. Cells in this zone exist singly or in pairs separated
by an abundant extracellular matrix, have low rates of proliferation and synthesise
only low levels of proteoglycans and Coll II (Kember, 1978; Schmidt, Rodergerdts &Chapter 1 Introduction and Literature Review
14
Buddecke, 1978; Sandell et al., in press). Intuitively there is agreement that a zone of
stem cells must exist proximal to the chondrocytes in the columns of the proliferative
zone, and there is a significant body of experimental evidence that these stem cells
can be stimulated to initiate clonal expansion as proliferative cells (Kember et al.,
1993). This is supported both by evidence demonstrating the responsiveness of these
cells to stimulation by circulating hormones such as growth hormone (GH), and by
observations with bromodeoxyuridine (BrdU) labelling that these cells have very long
cell cycle times compared to cells in the proliferative pool (Isaksson et al., 1982;
Farnum et al., 1993).
However, in most descriptions, the reserve cell zone is defined morphologically by
the size and spatial orientation of the cells, and refers to all chondrocytes that do not
align themselves in the columns that are characteristic of the proliferative cell zone
(Seinsheimer et al., 1981; Farnum et al., 1986; Farnum et al., 1987; Farnum et al.,
1993). If defined this way, the reserve zone may, in fact represent a heterogeneous
zone of cells with subpopulations of chondrocytes with different physiologic
functions. The size of the resting zone varies in growth plates from different bones in
the same species, and, for a given growth plate, the proportional size of the resting
zone relative to total growth plate size varies significantly from species to species
(Ishizaki et al., 1994). In humans, Kember and Sissons (1976) showed that, although
the overall width of the growth plate declines as growth rate diminishes, there is no
significant change in the size of the reserve cell zone. In larger species, a sizeable
resting cell zone is present even after formation of the secondary ossification centre is
complete. Therefore, one hypothesis is that the so-called reserve zone might serve as
a mechanical support to the actively growing chondrocytes of the growth plate inChapter 1 Introduction and Literature Review
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species that have relatively slow growth rates over long periods of time (Kember et
al., 1976; Ishizaki et al., 1994).
Recently, the reserve zone chondrocytes have also been shown to be crucial for
orientation of the underlying columns of chondrocytes and therefore unidirectional
bone growth, and it is thought that this is due to the secretion of a growth plate-
orienting factor (Abad et al., 2002). It has also been suggested that resting zone
chondrocytes may produce a morphogen that inhibits terminal differentiation of
nearby proliferative zone chondrocytes, and therefore may be partially responsible for
the organisation of the growth plate into distinct zones of proliferation and
hypertrophy.
1.4.3 The Proliferating Zone
The proliferative zone contains cells from the time clonal expansion begins until the
cell exits the cell cycle and begins terminal differentiation. The epiphyseal (proximal)
side of the proliferative cell pool can be defined using either thymidine or BrdU
labelling (Loveridge and Farquharson 1993). The number of cells in the proliferative
zone correlates positively with the rate of growth, and chondrocytes in this zone are
flattened, thin discs, arranged like a stack of coins (Buckwalter et al., 1985). Cellular
proliferation is required to maintain steady-state kinetics in a given growth plate by
offsetting cellular loss at the chondro-osseous junction (Farnum et al.,1989; Wilsman
et al., 1996a; Wilsman et al., 1996b). However, the number of cells contributing to
the proliferative pool changes over time and is different in growth plates growing at
different rates, although the mechanism by which cellular numbers change over time
is still unclear. Recent studies have shown that in one animal at one point in time,Chapter 1 Introduction and Literature Review
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cellular cycle times vary in growth plates growing at different rates. Cell cycle times
in the proximal tibia of 4-week-old rats was shown by repeated pulse labelling of
BrdU to be approximately 30 hours, compared to 76 hours in the proximal radius of
the same animals. (Wilsman et al., 1996b). Almost all of the difference in time was
associated with the G1 phase of the cell cycle. Therefore, at one point in time, cell
cycle times have an inverse relationship with the rate of growth.
Multiple mechanisms may exist by which subsets of chondrocytes regulate
proliferation leading to a modulation of growth rates in different bones and in one
bone over time. At separate stages of differentiation, chondrocytes may differentially
respond to the same external or internal cues. One specific example is that
parathyroid hormone (PTH) has different effects on collagen gene expression in
chondrocytes in different maturation stages, and that these effects are exerted by
distinct effector domains of the PTH molecule (Erdmann et al., 1996). At any given
moment, either by a finite number of cell divisions or by changes in exposure to a
local mediator such as GCs, proliferating chondrocytes lose their capacity to divide
and start to differentiate and become prehypertrophic, coinciding with an increase in
size. These chondrocytes then further progress in the differentiation pathway to
become hypertrophic chondrocytes.
1.4.4 The Transition Zone: Proliferation to Hypertrophy
When chondrocytes are examined consecutively within a growth plate column, there
are cells that are spatially distal to the last chondrocytes that incorporate BrdU, but
proximal to cells with a large increase in volume consistent with the hypertrophic
phase. This narrow zone of transition is coordinated by a number of complexChapter 1 Introduction and Literature Review
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regulatory mechanisms, and a number of unique genes involved with this transition to
terminal differentiation have been identified (Wang et al., 2004; Wang et al., 2005),
along with specific matrix markers, matrix proteins and specific receptors (Wang et
al., 2004; Han et al., 2005).
1.4.5 The Hypertrophic Zone
The initial work demonstrating that chondrocytic hypertrophy involved a rapid
increase in cell volume and change in shape was carried out by Hunziker (1987) and
Buckwalter (1986). This work led to further quantitative investigations that
demonstrated the strong positive correlation of final hypertrophic cell volume with
rate of growth (Breur et al., 1994). Although the actual rate and efficiency of volume
increase varies in growth plates from different species (Barreto et al., 1994; Kuhn et
al., 1996), the quantitative data supports the hypothesis that volume increase during
hypertrophy is a major contributor to the differential rates of growth occurring in
different growth plates of a given animal. In addition, a directed shape change
accompanies the volume increase, so that chondrocytic height parallel to the direction
of growth is increased disproportionately to width. This directed shape change
accompanying the volume increase is a major determinant of overall growth. The
hypertrophic chondrocytes have a round appearance and secrete large amounts of
matrix proteins, a characteristic which is essential for the propagation of
mineralisation, which occurs at the chondro-osseous junction.
1.4.6 Mineralisation and the Chondro-osseous junction
The chondro-osseous junction represents another transition point and is the most
complex transitional zone within the growth plate. It is, in fact, a true organ-levelChapter 1 Introduction and Literature Review
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system in which endothelial cells of the metaphyseal vasculature, blood cells,
osteoprogenitor cells, and osteoclasts are separated from the terminal hypertrophic
chondrocytes only by the distance of the last transverse septum of the hypertrophic
cell zone. Terminally differentiated hypertrophic chondrocytes are characterised by
an increase in intracellular calcium concentration. This is essential for the production
of matrix vesicles, which are small membrane-enclosed particles that are released
from chondrocytes (Wang et al., 2002; Anderson et al., 2003). These matrix vesicles
provide an environment permissive for calcium phosphate precipitation into
hydroxyapatite crystals. This mineralisation process takes the form of two distinct
phases; phase one occurring completely within the matrix vesicle. During this phase,
phosphatases associated with the matrix vesicle (such as alkaline phosphatase and
PHOSPHO1) supply the required phosphate (Roberts et al., 2007), whilst calcium is
captured by annexins and phosphatydyl serine, to produce mineral crystals. During
phase two, these mineral crystals pierce the matrix vesicle membrane and enlarge with
the addition of phosphate and calcium ions present in the extravesicular space. This
results in the formation of mineral sphericules which associate closely to collagen
fibrils. The mineralisation process, in combination with low oxygen tension, attracts
blood vessels from the underlying primary spongiosa (Schipani et al., 2001).
Subsequently, the remaining hypertrophic chondrocytes undergo apoptosis, leaving a
scaffold for new bone formation. The apoptotic process is, among other factors,
regulated by elevated intracellular calcium levels (leading to activation of proteases,
lipases and nucleases), retinoic acids and vitamin D. Longitudinal and transverse
septae, which keep the chondrocytes in a columnar orientation in the growth plate, are
resorbed by osteoclasts from the underlying primary spongiosum (Lewinson et al.,
1992; Vu et al., 1998). At the same time, osteoblasts enter the area to lay down newChapter 1 Introduction and Literature Review
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trabecular bone (although interestingly, only the longitudinal septae are actually
replaced with trabecular bone; Mitchell et al., 1982). The combination of the rate of
chondrocyte proliferation, the size of the proliferative pool, the enlargement of
maturing chondrocytes in the hypertrophic zone and the production of ECM are the
major contributors to longitudinal bone growth.
In the steady state, chondrocytic turnover at the chondro-osseous junction needs to be
offset literally on a one-to-one basis by cellular proliferation in order to maintain
growth plate width and constant numbers of chondrocytes in the differentiation
cascade that results in longitudinal growth. Turnover not compensated for by
proliferation leads first to a decrease in total cellular numbers and, ultimately, to
growth plate closure. It is known that rates of chondrocytic turnover at the chondro-
osseous junction can be delayed in several kinds of diseases, such as rickets or
osteochondroses (Farnum et al., 1984; Shapiro et al., 1987). Morphologically, this
delay is manifested as an accumulation of hypertrophic chondrocytes with cells
continuing to be added because proliferation is not impaired. In these diseases,
cellular volume increase is initiated, but the turnover events at the chondro-osseous
junction do not progress. In rickets, this situation indicates that events of matrix
calcification are coupled to the final hypertrophic volume increase. However, in
osteochondroses, there is evidence that matrix calcification, although initially delayed,
may ultimately go on and result in hypertrophic chondrocytes of abnormal
morphology surrounded by highly calcified longitudinal septae (Farnum et al., 1984).Chapter 1 Introduction and Literature Review
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1.4.7 The fate of the terminally differentiated chondrocyte
Despite the agreement on the significance of hypertrophic chondrocytes in regulating
both calcification of the matrix and the final extent of growth achieved, there remains
a controversy about whether the terminal chondrocyte continues to live beyond the
time of erosion of the last transverse septae, or whether its fate is death at the
chondro-osseous junction (Cancedda et al., 1995; Kwan et al., 1997; Shapiro et al.,
2005). There has been significant morphological evidence to suggest that terminal
hypertrophic chondrocytes die by apoptosis (Galotto et al., 1994), and more recently,
TUNEL labelling has supported this hypothesis (Zenmyo et al., 1996). Studies
looking at chondrocyte apoptosis identified a number of ions (such as the Ca2
+ and Pi
ion pair), peptides, and secreted matrix metalloproteins present at the chondro-osseous
junction that could act as pro-apoptotic factors (Mansfield et al., 1999; Mansfield et
al., 2003). Interestingly, some evidence has suggested that all chondrocytes have
some level of DNA fragmentation characteristic of apoptosis (Hatori et al., 1995).
However, others have suggested that chondrocytes can transdifferentiate into
osteoblasts (Roach et al., 1995; Adams and Shapiro 2002; Shapiro et al., 2005). The
hypothesis of transdifferentiation has been tested using cultured embryonic explants
from chick femurs which were cut at the hypertrophic zone of the growth plate.
Associated with the change from chondrogenic to osteogenic commitment was an
asymmetric cell division with diverging fates of the two daughter cells, where one
daughter cell remained viable and the other one died. This suggests that the viable
daughter cell then divided and generated osteogenic cells, while the other daughter
cell died by apoptosis (Roach et al., 1995). More recently, the concept of
chondrocyte death by autophagy has been hypothesised (Bohensky et al., 2007). In
this theory, it is suggested that chondrocytes express a survival phenotype in responseChapter 1 Introduction and Literature Review
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to changes in the cartilage microenvironment. This phenotype causes the
chondrocytes to oxidise their own structural macromolecules to generate ATP,
ultimately leading to tissue damage and cell death.
1.4.8 Extracellular Matrix Proteins
The chondrocytes are embedded in a surrounding ECM, which provides support to the
chondrocytes, and consists of matrix molecules, remodelling enzymes and growth
factors. The first group of matrix molecules are the collagens, of which types II, IX
and X are expressed predominantly in the proliferating, prehypertrophic and
hypertrophic zones, respectively, and are essential for the integrity of the ECM
(Horton et al., 2003). In addition, they play an essential role in sequestering growth
factors involved in the regulation of chondrocyte proliferation and differentiation.
Collagens are the most abundant proteins in mammals, and are structured in the form
of a triple helix with a regular arrangement of amino acids in each of the helices (Gly-
X-Pro or Gly-X-Hyp, where X may be any of various other amino acid residues).
Gene mutations in type II, IX or X collagens have been associated with disturbances
of the cartilage matrix causing spondyloepiphyseal dysplasia and hypochondriasis,
multiple epiphyseal dysplasia, or Schmid metaphyseal chondrodysplasia, respectively
(Spranger et al., 1994; Muragki et al., 1996; Wallis et al., 1996). These dysplasias are
all associated with short stature.
Another group of ECM molecules comprises the proteoglycans, including aggrecan,
biglycan and glypican. Proteoglycans consist of a core protein with one or more
covalently attached glycosaminoglycan chains. These glycosaminoglycan (GAG)
chains are long, linear carbohydrate polymers that are negatively charged underChapter 1 Introduction and Literature Review
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physiological conditions, due to the occurrence of sulphate groups. These groups are
essential for the activation of proteoglycans and for cross-linking of the ECM. A
common GAG chain is chondroitin sulphate, a sulphated GAG which is composed of
a chain of alternating N-acetlygalactosamine and glucuronic acid. Chondroitin
sulphate is a major component of the extracellular matrix, and its function largely
depends on the properties of the overall proteoglycan of which it is part. It has been
shown to be important in maintaining the structural integrity of the tissue, a function
which is typical of the large aggregating proteoglycans such as aggrecan, versican,
brevican and neurocan. As part of aggrecan, chondroitin sulphate is a major
component of cartilage, and the tightly packed, highly charged sulphate groups
generate electrostatic repulsion that provides much of the resistance of cartilage to
compression. Loss of chondroitin sulphate from cartilage is a major cause of
osteoarthritis, and consequently it is widely used as a dietary supplement for the
treatment of this disease (Barnhill et al., 2006; Bruyere et al., 2007). Heparin sulphate
is a linear polysachharide which also occurs in proteoglycans, and in the ECM, the
main heparin sulphate bearing proteoglycans are the multi-domain perlecan, agrin and
collagen type XVIII. Heparin sulphate is also a member of the GAG family, and
consists of a variably sulphated repeating disaccharide unit. Synthesis of under
sulphated GAGs, for example by mutations in the diastrophic dysplasia sulphate
transporter gene, causes several forms of autosomal recessive chondrodysplasias,
including diastrophic dysplasia, atelosteogenesis type II, and achondrogenesis type 1B
(Rossi et al., 2001).
Communication exists between the ECM and cellular responses within the
chondrocyte through cell surface adhesion receptors, known as integrins. TheyChapter 1 Introduction and Literature Review
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mediate the attachment of the chondrocytes to the surrounding ECM macromolecules,
thereby increasing the integrity of the growth plate (Ruoslahti et al., 1991).
Furthermore, there is a group of ECM-remodelling enzymes, known as matrix
metalloproteinases (MMPs) and their inhibitors (tissue inhibitor of MMP; TIMP).
These play a crucial role in the remodelling and degradation of the ECM and are
involved in the preservation of the ECM integrity and the initiation of angiogenesis
(Werb et al., 1997; Ortega et al., 2003). Mice lacking MMP-9 display abnormal
growth plate vascularisation and bone formation (Gerber et al., 1999), whereas
disruption of tissue inhibitor of MMP-1 in mice increases basement membrane
invasiveness of primitive mesenchyme (precursor of chondrocyte) cells in vitro
(Alexander et al., 1992). Moreover, MMP-13 (collagenase-3) has been shown to be
crucial for remodelling of the matrix in the transition zone of the growth plate (Wu et
al., 2002). Inhibition of MMP-13 inhibits degradation of collagen II, which is
predominant in the proliferating zone and suppresses the expression of collagen X,
which is the major collagen of the hypertrophic zone (Wu et al., 2002). The ECM also
functions as a reservoir of various growth factors that may be released and influence
chondrocyte function when the ECM is degraded. Moreover, the ECM may control
the diffusion capacity of growth factors, including fibroblast growth factors (FGFs)
and hedgehogs. The role of the ECM is crucial for the integrity of cartilage and for
normal longitudinal growth, but the interaction between collagens, MMPs, integrins,
and the multitude of growth factors within the ECM is still far from understood.Chapter 1 Introduction and Literature Review
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1.5 Longitudinal Bone Growth
1.5.1 The Process of Longitudinal Growth
Longitudinal bone growth is the result of chondrocyte proliferation and subsequent
differentiation in the epiphyseal growth plate. As previously discussed, it is regulated
by a multitude of genetic and hormonal factors, growth factors, environment, and
nutrition (Cancedda et al., 1998; Hering et al., 1999; Stevens et al., 1999, Robson et
al., 2002; Kronenberg et al., 2003). All of these factors contribute to establishing the
final height of an individual. There are at least three distinct endocrine phases of
linear growth during postnatal life in man. A high growth rate is observed from foetal
life, with a rapid deceleration up to about 3 years of age. The second phase is
characterised by a period of lower, slowly decelerating growth velocity up to puberty.
The last phase, puberty, is characterised by an increased rate of longitudinal growth
until the age of peak height velocity has been reached. Following this, growth
velocity rapidly decreases due to growth plate maturation in long bones and spine,
leading to fusion of the growth plate and cessation of longitudinal growth (Drop et al.,
1998). Recently, the process and moment of growth plate fusion has been elegantly
studied by Martin and co-workers (Martin et al., 2003), who determined the number
of bony bridges between the epiphysis and metaphysis by microcomputed
tomography in rats between 2 and 25 months of age. Although it is generally believed
that cessation of growth succeeds growth plate fusion, this has recently been disputed
by Parfitt (2002). He observed cessation of growth of a metacarpal in a patient with
pseudohypoparathyroidism, which was followed later by fusion of the growth plate.
In support of this, a recent study in aged rats has shown that, despite cessation of
growth, growth plates still exist with sporadic chondrocyte proliferation (Roach et al.,
2003).Chapter 1 Introduction and Literature Review
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1.5.2 Growth Disorders
Disturbances of longitudinal bone growth occur frequently with a high diversity in
aetiology. Both short and tall stature disorders are divided into primary (defect
presumed in bone/cartilage), secondary (defect located outside bone/cartilage), or
idiopathic (cause unknown) (Drop et al., 2001). Primary short stature disorders
include chromosomal disorders such as Down and Turner syndromes, genetic
disorders such as achondroplasia, hypochondroplasia and thanatophoric dysplasia,
Jansen’s metaphyseal chondroplasia (defects in the parathyroid hormone type 1
receptor (PTH1R)), and multiple epiphyseal dysplasia (defects in the expression of
type II, IX and X collagen). Primary tall stature disorders include chromosomal
disorders such as Klinefelter syndrome (or 47, XXY), and genetic syndromes such as
Sotos, Marfan and Weaver syndromes. Secondary disorders of short stature include
those related to GH deficiency or resistance (Pit-1, Prop-1, Larson syndrome, IGF-I
deficiency), hypothyroidism, malnutrition or renal failure. Secondary disorders of tall
stature include GH excess, pituitary gigantism, GH-secreting tumours such as
McCune Albright syndrome and pituitary adenomas, hyperinsulinism, sex hormone
resistance or deficiency, and precocious puberty. In addition to the psychological
problems associated with growth retardation, a number of studies have shown that
reduced growth during development can lead to disease in later life. Known at the
Barker hypothesis, it is now known that slow growth during foetal life and infancy is
followed by an increased risk of coronary heart disease, type 2 diabetes and
hypertension during adulthood. Mechanisms underlying this are thought to include
the development of insulin resistance in utero, reduced numbers of nephrons
associated with small body size at birth and altered programming of the micro-Chapter 1 Introduction and Literature Review
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architecture and function of the liver. Slow foetal growth might also heighten the
body's stress responses and increase vulnerability to poor living conditions in later
life. (Barker et al., 1989; Barker 2002).
1.5.3 Catch-up Growth
Many systemic diseases impair longitudinal bone growth. Interestingly, after
remission, growth often accelerates beyond the normal growth rate for that particular
age, a phenomenon called catch-up growth (Boersma and Wit 1997). This has been
observed in many growth-retarding conditions such as Cushing’s syndrome (Prader et
al., 1963), hypothyroidism (Boersma et al., 1995), celiac disease (Damen et al.,
1997), anorexia nervosa/malnutrition (Prader et al., 1963), and GH deficiency
(Boersma and Wit 1997). To explain catch-up growth, it was originally believed that
a mechanism exists in the brain that compares the actual body size with an age-
appropriate set point and adjusts the growth rate accordingly, and this is termed “sizo-
stat” (Onat et al., 1975). This neuroendocrine hypothesis was challenged by an
experimental study in the rabbit. In this experiment, the GC dexamethasone (Dex)
was infused by an osmotic minipump directly in the tibial growth plate, which slowed
bone growth of the treated leg but not of the contralateral vehicle-treated leg (Baron et
al., 1994). When Dex infusion was stopped, tibial bone growth was not just
normalised but even increased compared with the contralateral leg, thereby
demonstrating catch-up growth (Baron et al., 1994). Based on these findings, Gafni
and Baron (2000) proposed that the underlying mechanism for catch-up growth was
intrinsic to the growth plate. A mechanism explaining catch-up growth may be that a
maximum number of cell divisions exist for growth plate resting chondrocytes and
that at each cell division the proliferation rate decreases, a process known asChapter 1 Introduction and Literature Review
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senescence. Growth retardation reduces chondrocyte proliferation and thereby delays
senescence. When remission takes place, the cells within the proliferating zone have
a greater proliferating potential, explaining the increased growth rate compared with
the unaffected growth plate. This was recently supported by intra-muscular oestrogen
injections in rabbits resulting in a more rapid senescence of growth plate
chondrocytes, causing proliferative exhaustion and earlier growth plate fusion
compared with non-treated rabbits (Weise et al., 2001). However, these studies have
been performed in animals, and their pattern of catch-up growth is different from that
of humans. For example, in a child who displays catch-up growth, height velocity can
be four times that of normal growth, whereas in rats and rabbits the growth velocity
increment is minimal. To date, additional studies are required in humans to generate a
more solid and satisfactory hypothesis for the process of catch-up growth (Boersma
and Wit, 1997, Wit and Boersma, 2002).
1.6 Regulation of Longitudinal Bone Growth
1.6.1 Systemic Regulation
The major systemic factors that regulate longitudinal bone growth during childhood
are GH and IGF-I, thyroid hormone, and GCs, whereas during puberty, the sex
steroids (oestrogens and androgens) also contribute to this process. Although the
effects of these factors on longitudinal bone growth have been well reported, the
mechanisms underlying these effects remain largely unknown.
1.6.1.1 GH-IGF-I system
IGF-I and –II are believed to be the key regulators of GH-independent growth before
birth. This is based on findings in knockout mice, and also on the observation that inChapter 1 Introduction and Literature Review
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congenital GH deficiency, birth length is only mildly diminished, whereas in
congenital IGF-I deficiency birth length is severely diminished (Mehta et al., 2005).
Following birth, GH is an important modulator of longitudinal bone growth and,
together with IGF-I, plays a major role in the hypothalamus-pituitary (HPA) growth
plate axis (Figure 1.5). GH secretion from the pituitary is stimulated by Growth
Hormone Releasing Hormone (GHRH) and inhibited by somatostatin, which are both
released by the hypothalamus. GH is released in a pulsatile manner which is more
regular and contains higher peak levels in boys, whereas in girls this secretion is more
irregular (Veldhuis et al., 1998). A pituitary adenoma in childhood or adulthood
causes enhanced GH secretion, leading to pituitary gigantism, or acromegaly,
respectively (Daughaday et al., 1992; Ezzat et al., 1997). Conversely, defects in the
formation of GH-secreting cells (i.e. Prop-1 or Pit-1 mutations), synthesis or release
of GH (i.e. by GHTH-receptor or Pit-1 mutations), or GH insensitivity can result in
severe dwarfism (Wit et al., 1989; Pfaffle et al., 1993; Savage et al., 2001).
GH acts on its target tissue directly or through IGF-I and –II. There is now substantial
evidence that both IGFs have a unique and complementary role in regulating bone
growth (Le Roith et al., 2001). In 1957, Salmon and Daughaday postulated the
somatomedin (now called IGF) hypothesis in which the growth plate chondrocytes
response to GH was mediated through the hepatic production of IGF and its release
into the circulation. From there, IGF-I reaches its target tissues (cartilage and bone)
and interacts with its receptors, which convey a growth signal to the cell. This
hypothesis is compatible with an endocrine action of IGF-I and was based on
experimental evidence that the addition of GH to cartilage fragments in culture had
little effect, whereas the addition of serum stimulated cellular processes associatedChapter 1 Introduction and Literature Review
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with chondrocyte proliferation and differentiation. However, serum from
hypophysectomised animals had a lesser effect and subsequent GH therapy resulted in
a serum with normal growth promoting activities. The somatomedin hypothesis has
been questioned by other experiments showing that low concentrations of GH directly
infused into the growth plate showed stimulated longitudinal growth in comparison to
the contralateral limb (Isaksson et al., 1982). These and similar studies have led to an
alternative hypothesis of GH action in which GH has a direct effect on bone and other
peripheral tissues resulting in the local production of IGF-I (D’Ercole et al., 1984).
This hypothesis was supported by work carried out by Isaksson et al., who used
cultured growth plate chondrocytes to show that GH acts on resting zone
chondrocytes and is responsible for local IGF-I production, stimulating the clonal
expansion of proliferating chondrocytes in an autocrine/paracrine manner (Isaksson et
al., 1987). This hypothesis was named the dual-effector theory in analogy to the
proposed dual-effector theory in adipocytes by Green et al., (1985). Partly supporting
the dual-effector theory, Hunziker et al., (1994) showed that in hypophysectomised
rats, resting cell cycle times were reduced with either GH or IGF-I administration. In
addition, proliferating cell cycle time and duration of the hypertrophic phase were
reduced. From these studies, it was concluded that both GH and IGF-I were capable
of stimulating growth plate resting cells (Ohlsson et al., 1992).
In support of direct effects of circulating GH on the growth plate, GHR has been
detected in rabbit and human growth plate chondrocytes (Barnard et al., 1988), and
recently, both GHR and GH binding protein (GHBP) have been found in rat growth
plate chondrocytes during development (Gevers et al., 2002). Interestingly, theChapter 1 Introduction and Literature Review
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expression of GHR and GHBP in the growth plate were shown to be regulated by
thyroid hormone, GH and dexamethasone (Dex), and administration of GH into IGF-I
null mice increased the width of the resting zone, supporting a direct role for GH on
the growth plate. (Wang et al., 1999).
IGF-I also plays an important role in longitudinal bone growth, as IGF-I null mice
display severe dwarfism (Powell-Braxton et al., 1993), and children with a
homozygous IGF-I deletion have extremely short stature (Abuzzahab et al., 2003).
Mice with a double knockout for both GHR and IGF-I are smaller than mice with
either a GHR or IGF-I single knockout, suggesting that both GH and IGF-I contribute
significantly to longitudinal growth. In addition, mice with a double knock-out for
liver IGF-I and the acid-labile subunit displayed reduced linear growth and decreased
bone mineral density (Yakar et al., 2002).
1.6.1.2 Thyroid Hormone
In addition to GH and IGF-I, thyroid hormone (T3), and, to a lesser extent, its
precursor thyroxine (T4), are crucial for normal bone maturation (Shao et al., 2006).
In children, hypothyroidism causes growth arrest, delayed bone matruration and
epipyseal dysgenesis, with thyroxine replacement resulting in catch-up growth (Basset
et al., 2007). Conversely, thyrotoxicosis in children accelerates growth and advances
bone age, but ultimately leads to growth retardation due to premature growth plate
fusion. Many in vitro and in vivo studies have shown that T3 regulates the transition
between proliferation and terminal differentiation in the growth plate and specifically,
the maturation of growth plate chondrocytes into hypertrophic cells (Figure 1.5).Chapter 1 Introduction and Literature Review
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In organ cultures, T4 has been shown to stimulate chondrocyte differentiation (Miura
et al., 2002), whilst in vitro, T3 decreases chondrocyte proliferation (Ohlsson et al.,
1992; Robson et al., 2000). In addition, many in vitro studies have shown that T3
positively regulates the terminal differentiation of chondrocytes in several different
species (Ohlsson et al., 1992; Bohme et al., 1995; Leboy et al., 1997; Okubo and
Reddi 2003). Interestingly, mechanistic studies have shown that T4 stimulates the
expression of p21, an inhibitor of the cell cycle, in rat epipyseal chondrocytes in vitro
(Ballock et al., 2000), and also inhibits the expression of Sox-9, a transcription factor
that maintains chondrocytes in an undifferentiated state (Okubo and Reddi 2003). In
addition, T3 stimulates fibroblast growth factor (FGF) receptor expression in murine
chondrogenic ATDC5 cells, enhancing FGF signalling (Barnard et al., 2005).
T3 actions are mediated through nuclear T3 receptors (TR), which have been shown to
act as ligand-controlled transcription factors (Yen et al., 2006), and a number of
different isoforms of TR have been detected in the growth plate. TRα1 and TRα2 are
expressed in chondrocytes and osteoblasts, as is the TRβ1 isoform. Mice lacking
functional TRα1 and TRα2 display abnormal growth plate morphology and impaired
mineralisation during endochondral ossification (Gauthier et al., 2001), and this is
associated with reduced FGFR1 and FGFR3 expression in osteoblasts and
chondrocytes (Stevens et al., 2003; Barnard et al., 2005). In contrast, mice with a
mutation in TRβ1 have elevated T4 levels, advanced bone age and short stature,
resulting from a reduced width of the growth plate (O’Shea et al., 2003). A specific
role for TRβ in chondrocytes has also been suggested in studies using the selective
TRβ agonist GC-1 (Freitas et al., 2005). Hypothyroid rats displayed disorganised
chondrocyte columns, reduced hypertrophic chondrocyte differentiation and impairedChapter 1 Introduction and Literature Review
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mineralisation. These abnormalities were all rescued by the administration of T3, and
although the agonist GC-1 also rescued differentiation and mineralisation defects,
normal growth plate morphology was not restored.
Figure 1.5 Hormone action in the growth plate. (A) The effects of GH, IGF-I, GC,
and T3 on growth plate chondrocytes. (B) Regions of the growth plate in which IGF-I
and GHR, IGF-IR, GR, and TR are expressed. RZ indicates reserve zone; PZ,
proliferative zone; HZ, hypertrophic zone; PS, primary spongiosum. (C) The
Ihh/PTHrP feedback loop, which regulates the pace of endochondral ossification. Ihh
is secreted by prehypertrophic chondrocytes and acts on perichondrial cells during
development, or on proliferative chondrocytes during postnatal growth, to stimulate
release of PTHrP. PTHrP acts on PTHrP receptors (PTHrPR) that are expressed in
uncommitted prehypertrophic chondrocytes to delay differentiation and maintain cell
proliferation (Robson et al., 2002).
1.6.1.3 Sex Steroids
It has long been established that sex steroids are important for longitudinal growth,
especially during puberty. It was generally assumed that in girls, oestrogen was the
primary sex steroid regulating pubertal growth, whereas in boys this was achieved
primarily by androgen. However, the finding of a male patient with an inactivation
mutation in Oestrogen Receptor ERfundamentally changed this view (Smith etChapter 1 Introduction and Literature Review
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al., 1994). This patient, who was resistant to the actions of oestrogens, demonstrated
longitudinal growth well into adulthood, resulting in tall stature due to a lack of
growth plate fusion as well as severe osteoporosis, despite high levels of testosterone
(Smith et al., 1994). This finding led to the assumption that in both boys and girls,
oestrogen is the main determinant for the puberty-associated phenomena related to
longitudinal growth and bone quality (Grumbach 2001; Juul et al., 2001).
In vitro studies have shown that, in the growth plate, oestrogen alters alkaline
phosphatase activity, cell proliferation and proteoglycan synthesis (Schwartz et al.,
2002). Indeed, oestrogen has a biphasic effect on proliferation, which is stimulated by
low levels and inhibited by high levels of oestrogen (Frank et al., 2003). A number
of studies have demonstrated the presence of the androgen receptor and both
oestrogen receptors, ER and ER, in growth plate tissue at the mRNA and protein
level in several species, including rat, rabbit, and human (Chagin and Savendahl
2007), indicating that androgens and oestrogens directly regulate processes in the
growth plate. Furthermore, the growth plate possesses the ability for steroidogenesis
as well as aromatisation (Van der Eerden et al., 2004). However, it has been difficult
to prove whether androgens have direct effects on growth plate cartilage. Non-
aromatisable androgens, such as dihydrotestosterone, have been shown to regulate
both the proliferation and differentiation of cultured human epiphyseal chondrocytes,
probably by promoting local IGF-1 synthesis and increasing IGF-I receptor
expression (Blanchard et al., 1991; Krohn et al., 2003).Chapter 1 Introduction and Literature Review
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1.6.2 Local Regulation of the Growth Plate
1.6.2.1 Fibroblast growth factor (FGF) signalling
Recent studies have shown that many of the 22 FGF genes and 4 FGF receptor
(FGFR) genes are expressed by chondrocytes at every stage of endochondral bone
formation. Both FGF1 and -2, as well as FGFRs 1-3 are expressed in chondrocytes
(Peters et al., 1992; Jingushi et al., 1995; Leach et al., 1997), and in humans,
mutations in the FGFR3 gene cause achondroplasia, the most common type of human
dwarfism (Vajo et al., 2000). In addition, overexpression of FGF2 has been shown to
slow longitudinal growth (Coffin et al., 1995). Mancilla et al (1998) have also shown
that, in a metatarsal organ culture model, FGF2 decreased growth plate chondrocyte
proliferation, decreased cellular hypertrophy, and at high concentrations, decreased
cartilage matrix production. However, the multiple early effects of FGFs in the
development of bone have made the genetic analysis of the roles of FGF signalling
during bone development a particular challenge. During the early stages of bone
development, FGFs have been shown to stimulate Sox9 expression in a mesenchymal
cell line (Murakami et al., 2000). In proliferating chondrocytes, FGF signalling
through FGFR3 inhibits proliferation (Figure 1.6) (Sahni et al., 1999) by activation of
the Janus kinase-signal transducer and activator of transcription-1 pathway (JAK-
STAT1). In addition, activation of FGFR3 has been shown to decrease Indian
hedgehog (Ihh) expression (Naski et al., 1998), also leading to a decrease in
chondrocyte proliferation (Figure 1.6). Accordingly, FGF signalling shortens
proliferative columns both by decreasing chondrocyte proliferation directly and by
suppressing Ihh expression.Chapter 1 Introduction and Literature Review
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1.6.2.2 Bone Morphogenic Protein (BMP) and Transforming growth factor 
(TGF) signalling
The family of BMPs is comprised of at least 15 members, which are all part of the
TGF superfamily. BMPs were originally identified as stimulators of bone formation
but are now recognised as important regulators of growth, differentiation, and
morphogenesis during embryology (Reddi et al., 2001). Within the developing limb
cartilage elements, BMP2, -4, and -7 have been detected in the perichondrium,
whereas BMP6 was found in prehypertrophic and hypertrophic chondrocytes (Lyons
et al., 1989; Jones et al., 1991; Macias et al., 1997; Grimsrud et al., 1999; Haaijman
et al., 1999). The effects of BMPs are mediated by two type I receptors, BMPRIA
and -IB, which heterodimerise with the type II receptor, BMPRII. The type I
receptors are differentially localised in embryonic limbs; BMPRIB is detected in early
mesenchymal condensations and is involved in early cartilage formation, whereas
BMPRIA expression is confined to prehypertrophic chondrocytes (Zou et al., 1997).
Constitutive active and/or dominant negative forms of BMPRIA and -IB revealed that
the type IA receptor controls the pace of chondrocyte differentiation, whereas the type
IB receptor is involved in cartilage formation and apoptosis (Zou et al., 1997). Mice
bred with homozygous null mutations in BMP-2 and -4 do not survive (Winnier et al.,
1995), whereas other family members such as growth and differentiation factor 5
(GDF5) and BMP-5 are important mediators of chondrocyte differentiation in
mesenchymal condensations at various sites (Mikic et al., 1996, Storm et al., 1999).
Several mutations in the BMP antagonist noggin result in proximal symphalangism
(fusion of the joints in the carpal and tarsal bones) and multiple synostoses syndrome
(premature fusion of the joints) (Gong et al., 1999). Recently, BMP6 was introducedChapter 1 Introduction and Literature Review
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as a possible mediator in the growth-restraining feedback loop involving Ihh and
PTHrP (Grimsrud et al., 1999). The fact that BMPRIA is expressed in the same region
and that it has been shown to be critical for chondrocyte hypertrophy further
strengthens an autocrine/paracrine role for BMP6 in prehypertrophic chondrocytes
(Zou et al., 1997). It has also been shown that normal chondrocyte proliferation
requires parallel signalling of both Ihh and BMPs and that BMPs are capable of
inhibiting chondrocyte differentiation independently of the Ihh/PTHrP pathway
(Minina et al., 2000) (Figure 1.6).
In humans, only a few mutations in members of the TGF superfamily cause cartilage
disorders. Genomic mutations in the human GDF5 gene have been shown to cause
chondrodysplasia Grebe type, acromesomelic chondrodysplasia Hunter Thompson
type, and brachydactyly type C, all of which are mainly characterised by defects of
the limbs, with increasing severity towards the distal regions (Thomas et al., 1996;
Polinkovsky et al., 1997, Thomas et al., 1997). In another study, inhibition of
chondrocyte differentiation by TGF was shown to be at least partly mediated by
induction of PTHrP expression (Alvarez et al., 2001). These data imply that the
BMPs/ TGF and their receptors act as a signalling system, both dependently and
independently of the Ihh/PTHrP feedback loop, at different levels during embryonic
bone formation.
1.6.2.3 Ihh/PTHrP signalling
Ihh is a major regulator of bone development, controlling chondrocyte proliferation,
chondrocyte differentiation and osteoblast differentiation. Ihh is a member of the
hedgehog family of ligands, and during bone development, is synthesised byChapter 1 Introduction and Literature Review
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prehypertrophic chondrocytes and by early hypertrophic chondrocytes. The binding
of Ihh to its receptor (Patched-1), leads to activation of Smoothened, a membrane
protein that is essential for the cellular actions of Ihh. Ihh
-/- mice have normal bones
at condensation, but later develop abnormalities of bone growth and a decrease in
chondrocyte proliferation (St Jacques et al., 1999). In addition, the bones of Ihh
-/-
mice have an increase in the number of hypertrophic chondrocytes versus
proliferating chondrocytes. This is a result of chondrocytes leaving the proliferative
pool early, and is suggested to be due to the fact that the cartilage in Ihh
-/- mice fails to
produce PTHrP.
PTHrP acts upon the G-protein coupled receptor, PTH1R, and its main function
within the growth plate is to keep proliferating chondrocytes in the proliferative pool
and to control the pace of chondrocyte differentiation (Figure 1.6). In PTHrP
-/- or
PTH1R
-/- mice chondrocytes hypertrophy early and become hypertrophic close to the
ends of bones (Karaplis et al., 1994; Lanske et al., 1996). In contrast, overexpression
of PTHrP in chondrocytes delays the appearance of hypertrophic chondrocytes (Weir
et al., 1996). Interactions between Ihh and PTHrP were suggested when it was
discovered that Ihh can stimulate the expression of PTHrP and consequently delay
chondrocyte hypertrophy (Vortkamp et al., 1996). It has since been hypothesised that
together, Ihh and PTHrP control the decision of chondrocytes to leave the
proliferative pool through a feedback loop (Figure 1.6). In this loop, Ihh is produced
by prehypertrophic chondrocytes committed to hypertrophy and acting through its
receptor (Ptc-1) within the perichondrium, increases the expression of PTHrP in the
periarticular region. PTHrP then binds to PTH1Rs expressed on prehypertrophic
chondrocytes – i.e., prior to their conversion to Ihh expressing cells – and blocks theirChapter 1 Introduction and Literature Review
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further differentiation. As the population of committed cells progresses to the
hypertrophic phenotype, they stop expressing Ihh, thereby attenuating the negative
feedback loop and allowing the further differentiation of uncommitted
prehypertrophic cells. This feedback loop demonstrates the importance of the
interactions between PTHrP and Ihh to determine the lengths of proliferative columns
in individual bones (Kronenberg et al., 2001).
1.6.2.4 Vascular endothelial growth factor (VEGF)
During chondrocyte hypertrophy, ECM surrounding the hypertrophic cells becomes
calcified, which triggers the invasion of blood vessels from the underlying
metaphyseal bone. This is preceded by the expression of VEGF in hypertrophic
chondrocytes (Haigh et al., 2000). Inactivation of VEGF by systemic administration
of a soluble receptor to 24-d-old mice suppressed blood vessel invasion and trabecular
bone formation concomitant with an increased width of the hypertrophic zone (Gerber
et al., 1999), indicating that VEGF plays an important role in the events that take
place during the end-stage of endochondral bone formation such as terminal
differentiation of chondrocytes, vascular invasion, chondrocyte apoptosis, and their
subsequent replacement by bone (Gerber et al., 1999). Other promoters or inhibitors
of angiogenesis have been described in the literature, including transferrin (promoter)
(Carlevaro et al., 1997), chondromodulin (inhibitor) (Hiraki et al., 1997), and FGFs
(promoters) (Baron et al., 1994). In embryonic growth plates, Schipani et al. (2006)
described the role of hypoxia inducible factor (HIF-1), which is a transcription
factor that regulates VEGF expression (Semenza et al., 1999). Growth plate-specific
targeted deletion of HIF-1 caused increased cell death and reduced VEGF
expression (Schipani et al., 2005). At the same time, cells surrounding the area ofChapter 1 Introduction and Literature Review
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increased cell death contained enhanced VEGF levels, suggesting that VEGF
expression is regulated in an HIF-1-dependent and –independent manner (Schipani
et al., 2006).
Figure 1.6 Interaction of Ihh, PTHrP, BMP, and FGF signalling in modulating
chondrocyte proliferation and differentiation. Expression of Ihh in
prehypertrophic chondrocytes is up-regulated by BMPs but inhibited by FGFs. Ihh
activates adjacent chondrocytes and diffuses toward the lateral perichondrium, where
it can bind to its receptor Patched. PTHrP production is stimulated in the periarticular
perichondrium and diffuses toward the prehypertrophic zone, which expresses high
levels of PTH/PTHrP receptors and inhibits the differentiation of proliferating
chondrocytes. Besides modulating chondrocyte differentiation, Ihh also stimulates
chondrocyte proliferation, both directly and indirectly through BMP signalling. FGFs
are able to inhibit chondrocyte proliferation independently of the two stimulatory
pathways. BMP signalling inhibits terminal differentiation of chondrocytes, a process
that FGFs can promote. The balance between BMP and FGF signalling is crucial in
regulating proliferation, Ihh expression, and terminal differentiation of chondrocytes.
From Van der Eerden et al., 2003.
1.6.2.5 Sox9
The main role of the transcription factor Sox9 is controlling the conversion of
mesenchymal cells into chondrocytes. However, it also acts on chondrocytes through
every stage of differentiation. Sox9 is expressed in cells of mesenchymal
condensations and in proliferating chondrocytes, but not hypertrophic chondrocytes.Chapter 1 Introduction and Literature Review
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Sox9
-/- mesenchymal cells cannot form condensations or go on to form chondrocytes
(Mori-Akiyama et al., 2003), and when Sox9 was deleted from chondrocytes at later
stages of development, the chondrocytes displayed decreased proliferation, decreased
expression of matrix genes and decreased expression of the Ihh-PTHrP signalling
pathways (Akiyama et al., 2002). Sox9 is crucial for all phases of chondrocyte
development, and is considered the master regulator of chondrocyte formation. Sox9
has an essential role in determining the commitment and differentiation of
mesenchymal cells toward the chondrogenic lineage. Sox9 is expressed in
prechondrocytic and chondrocytic cells during embryonic development, and cells
lacking Sox9 fail to differentiate to a chondrocyte phenotype due to decreased
activation of COL2A1 (Coll II gene), an important element of differentiation
(Lefebvre et al, 1997). This results in campomelic dyschondroplasia, a severe form of
chondrodysplasia which is caused by a decrease in production of Coll II.
Mesenchymal cells from Sox9
-/- knockout mice cannot differentiate into chondrocytes
and cartilage cannot be formed from teratomas derived from Sox9
-/- embryonic stem
(ES) cells (Mori-Akiyama et al., 2003). Similarly, other studies have shown that the
inactivation of Sox9 in mesenchymal condensations during embryonic development
causes a severe decrease in differentiated chondrocytes, again resulting in severe
dyschondroplasia (Akiyama et al, 2002).
1.7 Cell Cycle Signalling
1.7.1 Control of Cell Cycle Gene Expression
As growth plate function is closely linked to the rates of cell cycle progression and the
timing of cell-cycle exit during differentiation, it has been suggested that cell cycle
genes play a crucial role in the control of longitudinal bone growth (Beier et al.,Chapter 1 Introduction and Literature Review
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1999a and b). Progression through the eukaryotic cell-cycle is controlled by cyclin-
dependent kinases (CDKs) (Lundberg and Weinberg 1999), and their partner proteins,
the cyclins. The activity of CDKs is highly regulated by the activity of their
respective cyclins; the levels of cyclin-dependent kinase inhibitors (CDKIs) of the
Cip/Kip family (p21, p27, p57), and Ink family (p15, p16, p18, p19); and inhibitory
and stimulatory phosphorylation of various CDK residues. High levels of cyclins
generally stimulate cell-cycle progression and proliferation through activation of
CKDs, whereas high levels of CKDIs antagonise these processes. As previously
mentioned, different growth plates within the same animal grow at different rates
(Wilsman et al., 1996). These differences are largely due to the duration of the G1
phase in proliferating chondrocytes (Wilsman et al., 1996), suggesting that cell-cycle
genes regulating G1 progression are of special importance in regulating endochondral
bone growth. In recent years, several studies have identified G1 cell-cycle genes as
targets of both extracellular signals and intracellular signalling pathways during
cartilage development. Among regulators of the G1 phase of the cell-cycle, the cyclin
D1 and p21
Cip1/Waf1 genes have been shown to be regulated by numerous upstream
signals, although other cyclins and CDKIs have also been identified as targets of
mitogenic and anti-mitogenic signals. The D type cyclins (cyclin D1, D2, and D3) are
the first cyclins to be induced in the mammalian cell-cycle and control progression
through the G1 phase in complexes with CDKs 4 and 6 (Bartek and Lukas, 2001;
Hulleman and Boonstra, 2001). Within the growth plate, cyclin D1 expression is
specific for the proliferative zone at the mRNA and protein levels (Beier et al., 2001),
consistent with its role in supporting progression through the G1 phase of the cell-
cycle (Figure 1.7)Chapter 1 Introduction and Literature Review
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p21
Cip1/Waf1 (referred to as p21 from now on) is one of seven CDKIs. Similar to cyclin
D1, expression of the p21 gene in chondrocytes is controlled by several different
pathways. p21 expression is upregulated in postmitotic, differentiating chondrocytes
in vivo (Stewart et al., 1997; Zenmyo et al., 2000). An important role of this gene in
skeletal development was first suggested when it was identified as a target of
activated FGF receptor 3 (FGFR3) in thanatophoric dysplasia, a severe human
chondrodysplasia (Su et al., 1997). Several other studies confirmed that p21
expression in chondrocytes is induced or enhanced by FGF signalling through the
transcription factor STAT1 (Sahni et al., 1999; Weksler et al., 1999; Aikawa et al.,
2001; Benoist-Lasselin et al., 2007). These studies suggest that induction of p21
expression and subsequent cell-cycle withdrawal likely contribute to the dwarfism
caused by mutations in the FGFR3 gene (Ornitz and Marie, 2002). However,
additional target genes are likely involved; for example, one study demonstrated that
overexpression of an activated FGFR3 gene in transgenic mice also induces
expression of the p16, p18, and p19 genes, CDK inhibitors of the INK family (Legeai-
Mallet et al., 2004). In addition, FGF1 induces expression of p27 and p57 in rat
chondrosarcoma cells (Laplantine et al., 2002). Expression of p21 and the related p27
protein in chondrocytes is also enhanced by thyroid hormone, a well-characterised
inducer of chondrocyte hypertrophy (Figure 1.7) (Ballock et al., 2000), and by BMP2
(Carlberg et al., 2001). Finally, Sox9 (Panda et al., 2001) and the c-Raf/MEK/ERK
MAPK signalling cascade (Beier et al., 1999; Stanton et al., 2003) have also been
shown to be important positive regulators of p21 expression, whereas PTH represses
p21 expression in the chondrogenic cell line ATDC5 (Negishi et al., 2001). In
addition, chondrocyte proliferation is enhanced and p57 expression decreased in miceChapter 1 Introduction and Literature Review
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with cartilage-specific inactivation of the gene encoding HIF-1a, a transcription factor
involved in the cellular response to hypoxia (Schipani et al., 2001).
Figure 1.7 p21 and cyclin D1 as targets of mitogenic and antimitogenic signals in
chondrocytes. Numerous extra- and intracellular signals target expression of cyclin
D1 and p21 genes in chondrocytes, suggesting that these genes act as integrators of
mitogenic and antimitogenic stimuli, respectively. Adapted from Beier et al., 2005.
1.7.2 Function of cell cycle genes in the growth plate
Gain- and loss-of function experiments have identified roles of multiple cell cycle
genes in endochondral bone growth. Targeted inactivation of the p57Kip2 (p57) gene
results in severe skeletal defects caused by delayed cell-cycle exit and disrupted
hypertrophic differentiation of growth plate chondrocytes (Yan et al., 1997; Zhang et
al., 1997). The endochondral skeleton seems to be the one of the most affected
tissues, indicating that cartilage development is particularly sensitive to changes in the
levels of cell-cycle proteins. Adenoviral overexpression of p57 in primary rat
chondrocytes induces cell-cycle exit, but is not enough to trigger expression of CollChapter 1 Introduction and Literature Review
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X, the classical marker of hypertrophic chondrocytes (Stewart et al., 2004). However,
p57 cooperates with BMP2 in the induction of Coll X expression. While p21-
deficient mice do not display any obvious developmental defects (Deng et al., 1995),
loss of p21 increases the severity of skeletal defects in p57 null mice (Zhang et al.,
1999). Furthermore, chondrocytes from p21 null mice show reduced antimitogenic
response to FGF in organ cultures (Aikawa et al., 2001), and expression of p21
antisense RNA in ATDC5 cells inhibits early chondrogenic differentiation (Negishi et
al., 2001).
In addition to p21, p27 has been detected immunohistochemically in hypertrophic
chondrocytes in foetal and early postnatal mice (Sunters et al., 1998; Horner et al,
2002). p27 has also been detected in cultured rat resting zone chondrocytes where its
expression is up-regulated during thyroid hormone-induced terminal differentiation
(Ballock et al., 2000). Targeted disruption of p27 in mice causes multi-organ
hyperplasia and increased body weight, with all tissues proportionally enlarged and
containing more cells (Drissi et al., 1999; Nagahama et al., 2001; Teixeira et al.,
2001), and Kiyokawa et al., (1996) reported an increased size and width of tibiae and
femora in p27-deficient mice compared with wild-type mice. A recent paper by
Emons et al (2007) has gone on to study the growth plate of p27 null mice in more
detail. Although the absence of p27 caused an increase in the number of proliferating
chondrocytes within the growth plate, there were no obvious differences in growth
plate morphology and no increase in tibial growth rate was observed. These findings
suggest that p27 has modest inhibitory effects on growth plate chondrocyte
proliferation but is not required for the spatial or temporal regulation of proliferation.Chapter 1 Introduction and Literature Review
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In contrast to the number of publications on the role of inhibitors of cell-cycle
progression, fewer functional studies have been reported for positive regulators of the
cell-cycle. As mentioned above, cyclin D1-deficient mice are dwarfed (Fantl et al.,
1995) with a smaller proliferative zone of the growth plate (Beier et al., 2001). Cyclin
D1 antisense oligonucleotides reduce proliferation and E2F activity, and delay cell
cycle progression in chondrogenic cells (Beier et al., 2001; Beier and LuValle, 2002).
In contrast, defects in cyclin D2 knockout mice appear to be restricted to reproductive
tissues (Sicinski et al., 1996). The last few years have seen both the identification of
novel regulatory mechanisms governing cell-cycle gene expression in the growth
plate and progression in the functional analyses of cell-cycle genes in cartilage
development. Complete elucidation of the signalling and transcriptional events
involved will be necessary to understand how the cell-cycle machinery integrates
multiple inputs and creates a coordinated response to the multitude of intrinsic and
extrinsic signals acting on chondrocytes. In addition, further mechanistic
investigations at the molecular, cellular, tissue and whole animal level will be
required to obtain a comprehensive view of the role of cell-cycle genes in
endochondral bone growth.
1.8 GCs and Growth Retardation
1.8.1 GC Physiology
GCs are synthesised and secreted by the adrenal cortex and are essential for the
function of most systems in the body. In physiological doses, they help the body
adapt to intermittent food intake by regulating blood sugar and electrolytes, promoting
gluconeogenesis, mobilising fats for energy metabolism and depressing inflammatory
and immune responses. Physiological GCs include the most predominant, cortisol,Chapter 1 Introduction and Literature Review
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cortisone and corticosterone. GCs are commonly known as the stress hormones, and,
under normal circumstances are crucial for the capability of the body to respond and
adapt to stress.
The main physiological stimulus for synthesis and release of GCs is
adrenocorticotrophic hormone, or ACTH, secreted from the anterior pituitary gland.
ACTH secretion is regulated partly by corticotrophin-releasing factor (CRF) derived
from the hypothalamus and partly by the level of GCs in the blood. The release of
CRF in turn is inhibited by the level of GCs and, to a lesser extent, of ACTH in the
blood, and is influenced by input from the central nervous system. There is a basal
release of GCs, and the concentration of endogenous GCs in the blood is higher in the
morning, and low in the evening. The starting substance for the synthesis of GCs is
cholesterol (Figure 1.8), which is obtained mostly from the plasma and is present in
the lipid granules in the zona fasciculata of the adrenal cortex. The first step, the
conversion of cholesterol to pregnenolone, is the rate limiting step and is regulated by
ACTH.Chapter 1 Introduction and Literature Review
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Figure 1.8 The GC Biosynthetic Pathway The first and rate-limiting step of GC
synthesis is the conversion of cholesterol to pregnenolone, which is stimulated by
ACTH. Pregnenolone is then converted to the GC cortisol through a series of
reactions catalysed by hydroxylase and dehydrogenase enzymes (italics).
The main metabolic effects of GCs are on carbohydrate and protein metabolism. GCs
cause both a decrease in the uptake and utilisation of glucose and an increase in
gluconeogenesis, resulting in a tendency to hyperglycaemia. In addition, GCs cause
decreased protein synthesis and increased protein breakdown, particularly in muscle,
and due to an increase in lipase activation through cAMP, large doses of GCs can also
result in fat redistribution as seen in Cushing’s syndrome.
Both endogenous and exogenous GCs have a negative feedback effect on the
secretion of CRF and ACTH. Administration of exogenous GCs depresses the
secretion of CRF and ACTH, thus inhibiting the secretion of endogenous GCs andChapter 1 Introduction and Literature Review
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causing atrophy of the adrenal cortex. When given therapeutically, GCs can also have
powerful anti-inflammatory and immunosuppressive effects. They inhibit both the
early (redness, heat, pain and swelling) and late (wound healing) manifestations of
inflammation, and when used clinically to suppress graft rejection, GCs suppress the
initiation of a ‘new’ immune response. In areas of acute inflammation, GCs cause a
decreased influx and activity of leukocytes, and in areas of chronic inflammation,
GCs are known to cause decreased activity of mononuclear cells, decreased
proliferation of blood vessels and less fibrosis. In addition, in lymphoid tissues, GCs
cause decreased clonal expansion of T and B cells, and decreased activity of cytokine-
secreting T cells. GCs also act directly on inflammatory mediators, and decrease the
production of cytokines including interleukins, TNF-γ and GM-CSF.  These actions 
result in a reduction in chronic inflammation and autoimmune reactions.
1.8.2 GC Mechanisms of Action
GC effects involve interactions between the steroids and intracellular steroid hormone
receptors. GCs, after entering the cell, bind to specific GC receptors (GR) in the
cytoplasm, activating the receptor by causing it to undergo a conformational change
exposing a DNA-binding domain. The receptor is composed of three main domains:
a DNA-binding domain (DBD); a C-terminal ligand binding domain (LBD), which
plays a role in ligand recognition through the ligand-dependent activation function
AF-2; and an N-terminal activation domain, which plays an important role in gene
regulation. The GR is capable of both positive and negative regulation of
transcription, and in the absence of a ligand, is located in the cytoplasm where it is
held in an inactive state by heat shock proteins (HSP). Upon the binding of a ligand,
the HSP dissociate from the GR, allowing it to dimerise and translocate to theChapter 1 Introduction and Literature Review
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nucleus. Once in the nucleus, the GR binds to promoters on the gene of interest
known as GC response elements (GRE), resulting in the activation or repression of a
specific set of transcription factors, through coactivators and corepressors,
respectively (Figure 1.9) (Jantzen et al., 1987; Beato et al., 1996). It is thought that
coactivators bind to the LBD of the GR in a ligand-dependent manner, and,
consequently, although coactivators bind readily in the presence of agonists, they fail
to bind in the presence of antagonist ligands, a likely mechanism of action for these
antagonists (Figure 1.9). These coactivators may also play a role in the tissue-specific
activity of GCs, as although many coactivators are expressed widely, some exhibit a
specific tissue expression pattern (Puigserver et al., 1999; Knutti et al., 2001). It has
also been shown that the GR is capable of binding directly to specific transcription
factors such as nuclear factor-B (NFB) and activator protein-1 (AP-1) which are
involved in the up-regulation of inflammatory genes. This mechanism is ligand-
independent and does not require receptor dimerisation, therefore rendering it
genetically separable from transcriptional activation (McKay & Cidlowski 1999)
(Figure 1.9).
In humans, mutations in the GR are known to cause familial GC resistance (FGR)
(Hurley et al., 1991). Patients with FGR often feel fatigue, but other signs of GC
insufficiency are rare as the ACTH-driven increase in cortisol compensates for
receptor insensitivity. However, a consequence of this increase in ACTH is the
elevation of mineralocorticoids and androgens, which can result in hypertension. In
the mouse, two critical transgenic mouse models have been developed. Knockout of
the GR gene in all tissues exerts minimal effects on embryonic development, but
results in perinatal lethality due to underdevelopment of the lungs (Cole et al., 1995).Chapter 1 Introduction and Literature Review
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A second mutation, GRdim, uncovers an essential duality of GR function. This
mutation prevents dimerisation of the receptor, and consequently prevents DNA
binding. Therefore, transactivation and transrepression that require direct DNA
binding of a dimeric GR are inactive, whilst transrepression involving a direct
interaction between a monomeric GR and transcription factors is unaffected.
Surprisingly, these mice are viable, and have no obvious defects in lung maturation or
anti-inflammatory actions of the receptor, suggesting that homodimer GR-DNA
binding is not essential for survival (Reichardt et al., 1998).Chapter 1 Introduction and Literature Review
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Figure 1.9 Mechanisms of GC-regulated gene transcription There are at least
three distinct mechanisms by which GCs can regulate gene transcription. First, GCs
bind to a cytosolic GR attached to a heat-shock protein (HSP). The HSP dissociates,
and the GR dimerises and translocates to the nucleus and, in the case of positive
regulation, transactivates through cis-activating palindromic GREs located in the
promoter region of responsive genes. Second, GCs are able to bind to negative GREs
resulting in the repression of gene transcription. There is now evidence to suggest that
GCs may control inflammation predominantly via a third mechanism involving the
transrepression of transcription factors, such as AP-1, NFĸB and NF-AT that regulate 
inflammatory gene expression. (Figure amended from Belvisi et al., 2001)
1.8.3 Systemic Side Effects of GCs
GCs affect most systems within the body. There are several situations when the
carefully balanced physiological production of GCs can become unbalanced.
Chronic, uncontrolled stress leads to long term activation of the HPA axis andChapter 1 Introduction and Literature Review
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sustained, high GC levels. Pathological conditions in which activation of the HPA
axis has been demonstrated include depression, obsessive-compulsive disorder,
alcohol and drug abuse, and anorexia nervosa (Chrousos et al., 2000). Imbalances in
cortisol production can also occur in certain conditions that overproduce GCs. These
patients present with a combination of symptoms grouped under the heading
‘Cushing’s syndrome’. The symptoms include central obesity, glucose intolerance,
myopathy and hypertension. However, the most common way in which imbalances in
the stress response system can present themselves is the administration of exogenous
GCs. Exposure to high, sustained levels of corticosteroids by any mechanism
uncouples the normal metabolic processes from autoregulatory feedback mechanisms
and induces a stress response that cannot be maintained in the long term without
severe consequences. The numerous side-effects experienced by patients undergoing
long term GC treatment are a clear testament to this. Complications are time- and
dose-dependent and can occur acutely with high doses or more slowly with chronic
exposure and lower doses. One of the most important side effects resulting from GC
therapy is osteoporosis, and this side effect alone accounts for a large degree of
morbidity in patients receiving GCs. This problem is exacerbated by the fact that
these patients also suffer from decreased muscle mass and are therefore more
susceptible to falling. Increased susceptibility to infection is also a major problem in
patients undergoing GC therapy. An additional side effect which can limit the use of
GCs is hyperglycaemia due to increased gluconeogenesis, insulin resistance and
impaired glucose tolerance, which can lead to diabetes. This side effect is
exacerbated by the fact that, in high doses, many GCs that have affinity for the
mineralocorticoid receptor (MR) can exert a mineralocorticoid effect, resulting in salt
and water retention, hypertension, potassium retention and metabolic alkalosis. InChapter 1 Introduction and Literature Review
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physiological GC doses, this mineralocorticoid effect is prevented by the rapid
degradation of GCs by 11-β-hydroxysteroid dehydrogenase type 2 (11βHSD2) in MR
target tissues. GCs have also been known to have psychogenic effects, and
approximately 5% of patients will experience some form of inappropriate euphoria,
psychosis or depression. Fat redistribution and weight gain is also a concern with
many patients, and facial, supraclavical and posterior cervical fat depots are
particularly sensitive to GCs, resulting in the moon-face and buffalo hump
characteristic of long term GC treatment (Baxter et al., 1992).
1.8.4 GC Therapy and Growth During Childhood
GCs are used in the treatment in a number of chronic inflammatory, autoimmune and
neoplastic diseases in children. The impairment of childhood growth with cortisone
was first described over 40 years ago, and since then has been observed with other
commonly used GCs such as Dex and prednisolone (Pred) (Avioli et al., 1993). The
increasing incidence of childhood asthma accounts for the largest group of children
who are chronically exposed to steroids. Oral GC therapy in asthma is associated
with a delay in growth and puberty, and there is some evidence to suggest that final
height may also be compromised (Allen et al., 1994). Although early studies failed to
show a link between inhaled steroids and growth retardation, evidence now suggests
that bone growth and collagen turnover are both reduced in children with mild asthma
who use inhaled steroids (Shaw et al., 1997), an effect that is most pronounced over
the first few weeks of treatment.
In children with inflammatory bowel disease, growth retardation is widely reported,
and seems to be related to disease activity in addition to its treatment (Markowitz etChapter 1 Introduction and Literature Review
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al., 1993; Savage et al., 1999), and vertebral fractures have also been described in
children with Crohn’s disease after a short period of steroid treatment (Semeao et al.,
1997). Impaired growth is one of the major complications of childhood renal
disorders and their treatment. Children receiving GC therapy for renal disorders such
as nephrotic syndrome have reduced growth and bone mineralisation (Lettgen et al.,
1994), and post transplantation, the dose of GC therapy is inversely related to the
relative change in height of the child (Saha et al., 1998). It has been suggested that
alternate-day GC therapy is less detrimental to longitudinal growth however, this may
still delay puberty and therefore cause a delayed growth spurt (Polito et al., 1999).
GCs are widely used for treating chronic connective tissue diseases in children, and
there is a considerable overlap between the inflammatory-effects and the steroid-
induced effects on bone growth. A failure to maintain bone mineralisation is common
in children with juvenile idiopathic arthritis (JIA), and is characterised by reduced
bone formation with a subsequent failure to undergo the expected increase in bone
mass during puberty (Polito et al., 1999). This reduction in bone mineral density is
exacerbated if GCs are used as therapy (Kotaniemi et al., 1999).
GCs have consistently been the primary therapy for childhood acute lymphoblastic
leukaemia (ALL). Dex is now replacing Pred as the drug of choice due to the fact that
it has greater lymphocytotoxicity and higher CNS penetration. Recent studies have
shown that bone mineralisation status as assessed by bone mineral density is
adversely affected immediately after completion of GC treatment for ALL (Arikoski
et al., 1999). Previous studies at the University of Glasgow have shown alterations in
bone turnover and short term growth of children during leukaemia treatment. TheseChapter 1 Introduction and Literature Review
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changes were most marked during periods of intensive chemotherapy and high dose
systemic glucocorticoid administration (Crofton et al., 1998; Ahmed et al., 1999;
Crofton et al., 1999).
1.8.5 GCs and IGF-I signalling in the growth plate
The growth-suppressing effects of GC appear multifactorial, and some GC actions in
bone modify skeletal responses to GH and IGF-I (Figure 1.7). The inhibitory actions
of GCs on longitudinal growth are suggested to be due, in part, to impaired action of
the components of the IGF axis (Klaus et al., 1998), and it has been shown that GCs
reduce IGF-I mRNA in growth plate chondrocytes (Luo et al., 1989). Studies of
linear bone growth have shown that Dex and IGF-1 have opposite effects, with Dex
decreasing and IGF-1 increasing cell proliferation (Mushtaq et al., 2004). IGF-I also
increases collagen synthesis and decreases collagenase 3 expression in bone, whereas
GCs do the opposite. Furthermore, GCs block the activation of GH-Receptor (GHR)
and IGF-I Receptor (IGF-IR) expression by GH and IGF-I in chondrocytes (Jux et al.,
1998), and this may account for the antagonism of the growth promoting actions of
GH by GC (although children with impaired growth due to GC excess can still
respond to pharmacological doses of GH therapy).
Of additional interest is the observation that GH, via IGF-I, inhibits activity of 11-
hydroxysteroid dehydrogense-1 (11HSD1) in human adipose and stromal cells
(Moore et al., 1999). 11HSD1 converts inactive cortisone to active cortisol in
humans to maintain circulating levels of GCs. The type 2 enzyme, 11-
hydroxysteroid dehydrogenase-2 (11HSD2) is a dehydrogenase that catalyses the
inactivation of GCs to protect the nonselective mineralocorticoid receptor from GCChapter 1 Introduction and Literature Review
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activation in target tissues such as the kidney. Therefore, local tissue GC
concentrations are modulated by 11HSD2, and both 11HSD1 and 2 have shown to
be active in osteoblasts and osteoclasts (Cooper et al., 2000; Cooper et al., 2003). If
11HSD enzymes are expressed in growth plate chondrocytes, they may act as
significant GH and IGF-I-sensitive regulators of local GC concentrations in the
growth plate.
1.8.6 Direct effects of GCs at the Growth Plate
Evidence for a direct effect of GC in the growth plate came from a study in which
pharmacological levels (approximately 10
-6M) of local Dex infusion significantly
decreased tibial growth compared with the contralateral limb (Baron et al., 1992).
The glucocorticoid receptor (GR) has since been identified in proliferating and
hypertrophic chondrocytes in the rat (Silvestrini et al., 1999) and has also been found
in hypertrophic chondrocytes in the human growth plate (Abu et al., 2000). In rats,
GC excess reduces bone growth, probably due to decreased numbers of proliferating
chondrocytes and increased apoptosis of hypertrophic chondrocytes in the growth
plate (Chrysis et al., 2003). These results are also consistent with the Dex-induced
inhibition of chondrocyte proliferation and cartilage matrix production observed in 12
week old rats in vivo (Annefeld et al., 1992), supporting the hypothesis that Dex is a
potent negative regulator of chondrocyte activities.
It is likely, however, that physiological levels of Dex also act as a stimulator of
chondroprogenitor cell recruitment and a supporter of chondrocyte viability
(Grigoriadis et al., 1996). Physiological concentrations of Dex enhance expression of
Sox9 (Sekiya et al., 2001), which regulates expression of genes encoding markers ofChapter 1 Introduction and Literature Review
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commitment to chondrogenesis, including Coll X and aggrecan, which supports the
hypothesis that Dex may be a maintenance factor for chondrogenic cells.
1.8.7 Glucocorticoids and catch-up growth
It is well established that the effects of GC are transient and that, after their removal,
there is a period of accelerated catch-up growth. It has been proposed that the
mechanism governing catch-up growth after exposure to excess GC resides in the
growth plate (Baron et al., 1992; Nilsson et al., 2005). This proposal was based on
the observation that suppression of growth within a single rabbit growth plate in vivo
by local administration of Dex was followed by catch-up growth restricted to the
affected limb. According to this model, growth inhibiting conditions of excess GC
reduce the growth and maturation of growth plate stem cells (chondroprogenitors),
and conserve their proliferative potential, whilst also slowing the onset of senescence
(where the proliferative capacity of chondroprogenitor cells is gradually exhausted
causing growth to slow and eventually stop) (Nilsson et al., 2005). Studies using the
ATDC5 chondrocyte cell line have also shown that Dex-treated cells retain the
capacity to re-enter chondrogenesis following the withdrawal of GC (Mushtaq et al.,
2002). Therefore it seems that, although Dex arrests growth and differentiation of
chondrocytes, the capacity for cells to undergo chondrogenesis is maintained in the
presence of GC despite the fact that progenitor cells are quiescent.
1.9 Aims and Strategy
The aim of this project was to investigate and identify novel mechanisms involved in
GC-induced growth retardation at the level of the growth plate chondrocyte. As
previously mentioned, it is now well known that GCs reduce longitudinal growth atChapter 1 Introduction and Literature Review
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the growth plate by inhibiting chondrocyte proliferation and hypertrophy. Therefore,
a large portion of this project will utilise in vitro models of chondrocyte proliferation
such as chondrocyte cell lines engineered to progress through maturational stages of
chondrogenesis and differentiation, primary chondrocytes, and organ cultures.
However, there are obvious limitations to such in vitro studies, and so murine in vivo
studies will also be used in an attempt to gain a better understanding of the
mechanisms involved in GC-induced growth retardation. My specific aims are to:
1) Identify novel GC-responsive chondrocyte genes using Affymetrix Microarray
technology on GC-treated chondrocyte RNA. Genes identified as novel
targets will then be studied in more detail using in vitro functional
experiments.
2) Further characterise the expression and mechanism of action of the GC-
responsive gene, lipocalin 2 in growth plate chondrocytes.
3) Study the effects of the CDKI p21 on GC-induced growth retardation. In order
to do this, I will first carry out preliminary in vitro experiments to confirm
previously reported data. I then plan to carry out a number of in vivo
experiments, in which I will use p21 knock-out mice to examine the role of
p21 in GC-induced growth retardation.
4) Examine the effects of a novel anti-inflammatory compound, AL-438, on
chondrocyte proliferation and bone growth compared to Dex and Pred. This
will be done through both in vitro and in vivo studies.Chapter 2 Materials and Methods
59
Chapter 2
Materials and Methods
Chapter Contents
2.1 Reagents and Solutions
2.1.1 Materials
2.1.2 Buffer Recipes
2.2 Cell Culture
2.2.1 Preparation of cell culture reagents
2.2.2 Isolation of primary cell lines
2.2.3 Maintenance and differentiation of ATDC5 cells
2.2.4 Freezing/Thawing cells
2.3 In vivo methods
2.3.1 Production of transgenic mice
2.3.2 Production of Knock-out Mice
2.3.3 Animal Maintenance
2.3.4 Animal Breeding
2.3.5 Tail Biopsy of Animals
2.3.6 Isolation and culture of embryonic murine metatarsals
2.4 Tissue Processing and Analysis
2.4.1 Paraffin Embedded Tissue
2.4.2 RNAse Free Frozen Tissue
2.4.2.1 Preparation of Hexane Freezing Bath
2.4.2.2 Preparation on polyvinyl alcohol (PVA)
2.4.2.3 Freezing and Cutting of Tissue
2.4.2.4 Cutting Undecalcified Frozen Tissue using the CryoJane Tape
transfer system
2.4.2.5 Laser Capture Microdissection
2.4.3 Immunohistochemistry
2.4.4 Toluidine Blue Staining
2.4.5 Histological Assessment of Bromodeoxyuridine (BrdU) uptake
2.4.6 Alkaline Phosphatase and Von Kossa staining
2.5 RNA Methods
2.5.1 Isolation of Total RNA from Cells and Tissues
2.5.2 Isolation of RNA from LCM samples
2.5.3 Reverse Transcription Polymerase Chain Reaction (RT PCR)
2.5.4 Polymerase Chain Reaction (PCR)
2.5.5 Real Time Quantitative Polymerase Chain Reaction (qPCR)
2.6 DNA Methods
2.6.1 DNA isolation from mouse tail biopsiesChapter 2 Materials and Methods
60
2.6.2 Genotyping transgenic mice
2.6.3 Agarose Gel Electrophoresis
2.6.4 Quantification of DNA Concentration
2.6.5 Restriction Endonuclease Digestion of DNA
2.6.6 DNA Ligation into Linearised Vectors
2.6.7 Isolation of DNA Fragments from Agarose gel
2.6.8 DNA Sequencing
2.6.9 Transformation of bacteria
2.6.10 Liquid Culture of Bacterial Clones
2.6.11 Minipreparation of Plasmid DNA
2.6.12 Endofree Maxipreparation (Qiagen) of Plasmid DNA
2.7 Protein Methods
2.7.1 Protein Concentration Determination – Bradford Assay
2.7.2 SDS Polyacrylamide Gel Electrophoresis
2.7.3 Western Blotting
2.8 Microarray
2.8.1 Hybridisation of RNA to Affymetrix Platform
2.8.2 Microarray Data Analysis
2.9 Cell Proliferation and Differentiation Assays
2.9.1 [
3H]-thymidine Incorporation Assay
2.9.2 Alcian Blue Staining of the Cell Monolayer
2.9.3 Alkaline Phosphatase Assay
2.1 Reagents and Solutions
2.1.1 Materials
All chemicals were purchased from Sigma Aldrich (Dorset,
UK) unless otherwise stated. PCR oligonucleotides were purchased from MWG
Biotech (Ebersberg, Germany), and antibodies were purchased from SantaCruz unless
otherwise stated.
2.1.2 Buffer Recipes
Cell Culture Buffers
Phosphate Buffered Saline (PBS)
140mM NaCl, 2.5mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4
Cell Freezing BufferChapter 2 Materials and Methods
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60% DMEM, 30% FBS, 10% Dimethyl sulfoxide; DMSO
RIPA Buffer
20mM Tris, 135mM NaCl, 10% glycerol, 1% IGEPAL, 0.1% SDS, 0.5% deoxycholic
acid, 2mM EDTA
Bacterial Culture
Luria Broth (LB) media
1% bacto-tryptone, 0.5% bacto-yeast extract, 150mM NaCl, adjusted to pH 7.5
LB agar
LB supplemented with 1.5% bactoagar
Super Optimal Broth with Catabolite repression (SOC) Media
2% bacto-tryptone, 0.5% bacto-yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM
MgCl2, 10 mM MgSO4, 20 mM glucose
Gel Electrophoresis
Tris-Acetate-EDTA (TAE)
40mM Tris, 1mM EDTA, 0.1% acetic acid
Tris-Boric Acid-EDTA (TBE)
90mM Tris, 2mM EDTA, 90mM boric acid
Agarose Gel Loading Buffer
1.2mM bromophenol blue, 50% (w/v) glycerol, 10% (v/v) 10x TAE/TBE
Qiagen Kit Buffer Compositions
Re-suspension Buffer P1
50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 100 μg/ml RNase AChapter 2 Materials and Methods
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Bacterial Lysis BufferP2
200 mM NaOH, 1% SDS
Elution Buffer EB
10 mM Tris-HCl, pH 8.5
Neutralisation Buffer P3
3 M Potassium Acetate, pH 5.5
Equilibration Buffer QBT
750 mM NaCl; 50 mM 3-[N-morpholino] propanesulfonic acid (MOPS), pH 7.0; 15%
isopropanol (v/v); 0.15% Triton X-100 (v/v)
Column Wash Buffer QC
1M NaCl, 50mM MOPS pH7.0, 15% isopropanol (v/v) and 0.15% Triton X-100 (v/v)
Elution Buffer QN
1.6 M NaCl, 50 mM MOPS, pH 7.0, 15 % isopropanol (v/v)
DNA Re-suspension Buffer TE
10 mM Tris HCl, pH 8.0, 1 mM EDTA
PolyAcrylamide Gel Running and Staining Buffers
MOPS Running Buffer
50 mM MOPS pH 7.7, 50 mM Tris, 0.1% SDS, 1mM EDTA
NuPAGE Transfer Buffer
25 mM Bicine pH 7.2 , 25 mM Bis-tris , 1 mM EDTA, 0.05 mM Chlorobutanol
LDS Sample Buffer
10% Glycerol, 141 mM Tris Base, 106 mM Tris HCl, 2% LDS, 0.51 mM EDTA, 0.22
mM SERVA® Blue G250, 0.175 mM Phenol Red, pH 8.5Chapter 2 Materials and Methods
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Western Blotting
Tris-Buffered Saline with Tween 20 (TBST)
10mM Tris HCl pH8.0, 150mM NaCl, 0.1% Tween-20
Blocking Solution
5% (w/v) dried milk protein (Marvel) in TBST
2.2 Cell Culture
2.2.1 Preparation of Cell Culture Reagents
Dulbecco’s Modified Eagle Medium/Ham’s F12 (DMEM: F12), containing 4500g/L
glucose and L-glutamine, was purchased from Gibco (Gibco BRL, Paisley, UK). All
tissue culture reagents were prepared in a sterile category 2 hood. DMEM: F12 was
supplemented with 0.5% of the antibiotic gentamycin (Gibco) and 10% heat
inactivated foetal bovine serum (FBS) (Gibco) before use. All media was filter-
sterilised through a 0.22μM filter and stored at 4C.
2.2.2 Isolation of Primary Cell Lines
Primary chondrocytes were isolated from the rib cages of 2-day-old Swiss mice culled
by cervical dislocation. Chondrocytes were isolated from the ventral parts of the rib
cage in a sterile environment and incubated in a sterile petri dish in pronase (2mg/ml
in PBS) for 30mins at 37
oC whilst shaking. After rinsing in PBS, the rib cage was
incubated in 3mg/ml collagenase in DMEM for 90mins at 37
oC, and repeatedly
pipetted until all soft tissues and mineralised tissues were detached from the cartilage
matrix. The cartilage was washed again and incubated until completely digested (up
to 3hrs) in collagenase (3mg/ml), at which point the suspension was filtered. The
chondrocytes were then pelleted by centrifugation, resuspended in DMEMChapter 2 Materials and Methods
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supplemented with 50g/ml ascorbic acid, and counted in a haemocytometer
chamber. An average of 1x10
6 chondrocytes were obtained per mouse.
Figure 2.1 Isolation of Primary Murine Chondrocytes from the Rib Cage of 3-
day-old Swiss Mice (Arrows = Chondrocytes were isolated from the ventral parts of
the rib cage by digestion in pronase and then collagenase; scale bar = 1mm).
2.2.3 Maintenance and Differentiation of ATDC5 Cells
The ATDC5 cell line established by Atsumi et al. (1990) from the mouse
teratocarcinoma cells AT805, mimics manyof the events described for differentiation
of epiphyseal chondrocytes. This line has less phenotypic diversity than cell cultures
of primary chondrocytes, and also allows the study of the differentiation of
mesenchymal cells into chondrocytes and the terminal differentiation of proliferating
to hypertrophic chondrocytes (Mushtaq et al., 2002). The ATDC5 chondrocyte cell
line was obtained from the RIKEN cell bank (Ibaraki, Japan), and cells were cultured
at a density of 6000 cells per cm
2 in multi-well plates (Costar, High Wycombe, UK).
Maintenance medium (DMEM/Ham’s F12; Invitrogen, Paisley, UK) was
supplemented with 5% FCS (Invitrogen), 3x10
-8M sodium selenite and 10g/ml
human transferrin (Sigma, Poole, UK) and cells were grown until confluent. Adherent
cells were passaged by trypsinisation at sub-confluence. The cell culture media wasChapter 2 Materials and Methods
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removed and the monolayer washed with serum free medium. The cells were then
covered with trypsin/EDTA solution and incubated at 37C until cells became
detached. Growth media containing serum was then added to the cell suspension to
neutralise the trypsin, and the suspension was then pipetted repeatedly to create a
single cell solution, counted using a haemocytometer, and split into fresh flasks.
Differentiation was made by the addition of insulin (10g/ml; Sigma) to the
maintenance medium. Cells were incubated at 37
oC in a humidified atmosphere
containing 5% CO2/95% airand the medium was changed every second day.
2.2.4 Freezing/Thawing Cells
To freeze cells a monolayer was stripped as described in 2.2.3 and counted. The cells
were centrifuged at 717 x g for 5 minutes and resuspended in the appropriate volume
of cell freezing buffer to give a cell concentration of between 2-4 x 10
6 cells per ml.
The cells within a cryovial (Corning, Surrey, UK) were then transferred to a
temperature of -80C for between 4-7 days and then to -150C for longer term
storage. Cells were thawed at 37C and added drop wise to 10ml complete media.
The cell suspension was then mixed and spun at 717 x g for 5 minutes to remove the
DMSO. The cell pellet was resuspended in complete media and transferred to a t175
tissue culture flask.
2.3 In Vivo Methods
2.3.1 Production of Knock-Out Mice
p21
-/- mice were purchased from Jackson Laboratories (Massachussets Institute for
Technology, Massachussets, USA). These mice were originally created by Hannon et
al. (1995) at the Howard Hughes Medical Institute in Cambridge Massachussets. TheChapter 2 Materials and Methods
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method involved generating a null allele in 129/Sv embryonic stem (ES) cells by
replacing the p21 coding sequence with a neomycin-resistance cassette (neo
r).
Homozygous p21
-/- ES cells were produced by subjecting two heterozygous p21
+/- cell
lines to selection in an increased concentration of G418. One p21
-/- ES cell clone was
recovered from each parental p21
+/- line. 129/Sv cells lacking p21 were then injected
into normal B6 blastocysts, creating B6-129/Sv p21
-/- chimaeric mice.
2.3.2 Animal Maintenance
Transgenic mice were produced as described (2.3.2) and non-transgenic mice were
supplied by B&K Universal Ltd, UK. All animals were maintained under
conventional housing conditions with a 12h light/dark cycle where the dark cycle
consisted of 2h night light and 10h of complete darkness.
2.3.3 Animal Breeding
Mice identified as being positive for transgene incorporation (identified by PCR;
section 2.6.2), were selected and bred with non-transgenic C57BL6/CBA stock mice
to expand transgenic lines. Offspring carrying the transgene were maintained and
negative littermates were culled. p21 null mice (strain Cdkn1a
tm1Tyj) were obtained
from the Jackson Laboratory (Maine, USA). Mice identified as being heterozygous
for the p21 null allele were again selected by PCR as described in 2.6.2, and were
bred with other heterozygotes to obtain homozygote null mice for experimental
procedures.Chapter 2 Materials and Methods
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2.3.4 Tail Biopsy of Animals
Animals requiring tail biopsy for genotyping were anaesthetised using halothane and a
1-2cm portion of the tail was removed using a preheated scalpel. By preheating the
scalpel, upon cutting, blood vessels in the tail become cauterised and bleeding is
prevented.
2.3.5 Isolation and Culture of Embryonic Murine Metatarsals
The foetal mouse metatarsal explant culture provides a more physiological model for
studying bone growth. It maintains cell-cell and cell-matrix interactions and the direct
assessment of bone growth and histological architecture can be determined (Scheven
et al., 1991; Coxam et al, 1996). The middle three metatarsals were aseptically
dissected from 18-day-old embryonic Swiss mice that had been killed by decapitation.
The experimental protocol was approved by Roslin Institute’s Animal Users Committee
and the animals were maintained in accordance with Home Office guidelines for the care
and use of laboratory animals. Bones were individually cultured at 37°C in a humidified
atmosphere of 95% air/5% CO2 in 24-well plates (Costar) for up to 12 days. Each well
contained 300μl of α-MEM without nucleosides (Invitrogen) supplemented with 0.2%
BSA Cohn fraction V (Sigma), 0.1mmo/l β-glycerophosphate (Sigma), 0.05mg/ml L-
absorbic acid phosphate (Wako, Japan), 0.292mg/ml L-glutamine (Invitrogen),
0.05mg/ml gentamicin (Invitrogen) and 1.25μg/ml fungizone (Invitrogen).Chapter 2 Materials and Methods
68
Figure 2.2 Murine Metatarsal Dissection from the hind legs of 18-day-old
embryos. The middle three metatarsals are dissected and cultured for up to 12 days at
37
oC.
2.4 Tissue Processing and Analysis
2.4.1 Paraffin Embedded Tissue
Bone tissue was harvested from mice culled by cervical dislocation immediately prior
to use and was trimmed to the required size, before fixation in either 70% ethanol or
4% paraformaldehyde for 24h at room temperature. After removal of the fixative, the
tissue was decalcified in 10% EDTA (pH 7.4) at 4
oC for 4 days, with a change of
EDTA on day 2. The tissue was then washed in dH2O, and placed in 70% ethanol
overnight. The following day, fresh 70% ethanol was added for 30mins, and then
replaced with successive 30min incubations of 80% ethanol (twice), and 95% ethanol
(twice). After a further overnight incubation in 95% ethanol, the tissue was placed in
100% ethanol for two 1h incubations, followed by two 1h incubations in xylene under
a fume hood, before being placed into pre-melted wax for two 1h periods.Chapter 2 Materials and Methods
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Once processed, the tissue was embedded in paraffin wax with a melting point of
60
oC using appropriate sized plastic moulds. The wax blocks were allowed to cool,
and excess wax was trimmed away on the microtome to leave the sample surface
exposed for cutting. Once trimmed, the blocks were cooled on ice for 30mins before
sections of 5μm thickness were cut. The sections were transferred to a 40
oC water
bath and left to soften for 1min before being transferred to a poly-l-lysine coated
microscope slide (VWR International Ltd, Lutterworth, UK). The slides were then
placed in an oven at 50
oC overnight to ensure secure attachment of the sections to the
slide.
2.4.2 RNAse Free Frozen Tissue
2.4.2.1 Preparation of Hexane Freezing Bath
As with paraffin-embedded sections, bone tissue was harvested from mice culled by
cervical dislocation immediately prior to use and was trimmed to the required size
using RNAse free dissection instruments. Tissues were then placed in RNA-later In
order to freeze the tissue, a large glass jar was inserted into a polystyrene base and
filled 1/3 full with 100% ethanol. A small beaker was placed inside the alcohol-filled
jar and dry ice chips were added to the alcohol until a saturated solution was obtained
and the ethanol became viscous. The beaker was then filled with Hexane and the jar
covered for 30mins to allow the hexane bath to cool to -70
oC.
2.4.2.4 Preparation on Polyvinyl Alcohol (PVA)
PVA (Sigma) aids the cutting of frozen mineralised tissue. A 5% solution was
prepared by gradually adding 5g of PVA to 100ml of warm DEPC treated H2O on aChapter 2 Materials and Methods
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heated magnetic stirrer within an extraction hood. The solution was left stirring at a
low heat for 1h, and then allowed to cool.
2.4.2.5 Freezing and Cutting of Tissue
Bone tissue samples were individually dipped in PVA and then immersed in pre-
cooled hexane for 30secs, at which point they were retrieved using forceps treated
with RNAse zap and pre-cooled in dry ice. Tissues were then placed into pre-cooled
self-sealing bags containing a piece of tissue to absorb any remaining hexane. The
tissue was stored at -80
oC until use. Using optimal cutting temperature compound
(Brights, Huntingdon, UK) to attach the tissue to a metal chuck, sections of 10m
were cut at -30
oC (Brights, OT model cryostat), and picked up on poly-l-lysine coated
microscope slides. The sections were then air dried at RT.
2.4.2.6 Cutting Undecalcified Frozen Tissue - CryoJane Tape transfer system
The CryoJane tape transfer system (Instrumedics Inc, St Louis, MO, USA) has been
specifically designed for sectioning tissues that are notorious for losing their
morphology or shredding upon cutting. Undecalcified bone tissue is especially
difficult to cut due to the presence of mineralised tissue, and sections often shred upon
cutting. Sections were cut using this technique by capturing the frozen section on a
cold tape window as it was being cut. The tape window attached-section was then
placed onto an adhesive-coated slide and transferred by applying a flash of ultraviolet
(UV) light through the slide. The UV light polymerises the adhesive layer on the
slide into a hard, solvent-resistance plastic, tightly attaching the section to the slide.
The tape was then peeled away leaving the frozen section tightly bonded to the plastic
layer (Figure 2.4.1).Chapter 2 Materials and Methods
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Figure 2.3 The CryoJane Tape transfer System This system was specifically
designed for cutting tissues such as undecalcified bone which can often tear upon
cutting (www.cryojane.com)
2.4.2.7 Laser Capture Microdissection
Laser capture microdissection (LCM) has been developed to provide a fast one step
method of isolating specific cell populations from a complex heterogeneous tissue.
This technique uses a standard histological tissue section of stained tissue under a
microscope. The section is covered in part by a cap covered with a thermal polymer.
Upon identification of the desired cells a Class IIIb invisible infrared laser is pulsed,
melting the polymer film directly above the cells of interest. The film drips onto the
desired cells in the section, solidifying and retaining the cells when the cap is removed
1. Cutting
After the block is trimmed, a cold
adhesive tape is adhered to the block
face. The tape supports and captures
the section as it is being cut
2. Transfer to Slide
A cold adhesive-coated slide is placed on a
temperature-controlled pad. The adhesive
tape is placed section-side-down on the
adhesive-coated slide, and is laminated to the
adhesive layer using a cold roller.
3. Curing the Adhesive Coating
A flash of ultraviolet light passes through the
slide to polymerize the adhesive layer on the
slide into a hard, solvent-resistant plastic,
tightly anchoring the section to the slide.
4. Removal of Tape
The tape is peeled away leaving the
still frozen section tightly bonded to
the plastic layer.
1
2
3
4Chapter 2 Materials and Methods
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(Figure 2.4). By repeating this process of cell identification and laser pulsing it is
possible to capture a homogeneous cell population from a tissue section. Using the
PixCell II LCM microscope in combination with Arcturus software and CapSure HS
LCM caps (Arcturus), specific cells within frozen sections were captured and the
RNA extracted. Before LCM commenced, a ‘before manipulation’ picture of the
section was taken. The laser was set to the desired size depending on the cell type to
be captured, and then focused to ensure accurate capture. Desired cells were captured
by pulsing the laser and moving the slide platform with the manipulator to guide the
laser over the relevant cells. The LCM cap was removed and an ‘after manipulation’
picture was taken of both the section and the captured cells. Following capture, each
cap was removed and placed in the incubation block, before attaching the CapSure
adapter and a 0.5ml eppendorf. The samples were then stored in a dry environment
until analysis.
Figure 2.4 The Laser Capture
Microdissection Process. Individual cells
are isolated from frozen tissue sections by
pulsing a laser directly over the required
cells, and collecting the cells on the surface
of a specially designed cap containing an
adhesive polymer. Picture from
www.Arcturus.com.Chapter 2 Materials and Methods
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2.4.3 Immunohistochemistry
Paraffin sections were dewaxed in xylene and rehydrated through a graded series of
alcohol solutions as follows; 100% xylene, 2x5mins; 100% ethanol, 2x1min; 70%
ethanol, 1x2mins; 50% ethanol, 1x2mins; tap water, 1x30secs; dH2O, 1x5mins. To
obtain antigen retrieval, samples were submerged in 0.1M sodium citrate for 90
minutes at 70 °C and then washed in PBS. Endogenous peroxidases were blocked by
incubating the sections with 3% hydrogen peroxide (in methanol), followed by 3
washes in PBS. Unspecific protein binding was blocked by normal goat serum (1:5)
diluted in PBS for 30 min at RT. Specific primary antibodies were diluted to the
recommended concentration (Appendix 4) in PBS/5% FCS, and sections were
covered with diluted antibody solution and incubated in a humidified chamber
overnight at 4
oC. Control sections received a similar dilution of normal serum or IgG
specific to the primary antibody used. Following this the sections were washed in
PBS, and incubated with a 1:100 dilution of secondary antibody for 60 min at RT
(Appendix 4). DAB substrate reagent (0.06% DAB, 0.1% H2O2 in PBS) was
incubated for 8 minutes at RT, rinsed in PBS and counterstained with Meyer’s
haematoxylin (Sigma) for 5 min. The sections were dehydrated through alcohols and
mounted in DePeX (DPX) for visualisation under a light microscope.
2.4.4 Toluidine Blue Staining
Toluidine blue is a metachromatic dye that stains cartilage, and is therefore useful for
staining the growth plate, and in particular, defining the proliferative and hypertrophic
zones. Sections were dewaxed through graded alcohols as previously described
(2.4.3), and sections immersed in 1% Toluidine blue in 50% isopropanol for 2mins at
room temperature (RT). The sections were then rinsed twice with isopropanol, andChapter 2 Materials and Methods
74
placed in 2 changes of fresh isopropanol for 30secs each, before being cleared in
xylene for 2mins and mounted in DPX.
2.4.5 Histological Assessment of Bromodeoxyuridine (BrdU) Uptake
BrdU was added to the culture medium of metatarsals for the last 6h of culture. At
the end of the incubation period, the tissue was washed in PBS and fixed in 70%
ethanol, dehydrated, and embedded in paraffin wax. Sections 10µm in thickness were
cut along the longitudinal axis, and chondrocyte nuclei with incorporated BrdU were
detected using an indirect immunofluorescence procedure. Briefly, sections were
denatured with 1.5 m HCl for 30 min before incubation with an antibody to BrdU
(DAKO, Ely, UK; Appendix 4) diluted 1:50 in PBS for 1 h. After washing, the
sections were incubated for an additional 1 h in fluorescein isothiocyanate-labeled
(FITC) goat anti-mouse IgG (Sigma) diluted 1:50 in PBS (Appendix 4). The sections
were finally mounted in PBS/glycerol (Citifluor, Agar Scientific, Essex, UK).
Sections were examined using a Leica BMRB fluorescent microscope, and the total
number of BrdU positive chondrocytes within both the proximal and distal growth
regions was counted. To determine the proliferation index, the total number of BrdU
positive cells were divided by the total area of the metatarsal section.
2.4.6 Von Kossa and ALP Staining
Wax sections (10µm in thickness) were reacted for ALP activity for the demarcation
of the hypertrophic and proliferating zones within the growth plate. This procedure is
a simultaneous coupling azo dye method utilising sodium α-naphthyl phosphate as
substrate for ALP in the presence of fast blue RR (a diazonium salt). When the α-
naphthyl phosphate is hydrolysed by ALP the α-naphthyl couples with the diazoniumChapter 2 Materials and Methods
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salt, forming an insoluble, visible pigment at sites of phosphatase activity. Sections
were dewaxed as previously described (2.4.3), and incubated in sodium barbitone
buffer with fast blue salt for 2mins at 37
oC (100ml sodium barbitone; 400µl 10%
MgCl2, 50mg α-napthylphosphate; 100mg fast blue salt). The reaction was stopped
with 0.1M acetic acid and the sections washed twice with distilled water, and mounted
in aqueous mounting solution. Sections were also stained with von Kossa and
haematoxylin and eosin using standard protocols to identify the zone of cartilage
mineralisation (Mushtaq et al., 2004). This stain is used to detect the presence of
calcium salt deposits in cell monolayers. It utilises silver nitrate in the staining
solution (silver ion carries a positive charge) binding with the anionic (negative
charge) region of the salt (in this case phosphate). As the major calcium salt found in
mineralising cells is calcium phosphate this stain will show regions where crystals of
calcium phosphate (hydroxyapatite) are present. The growth media was removed from
the cell monolayer and the cells washed 3x with distilled H2O. The cell monolayer
was then immersed in 5% silver nitrate for 30 minutes under strong light, this actively
reduces the calcium and replaces it with silver thus creating black deposits. The
monolayer was then washed 3x in distilled H2O and incubated with 2.5% sodium
thiosulphate for 5 minutes to remove unreacted silver ions. The monolayer was then
stored under distilled H2O until a digital image was taken. The sections were then
counterstained and mounted as previously described (2.4.3). Images of the stained
metatarsals were captured and the size of the ALP-negative proliferating zone was
determined (proliferating zone = total length – (hypertrophic zone + mineralizing
zone). The size of the hypertrophic zone was determined by subtracting the von
Kossa stained mineralizing zone from the ALP-positive zone, and the size of the
mineralizing zone was determined directly from the von Kossa-stained sections.Chapter 2 Materials and Methods
76
2.5 RNA Methods
2.5.1 Isolation of Total RNA from Cells and Tissues
Ultraspec RNA isolation reagent was used to isolate RNA from both cell monolayers
and tissues. When isolating RNA from a cell monolayer the cells were scraped
directly in ultraspec (1ml per 25cm
2) and transferred to a nuclease free universal.
Similarly for tissue the dissected organ was immersed in ultraspec (approx 1ml/g
tissue). The tissue/cells were homogenised using an electric homogeniser in five 10-
second bursts. The universal was returned to ice between each of the bursts to prevent
heat build up. The homogenised lysate was then passed though a 25G needle ten times
to ensure the production of a uniform lysate. Chloroform (200l per ml) was added
and vortexed for 15 seconds, the sample was then incubated on ice for 5 minutes,
before centrifuging at 12,000g (4C) for 15 minutes; this separates the sample into
two phases – the upper, aqueous phase and the lower organic phase. The RNA is
contained in the aqueous phase and proteins/DNA in the organic phase. The aqueous
phase was removed and transferred to a sterile tube, and 0.5x the volume of
isopropanol added to the RNA. 50l RNA Tack resin was added to the RNA and
vortexed for 30 seconds. The mixture was spun for 1 minute at 12,000g and
supernatant discarded. The pellet was then washed twice with 75% ethanol by serial
vortexing and centrifugation. The pellet was then left to air dry for 30 minutes. The
RNA was eluted from the resin pellet by the addition of 100l nuclease free H2O. To
each 100l of RNA, 10l 10x DNase 1 Buffer (Ambion, Huntingdon, UK) was added
along with 2.5l RNase inhibitors (Promega, Southampton, UK). This was vortexed
before 5l DNase (Ambion) was added. The RNA was mixed and incubated at 37CChapter 2 Materials and Methods
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for 60 minutes. The DNase was inactivated using 0.2 x the volume of inactivation
reagent (Ambion).
2.5.2 Isolation of RNA from LCM Samples
Using the RNeasy micro extraction kit (Qiagen), 40μl of RLT buffer was placed into
the cap within the eppendorf tube (see section 2.4.2.5) at RT for 30mins. The
cap/eppendorf assembly was then centrifuged at 12000g for 1min, and an additional
35μl RLT buffer added. After addition of 75μl ethanol, the contents were loaded into
an RNeasy MiniElute Spin column (Qiagen),centrifuged at 8000g for 30secs and the
flow-through discarded. The spin column was then washed with 350μl buffer RW1
(Qiagen; 8000g for 30secs) and the flow through discarded. Any contaminating
genomic DNA was removed with the addition of DNase I (80μl; 15mins at RT) to the
spin column. This was then washed through with 350μl buffer RW1 centrifuged at
8000g for 30secs, and the flow through discarded. 500μl of RPE buffer was added to
the spin column and centrifuged (8000g; 30secs), the flow through discarded, and
500μl of 80% ethanol was then passed through the column and discarded (8000g;
2mins). To elute the RNA, 14μl of nuclease-free water was added to the column, and
centrifuged at 12000g for 1min. The RNA was stored at -80
oC until analysis.
2.5.3 RNA Amplification
RNA amplification was carried out using the RiboAmp RNA amplification kit
(Ambion, TX, USA). This procedure consists of reverse transcription with an
oligo(dT) primer bearing a T7 promoter and in vitro transcription of the resulting
DNA with T7 polymerase. This generates hundreds to thousands of antisense RNA
copies of each mRNA in a sample. For first strand cDNA synthesis, the RNA wasChapter 2 Materials and Methods
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mixed with the oligo(dT) primer up to a volume of 12µl and incubated at 70
oC, before
being placed on ice. 8 µl of reverse transcription master mix (2µl 10X First Strand
buffer; 1µl Ribonuclease inhibitor; 4µl dNTP mix; 1µl Reverse Transcriptase) was
added to the cDNA/oligo(dT) mix, and incubated at 42
oC for 2h. For the second
strand cDNA synthesis, 80µl of second strand master mix (63µl NFW; 10µl 10X
second strand buffer; 4µl dNTP mix; 2µl DNA Polymerase; 1µl RNase H) was added
to each 20µl sample, and incubated for 2h at 16
oC. The cDNA was then purified by
equilibrating the cDNA filter cartridge, and adding 250μl of cDNA Binding Buffer to
each cDNA sample. The mixture was applied to an equilibrated cDNA filter
cartridge, and the cartridge washed with 500μl cDNA Wash Buffer. The cDNA was
eluted with 2 x 10μl NFW. To synthesise amplified RNA (aRNA), in vitro
transcription was carried out. Firstly, a 24μl transcription reaction mix was made
containing the following: 4μl T7 ATP solution (75mM); 4μl T7 CTP solution
(75mM); 4μl T7 GTP solution (75mM); 4μl T7 UTP solution (75mM); 4μl T7 10X
reaction buffer; 4μl T7 enzyme mix. This was added to 16μl of the eluted cDNA, and
incubated for 24h at 37
oC. Following this, 2μl DNase I was added to the mix and
incubated for 30min at 37°C, and 60μl of Elution Solution was then added to each
aRNA sample. To purify the aRNA, 350μl of aRNA Binding Buffer and 250μl of
100% ethanol were added to the sample, which was then passed through an aRNA
Filter Cartridge. This was washed with 650μl aRNA Wash Buffer, and the aRNA
eluted with 2 x 50μl 50°C Nuclease-free Water.
2.5.4 Reverse Transcription
Reverse transcriptase is a RNA-dependent DNA polymerase which is encoded by
retroviruses. Their viral function is to copy the viral RNA genome into DNA prior toChapter 2 Materials and Methods
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its integration into host cells. This can be exploited to allow production of DNA
(cDNA) from any RNA template and is known as reverse transcription PCR. The
Superscript - First Strand synthesis system for RT-PCR was used for reverse
transcription (Invitrogen) along with Oligo dT (Roche, East Sussex, UK). 5μg RNA
sample and 500ng Oligo dT were mixed and incubated at 70◦C for 10 min to denature
the RNA, this was subsequently incubated on ice for 1 minute. 2μl 10 x RT buffer,
2mM MgCl2, 10mM DTT and 0.5mM dNTP’s were added to each RNA sample and
mixed, finally 200units (u) Superscript enzyme was added and mixed. The following
PCR cycle was used; 25◦C for 10 min, 42◦C for 50 min and 70◦C for 15 min for
annealing, elongation and termination respectively. The cDNA was stored at -20◦C
until required.
2.5.5 Polymerase Chain Reaction (PCR)
PCR was performed on either cDNA produced from reverse transcription or on
genomic DNA, as a diagnostic tool or to allow the amplification of a gene for
functional studies. In a typical 50l PCR reaction the following quantities of
reactants were used; 0.2 mM dNTP mix (Promega), 5l 10x PCR Buffer (Roche), 5
units Taq polymerase (Roche), 0.5M of the forward and reverse primers, 4l DNA
(at appropriate concentration) and nuclease free H2O up to 50l. This was then cycled
in a ThermoHybaid Px2 Thermal Cycler under the following conditions: 94C for 5
minutes for one cycle, thirty cycles of 94C for 30 seconds 55-60C (depending on
the melting temperature of the primers) for 30 seconds and 72C for 1 minute and
finally one step of 72C for 10 minutes. The PCR products were then run on an
agarose gel, as outlined in section 2.6.3. For all PCRs, Classic 18S (Ambion) wasChapter 2 Materials and Methods
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used as an internal standard (Primer sequences unknown). Because of its invariant
expression across tissues and treatments, 18S ribosomal RNA is an ideal internal
control for RNA analysis.
2.5.6 Quantitative Polymerase Chain Reaction (qPCR)
RNA was isolated by phenol/chloroform extraction and used directly in a quantitative
PCR reaction. The Platinum
® SYBR
® Green qPCR SuperMix Kit (Invitrogen)
method was utilised to allow quantification by fluorescence during the PCR reaction.
Briefly 40l SYBR green mastermix was added to 10ng RNA along with 0.2M of
the required forward and reverse primers. The qPCR reaction was cycled in a
Stratagene Mx3000P qPCR system as follows: 1 cycle of 50C for 2mins, 95
oC for
2mins (RT step), then 45 cycles of 95C for 15secs, 55C for 30secs and 72C for
30secs. Each tissue sample was tested in triplicate and compared to GAPDH RNA
(Primers: forward 5’ TGAGGCCGGTGCTGAGTATGTCG 3’; reverse 5’
CCACAGTCTTCTGGGTGGCAGTG 3’) as an external control which allowed
normalisation of results. An identical PCR was carried out on a dilution series of RNA
using both gene of interest and external to allow estimation of PCR efficiency. The
raw data is in the form of a Ct value which is the cycle number at which the
fluorescence in the tube passed above a predefined threshold. This Ct value is used in
the calculations to show relative differences in gene expression in different samples.
Briefly the difference in Ct values between the gene of interest and the control was
calculated and used to determine relative quantification by expressing the values as 2
-
CT.Chapter 2 Materials and Methods
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2.6 DNA Methods
2.6.1 DNA isolation from mouse tail biopsies
Tail biopsies were carried out on halothane anaesthetised mice, and the tail biopsy
placed into a labelled tube containing 750μl tail digest buffer (0.3M sodium acetate,
10mM TrisHCl pH 7.9, 1mM EDTA pH 8, 1% SDS and 200μg/ml Proteinase K.
Samples were incubated overnight at 37
oC and frozen at -20
oC for storage until
needed. Prior to PCR analysis, samples were centrifuged at 16000g at 4
oC for
15mins, and frozen. This process was repeated twice, and ensured the sodium
dodecyl sulphate (SDS) present in the tail digest buffer was sedimented and did not
interfere with the PCR reaction.
2.6.2 Genotyping Transgenic Mice
PCR reactions were carried out as described in section 2.5.4. Tail digests were spun
at 16000g for 15mins at 4
oC and stored on ice to prevent SDS in the digest buffer
from floating in the supernatant. The supernatant was then diluted 1:10 to minimise
the risk of SDS interfering with the PCR reaction. A master mix containing nuclease-
free H2O, 10xPCR buffer, 2mM dNTP, 25mM MgCl2, 10μM primers and Taq was
made, and 18μl of master mix was added to 2μl of 1:10 diluted DNA. This was then
cycled in a ThermoHybaid Px2 Thermal Cycler under the following conditions: 94C
for 5 minutes for one cycle, thirty cycles of 94C for 30 seconds 55-60C (depending
on the melting temperature of the primers) for 30 seconds and 72C for 1 minute and
finally one step of 72C for 10 minutes. The PCR products were then run on an
agarose gel, as outlined in section 2.6.3Chapter 2 Materials and Methods
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2.6.3 Agarose Gel Electrophoresis
DNA fragments were separated by horizontal agarose gel electrophoresis on 1.5 - 2%
Agarose gels. The gels were produced by dissolving powdered agarose in TAE buffer
by heating to the point of boiling. Ethidium bromide (EtBr) was added to a final
concentration of 0.5g/ml to allow visualisation of the DNA under UV light. The gel
was then poured into a cassette with slot former and allowed to set. The DNA samples
were mixed with loading buffer and loaded onto the submerged gel. The fragments
were separated according to size by applying a voltage of 120V across the gel for 1-2
hours. DNA bands were visualised using a UV transilluminator and photographed
using attached camera.
2.6.4 Quantification of DNA Concentration
DNA concentration was calculated by UV spectroscopy. Readings were taken at
260nm and 280nm. The concentration of DNA was automatically calculated by the
biowave reader using the following equation: A260 x 50 x dilution factor. The ratio of:
A260/ A280gives an indication to how pure the DNA is, proteins have an absorbance at
around A280 therefore the lower the number the less pure the DNA preparation is.
2.6.5 Restriction Endonuclease Digestion of DNA
Digestion of DNA using restriction endonucleases was carried out both as a
diagnostic tool and to allow the formation of a DNA fragment to engineer into
plasmid DNA. Roche restriction endonucleases were used for this process along with
their optimised buffer. A typical 20l digest contained 1g DNA, 1 unit of the
restriction enzyme and 2l 10x reaction buffer, made up to 20l with distilled H2O.Chapter 2 Materials and Methods
83
The restriction reaction was carried out at 37C for 1-2 hours, and 1 unit of each
enzyme was used per 1g of DNA in a 20l reaction.
2.6.6 DNA Ligation into Linearised Vectors
The vector of choice was linearised by restriction enzyme digestion using enzyme
sites contained within the vector multiple cloning site. The insert will also have
complementary sites at either terminus making “sticky ends” for ligation. A molar
ratio of 3:1 insert to plasmid was used for all ligations of this nature. The Roche rapid
ligation kit was used and manufacturer’s instructions followed. Briefly both insert and
vector were diluted in DNA dilution buffer so that the final volume equalled 10l,
reaction buffer (10l) was then added and mixed. Finally 1l DNA ligase was added
to the reaction which was incubated at 4
oC overnight. This ligation mixture was used
directly for transformation of supercompetent SURE 2 cells.
2.6.7 Isolation of DNA Fragments from Agarose gel
DNA was separated as detailed in section 2.6.3. The DNA band was visualised over
UV light (due to EtBr intercalation) and excised using a scalpel blade, taking care to
trim all unstained gel from the slice. The agarose gel slice was weighed and then
subjected to the DNA extraction protocol set out in the QiaQuick gel extraction kit
(Qiagen). Briefly 300l of QG buffer was added per 100mg of agarose and heated to
50C for 10 minutes to dissolve the gel. 100l isopropanol per 100mg agarose was
added to the mixture to help increase the DNA yield. The mixture was then applied to
a spin column and centrifuged at 17,900 x g for 1 minute. This allows the DNA to
bind to the silica membrane of the column. The DNA was then washed with 750lChapter 2 Materials and Methods
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wash buffer (PE) by applying it to the spin column and centrifuging at 17,900 x g for
1 minute. The empty spin column was then spun for an additional minute to remove
traces of ethanol. The DNA was eluted by the addition of 50l buffer EB or nuclease
free H2O and centrifuging at 17,900 x g for 1 minute. The DNA was stored at -20C
until needed.
2.6.8 DNA Sequencing
DNA sequencing was carried out commercially at the DNA sequencing facility at
Dundee University.
2.6.9 Transformation of Bacteria
SURE 2 (Stop Unwanted Rearrangement Events) supercompetent Escherichia coli
cells (E.coli) (Stratagene, The Netherlands) were used for transformations in this
study, due to the fact that these cells have been engineered to lack components of
pathways that cause the rearrangement and deletion of non-standard secondary and
tertiary structures. This property makes these cells ideal for the cloning of DNA
segments that are difficult to clone in conventional E.coli strains. For
transformations, 100l SURE 2 cells were incubated with 2l β-mercaptoethanol on
ice for 10mins. Approximately 20ng plasmid DNA was then added to the cells,
mixed, and incubated on ice for 30mins, at which point the cells were subjected to
exactly 30secs heat shock at 42
oC, before being placed back on ice for a further
2mins. 900μl SOC (Hanahan, 1983) media (Invitrogen, Paisley, UK) was added to
the cells and incubated at 37C for 1 hour with constant agitation. Aliquots of theChapter 2 Materials and Methods
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transformation mixture were spread on LB (Bertani, 2004) agar plates containing
100μg/ml ampicillin and incubated overnight at 37C.
2.6.10 Liquid Culture of Bacterial Clones
Individual colonies were picked from the agar plates of transformed bacteria into a
10ml LB culture media containing 100μg/ml ampicillin. This was incubated overnight
at 37C with constant agitation. 2ml of the bacterial culture was spun at 6,000g and
pelleted bacteria resuspended in 1ml LB containing 50% glycerol. These glycerol
stocks were stored at -20C until required.
2.6.11 Minipreparation of Plasmid DNA
The remaining 8ml of bacterial culture was used for plasmid DNA production
utilising the Qiagen miniprep spin kit (West Sussex, UK). Briefly the 8ml of culture
was spun at 8950 x g for 15 minutes and resuspended in 250μl buffer P1. The cells
were then lysed by addition of 250μl buffer P2, and incubated at room temperature for
5 minutes. The genomic DNA and proteins were precipitated from the lysate by
addition of 350μl buffer N3 and centrifuged at 17,900 x g for 15 minutes to clear the
lysate. The supernatant was centrifuged through a Qiagen column containing a silica
membrane to selectively adsorb plasmid DNA in the high salt buffer. The membrane
was the washed with buffer PE and plasmid DNA eluted by centrifugation at 17,900 x
g with 50μl buffer EB or distilled water.
2.6.12 Endofree Maxipreparation (Qiagen) of Plasmid DNA
Endotoxin-free DNA improves the efficiency of transfection into sensitive or
immunologically active cells, and Endofree Maxi Prep kits remove endotoxinChapter 2 Materials and Methods
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generated from gram-negative bacteria such as E. coli. A 10ml liquid culture was set
up as detailed above and grown for 8 hours at 37°C with vigorous shaking. The 10ml
E. coli culture was then transferred into a flask containing 200ml LB (with 100μg/ml
ampicillin) and grown overnight at 37°C with vigorous shaking. The bacterial cells
were harvested by centrifugation at 6000 x g for 15 min at 4°C. The supernatant was
removed and bacterial pellet resuspended in 10ml buffer P1. The cells were then
lysed through addition of 10 ml buffer P2 which was mixed thoroughly by inverting
and incubated at room temperature for 5 minutes. The genomic DNA, proteins, cell
debris, and SDS were precipitated by addition of 10 ml chilled buffer P3, which was
mixed by inverting 4–6 times. The lysate was poured into the barrel of the QIAfilter
cartridge and incubated at room temperature for 10 min. The lysate was then passed
into a sterile tube and 2.5 ml buffer ER was added to remove endotoxin and incubated
on ice for 30 minutes. The filtered lysate was applied to a QIAGEN-tip equilibrated
with buffer QBT and allowed to enter the resin by gravity flow. The QIAGEN-tip
was washed with 2 x 30 ml buffer QC, and the DNA was eluted by addition of 15 ml
buffer QN and precipitated by the addition of 0.7 volumes of room temperature
isopropanol. This was mixed and centrifuged at 15,000 x g for 30 min at 4°C to pellet
the plasmid DNA. The supernatant was decanted and pellet washed with 5 ml of
endotoxin-free 70% ethanol and centrifuged at 15,000 x g for a further 10 min. The
supernatant was decanted and the pellet left to air dry for 10 min. The DNA pellet was
then re-dissolved in 100μl endotoxin-free buffer TE and stored at -20°C until
required.Chapter 2 Materials and Methods
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2.7 Protein Methods
2.7.1 Protein Concentration Determination – Bradford Assay
The Bio-Rad protein assay kit used is based on the method described by Bradford
(Bradford, 1976). The Bradford protein assay is a simple procedure for determination
of protein concentrations in solutions and utilises the change in absorbance of
Coomassie Blue upon binding to protein. The Bradford protein assay is not sensitive
to interference by chemicals in the lysis buffer, however high concentrations of
detergent do cause anomalies in results. The method employed uses gamma-globulin
as a standard. Nine standards of gamma globulin were prepared ranging from 10μg/ml
to 90μg/ml. 160μl of each standard was pipetted in duplicate into a 96 well plate along
with a buffer blank. The protein that was to be measured was diluted in the same
buffer as gamma-globulin and also added to the individual wells in duplicate. 40μl of
dye reagent concentrate (Bio-Rad, Herts., UK) was added to each well and mixed.
The plate was incubated at room temperature for 5 minutes and the absorbance read at
595 nm. The absorbencies of the samples were compared to a standard curve
generated from the absorbencies from the standards.
2.7.2 SDS Polyacrylamide Gel Electrophoresis (SDS PAGE)
Cells were scraped in RIPA buffer containing 1.6 mg/ml of Complete
® protease
inhibitor cocktail (Roche), and proteins were separated according to weight on Novex
Bis-Tris gels (Invitrogen). The comb was removed from the pre-cast gel and the wells
rinsed with distilled water. The gel was then placed in to a tank filled with 1x MOPS
running buffer (Invitrogen), and the centre of the tank was filled with an anti-oxidant
to maintain reduced proteins their reduced state. Protein samples in 1x LDS sample
buffer (containing DTT reducing agent) were heated to 70C for 15 minutes andChapter 2 Materials and Methods
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cooled on ice. The samples were then centrifuged at 17,900 x g for 30 seconds. The
samples (containing 50g lysate protein) and a pre-stained molecular weight marker
(See Blue plus 2; Invitrogen) were loaded onto the gel, and the gel was run at 200V
for 60 minutes.
2.7.3 Western Blotting
Following electrophoresis, the gel was removed from the cassette and immersed in
transfer buffer. An individual sheet of nitrocellulose membrane was washed in dH2O
for 5mins, and then washed in transfer buffer along with two 3M papers, cut slightly
larger than the gel, and four foam pads. The nitrocellulose was laid on top of the gel
and sandwiched between the two 3M papers, ensuring exclusion of any air bubbles.
This sandwich was placed in the X-blot module (Invitrogen) between the four foam
pads. The module was then clamped onto the gel tank and topped up with ice-cold
transfer buffer. The proteins in the gel were electro-blotted on to the nitrocellulose at
30V for 90 minutes on ice. The nitrocellulose was then blocked for 1h in 5% milk
protein (Marvel) in TBST (blocking solution) at RT to reduce non-specific antibody
binding. The primary antibody was added at an appropriate dilution (Appendix 4) in
blocking solution and incubated at 4
oC, with gentle agitation overnight. The
nitrocellulose was subsequently washed 3 times in 50ml TBST to remove any
unbound antibody, and then incubated at RT for 60 minutes with anti-IgG-peroxidase
diluted in blocking solution (specificity dependent on primary antibody). The blot was
again washed 3 times in 50ml TBST and the immune complexes then visualised by
enhanced chemiluminescence (ECL) (Amersham, Buckinghamshire, UK). This kit
operates using an acridan-based substrate which when in close proximity to
peroxidase releases light. The position of the immune complexes were visualised byChapter 2 Materials and Methods
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exposure of the membrane to ECL film (Amersham), which was subsequently
developed in a Kodak automatic developer. To assess equal loading the proteins on
the blot were stained with Indian ink after alkali pre-treatment, as described by
Sutherland and Skerrit (1986). Briefly the membranes were washed in TBST before
incubation with 0.2M NaOH for 5 minutes. The membrane was then submerged in
10% India ink solution for 120 minutes and finally washed repeatedly in TBST until
only the protein bands were visible.
2.8 Microarray
2.8.1 Hybridisation of RNA to Affymetrix Platform
The fundamental basis of DNA microarrays is the process of hybridisation. Two
DNA strands hybridise if they are complementary to each other, and one or both
strands of the DNA hybrid can be replaced by RNA and hybridisation will still occur.
Affymetrix microarrays use a photolithographic mask to control synthesis of
oligonucleotides on the surface of a chip (Figure 2.5). The masks control the
synthesis of several hundred thousand squares, each containing many copies of an
oligo. For expression analysis, up to 40 oligos are used for the detection of each gene.
From a region of each gene, 11-20 oligos are chosen as perfect matches (PM; i.e.
perfectly complementary to the mRNA of that gene), and another 11-20 oligos are
chosen as mismatch oligos (MM). The MM oligos are identical to the PM oligos
except for at position 13, where one nucleotide has been exchanged to its
complementary nucleotide. The MM oligos will detect non-specific and background
hybridisation, which is important for quantifying weakly expressed mRNAs.
Hybridisation of ATDC5 RNA to the Affymetrix Genechip was carried out at the
Human Genome Mapping Project (HGMP) Gene Service (Cambridge, UK).Chapter 2 Materials and Methods
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Following extraction of total RNA from ATDC5 cells, mRNA was converted to
cDNA using reverse transcriptase and a poly-T primer. The resulting cDNA was
amplified using T7 RNA polymerase in the presence of biotin-CTP, so each cDNA
produced 50-100 copies of biotin-labelled cRNA. The cRNA was then incubated at
94 degrees in fragmentation buffer to produce cRNA nucleotide fragments of 35 to
200 nucleotides in length. These fragments were hybridised to the Affymetrix chip,
and any non-hybridised material washed away. The hybridised biotin-labelled cRNA
was then stained with Streptavidin-Phycoerythrin and washed, and the chip scanned in
a confocal laser scanner. The signal on the chip was then amplified with goat IgG and
biotinylated antibody, before being scanned again. The absolute expression value for
each transcript was then calculated from the combined PM-MM differences of all the
pairs in the probe set by Affymetrix softwareChapter 2 Materials and Methods
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Figure 2.5 Affymetrix Microarray overview. (A) Affymetrix microarray involves
the reverse transcription of total RNA into cDNA. This cDNA then undergoes in
vitro transcription into cRNA, during which point a biotin label is attached. The
labeled RNA is then fragmented, and hybridised to a GeneChip containing thousands
of oligonucleotide probes for specific genes. The hybrisied chip is then washed and
stained, and can then be scanned for the detection of specific genes. (B) Affymetrix
GeneChip showing a hybridised sample. This chip can then be scanned and analysed
for the expression of genes of interest. Diagram taken from www.affymetrix.com.
A
BChapter 2 Materials and Methods
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2.8.2 Microarray Data Analysis
The data obtained from the Affymetrix hybridisation was pre-processed using the
Robust Multichip Analysis (RMA) algorithm in GeneSpring 7.0 (Silicon Genetics,
CA, USA) The Robust Mutichip Analysis algorithm (RMA; Irizarry et al., 2003) is
commonly used to normalise Affymetrix data, and uses the PM value only, ignoring
the expression value obtained for the MM probe. RMA analysis involves calculating
the average background for the entire chip (*BG), and then subtracting this from the
PM of a given probe. Intensity dependent normalisation of this value (PM-*BG) is
carried out, and then log transformed. RMA normalisation is carried out on all probe
pairs within a given set, and a single value is obtained using Tukey’s median
polishing procedure. RMA normalisation is an effective method for normalising
microarray data, as, by ignoring the MM value, less ‘noise’ is produced, therefore
reducing the chance of false positives. The uploaded data was first separated into 2
groups according to treatment type, and then normalised. Measurements of less than
0.01 were set to 0.01, and each chip (i.e. sample) was normalised to the 50
th percentile
(i.e. all of the measurements on each chip were divided by a percentile value of 50%).
Per Chip normalisations control for chip-wide variations in intensity. Such variations
may be due to inconsistent washing, inconsistent sample preparation, or other
microarray production or microfluidics imperfections. Each gene was then
normalised to the control sample. In this normalisation, each gene is divided by the
average intensity of that gene in the control samples. To assess differential gene
expression between treatments, expression values were further filtered by retaining
only those probe sets with a fold change of at least 1.5 in Dex samples compared with
Controls. A two-sample t-test was then carried out, resulting in a list of genes whose
expression was significantly changed by 1.5-fold or more in Dex-treated samples.Chapter 2 Materials and Methods
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2.9 Cell Proliferation and Differentiation Assays
2.9.1 [
3H] Thymidine Incorporation
Chondrocyte proliferation was assessed by incubating the cells with 0.2Ci/ml
[
3H]thymidine (37MBq/ml; Amersham Pharmacia Biotech, Bucks, UK) for the last 2h
of the incubation period. Following removal of the [
3H]thymidine, the cells were
fixed in ice-cold TCA (5%) for 15mins, washed, and lysed in 0.1M NaOH for up to
30mins. Scintillation fluid was then added, and the amount of radioactivity
incorporated into trichloroacetic acid insoluble precipitates was measured using a
scintillation counter.
2.9.2 Alcian Blue Staining of the Cell Monolayer
Proteoglycan synthesis was evaluated by staining with Alcian Blue. In brief, cells
were washed twice with PBS, fixed in 95% methanol for 20 min and stained with 1%
Alcian Blue 8 GX (Sigma) in 0·1 M HCl overnight and rinsed with distilled water.
Alcian Blue-stained cultures were extracted with 1 ml 6M guanidine-HCl for 6 h at
room temperature and the optical density (O.D.) was measured at 630 nm using a
Jenway 6105 spectrophotometer.
2.9.3 Alkaline Phosphatase Assay
Cell layers were rinsed with PBS and lysed with 0·9% NaCl and 0·2% Triton X-100
and centrifuged at 12000g for 15 min at 4
oC. The supernatant was assayed for protein
content and ALP activity as a measure of cell number and chondrocyte differentiation
respectively. The protein content of the supernatant was measured using the Bio-Rad
protein assay reagent (Bio-Rad Laboratories) as previously described (2.7.1). EnzymeChapter 2 Materials and Methods
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activity was determined by measuring the cleavage of 10 mM p-nitrophenyl
phosphate (pNPP) at 410 nm. Total ALP activity was expressed as nmoles pNPP
hydrolysed/min/mg protein.Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
95
Chapter 3
Identification of Novel Glucocorticoid-
Responsive Chondrocyte Genes
Chapter Contents
3.1 Introduction
3.2 Hypothesis
3.3 Aims
3.4 Materials and Methods
3.4.1 Cell Culture
3.4.2 RNA Extraction and Hybridisation to the Affymetrix GeneChip
3.4.3 Data Normalisation
3.4.4 Gene Ontology Analysis
3.4.5 Gene Ontology Enrichment and Functional Annotation
Clustering
3.4.6 Validation of Affymetrix Microarray Data with qPCR
3.5 Results
3.5.1 Microarray Analysis
3.5.2 Identification of Trends in Gene Expression
3.5.3 Validation of Microarray Expression Data
3.6 Discussion
3.7 ConclusionsChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
96
3.1 Introduction
GCs are used extensively for the treatment of autoimmune and inflammatory diseases,
including arthritis, asthma, multiple sclerosis, inflammatory bowel disease and
chronic active hepatitis. In addition, GCs are also used in combination with other
drugs to reduce inflammation associated with leukaemia, and to suppress the immune
system following transplantation. GCs are also used extensively in paediatric practice
for the treatment of chronic inflammatory, autoimmune and neoplastic diseases, and it
is estimated that 10% of children may require some form of GC therapy during
childhood (Warner 1995).
Impairment of childhood growth with GCs was first described over 40 years ago
(Blodgett et al., 1956), and since then, a number of studies in experimental animal
models have also shown that high levels of GCs have a suppressive effect on
longitudinal bone growth (Rooman et al., 1999; Stevens et al., 1999; Silvestrini et al.,
2000).
Multiple mechanisms have been proposed to explain the growth-suppressing effect of
supraphysiological GCs, and it is now known that GCs act locally to inhibit
longitudinal bone growth, suggesting a mechanism intrinsic to the growth plate
(Baron et al., 1992). In rats, GC excess reduces bone growth, probably due to
decreased numbers of proliferating chondrocytes and increased apoptosis of
hypertrophic chondrocytes in the growth plate (Chrysis et al., 2003). These results
are also consistent with the Dex-induced inhibition of chondrocyte proliferation and
cartilage matrix production observed in 12 week old rats in vivo (Annefeld et al.,
1992), and with in vitro models of chondrocyte growth, which show thatChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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pharmacological doses of Dex reduce the proliferation of murine chondrogenic
ATDC5 cells (Mushtaq et al., 2002). GCs have also been shown to promote
apoptosis and reduce proliferation through suppression of the phosphatidylinositol 3-
kinase (PI3K) pathway (Chrysis et al., 2003; Chrysis et al., 2005; Macrae et al.,
2007), and down-regulate chondrocyte marker genes Coll II, Coll X and aggrecan
(Owen et al., 2007; also see 6.5.4). Other GC-target genes that have been recently
identified include C-type natriuretic peptide (Agoston et al., 2006) and vascular
endothelial growth factor (VEGF) (Koedam et al., 2002). The IGF-I/GH system is
also thought to play a major role in GC-regulation of the growth plate and it has been
shown that GCs cause antagonism of growth hormone (GH) secretion and action. It
has also been shown that GCs inhibit pulsatile GH release (Wehrenber et al., 1992;
Giustina et al., 1992; Giustina et al., 1998), reduce GH receptor expression, and
inhibit IGF-I activity (Unterman et al., 1985).
Although many of the molecular factors involved in GC-induced growth retardation
have been identified, a comprehensive understanding of the mechanisms governing
GC effects at the growth plate has not been achieved. The advent of functional
genomics in combination with systems biology and integrative physiology approaches
has equipped us with the tools to overcome some of the challenges associated with
understanding these complex interactions. In this study, comprehensive gene
expression profiling of the murine chondrogenic ATDC5 cell line by Affymetrix
microarray has been used to systematically investigate the modulation of factors that
modulate GC-induced growth retardation. This study identified numerous genes that
undergo significant changes in expression with GCs. One of these genes, lipocalin 2,
was then selected for further functional analysis.Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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3.2 Hypothesis
The hypothesis of this study was that a pharmacological dose of the commonly used
GC, Dex, would up- or down- regulate genes not previously linked with GC-induced
growth retardation at the growth plate.
3.3 Aims
I. Carry out an Affymetrix microarray on Dex-treated ATDC5 cells and identify
novel genes involved in GC-induced growth retardation by gene ontology
analysis.
II. Identify novel pathways involved in growth retardation by bioinformatics
methods such as Functional Annotation Clustering.
III. Confirm changes in expression of selected genes with q-PCR.
3.4 Materials and Methods
3.4.1 Cell Culture
The ATDC5 chondrocyte cell line was obtained from the RIKEN cell bank (Ibaraki,
Japan), and cells were cultured at a density of 6000 cells per cm
2 in differentiation
medium as described in section 2.2.3. ATDC5 cells were differentiated for 15 days,
by which point the cells are considered to be in the chondrocytic phenotype, with the
expression of chondrocyte marker gene aggrecan, and the formation of nodules. At
day 15, the cells were incubated with 10
-6M Dex (Sigma; water soluble) (in
differentiation medium), for 24h, and control cells received differentiation medium
only.Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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3.4.2 RNA Extraction and Hybridisation to the Affymetrix GeneChip
Total RNA was extracted from duplicate control and Dex-treated cultures at 24h
following treatment using the phenol/chloroform extraction method as described in
section 2.5.1. RNA integrity and quantity was assessed using the Agilent 2000 Bio
analyzer system, and RNA samples were subsequently hybridised to the Affymetrix
Mouse Genome 430 2.0 Gene Chip array for 16h (2.8.1). This GeneChip contains
45101 probe sets, and can analyse the expression level of over 39000 transcripts and
variants from 34000 characterised mouse genes. Following hybridisation, the
GeneChip arrays were stained, washed and scanned. Bio analysis, microarray
hybridisation and scanning were completed at the Human Genome Mapping Resource
Centre (HGMP) in Cambridge. A detailed description of the hybridisation protocol
can be found in section 2.8.1.
3.4.3 Data Normalisation
The data obtained from the Affymetrix hybridisation was pre-processed using the
RMA algorithm in GeneSpring 7.0 (Silicon Genetics, CA, USA) (2.8.2). Each gene
was then normalised to the control sample. In this normalisation, each gene is divided
by the average intensity of that gene in the control samples (Figure 3.1). To assess
differential gene expression between treatments, expression values were further
filtered by retaining only those probe sets with a fold change of at least 1.5 in Dex
samples compared with Controls. Due to the fact that there were only 2 replicates per
treatment, a two-sample t-test was carried out for each sample. This test looks for
differentially expressed genes between each condition, and is applied to the mean of
each of the 2 normalised values for each treatment against the baseline value of 0 (in
log scale). (All genes are centred around 0 after normalisation in GeneSpring, whichChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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represents the baseline expression level where genes do not show any differential
expression compared to controls). Therefore, genes associated with a p-value lower
than 0.05 were regarded as statistically significant (i.e up- or down-regulated
compared to an expression baseline of 0). This analysis resulted in a gene list of 96
transcripts, whose expression was significantly changed by 1.5-fold or more in Dex-
treated samples.
Figure 3.1 Line graph of Control and Dex sample data loaded into GeneSpring.
Gene expression values were pre-normalised with the RMA algorithm, and log
transformed. Average gene expression values for control (Con) samples are
represented by the left y-axis and values for Dex samples by the right y-axis.Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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3.4.4 Gene Ontology Analysis
Probe set lists resulting from the comparison of Control versus Dex samples filtered
using a 1.5-fold cutoff were assigned a molecular function with the NetAffx
annotation programme (http://www.affymetrix.com/analysis).
3.4.5 Gene Ontology Enrichment and Functional Annotation Clustering
Gene sets were created using the Functional Annotation Analysis option on the
Database for Annotation, Visualisation, and Integrated Discovery (DAVID; The
National Institute of Allergy and Infectious Diseases) (Dennis et al., 2003). Gene
ontology (GO) is a method for describing (annotating) gene terms, and the most
significant annotated terms can be found by looking at the probabilities that the terms
are counted by chance. This is done by GO enrichment analysis, which gives an
enrichment score associated to each term. A list of the most significant GO terms can
then be created by ordering the enrichment scores.
3.4.5 Validation of Affymetrix Microarray Data with qPCR
Total RNA was extracted from triplicate control and Dex-treated ATDC5 cultures at
24h following Dex (10
-6M) treatment using the phenol/chloroform extraction method
as described in section 2.5.1. RNA quantity and integrity was assessed using the
Bioanalyzer 2000 system (Agilent). RNA samples or blanks (containing nuclease-free
water in place of RNA) were reverse transcribed in 20µl reactions with 200ng random
hexamers and 200U Superscript II reverse transcriptase using the Superscript
preamplification protocol (2.5.4) (Invitrogen). qPCR was performed using the
Stratagene Mx3000P real-time QPCR system (Stratagene, California, USA) as
previously described (2.5.5). Primers were designed using the software programmeChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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Primer3 (Whitehead Institute for Biomedical Research), and were made to span at
least one intron to prevent any amplification from contaminating genomic DNA by
semi-quantitative PCR. Genes selected for further analysis by qPCR were as follows:
Lipocalin 2, Secreted frizzled-related protein 2 (SFRP2), connective tissue growth
factor (CTGF), IGF-I, Lumican, integrin 10, dentin matrix protein 1 (DMP1) and
serum-glucocorticoid regulated kinase (SGCK). Primer sequences are displayed in
Table 3.1, and amplicon locations in Appendix 5. Fold changes were normalised for
the expression of GAPDH, and calculated using the comparative method as
previously described (section 2.5.5).
Table 3.1 Primer sequences for qPCR confirmation of Microarray data
Gene
Name
Forward (5’-3’) Reverse (5’-3’) Amplicon
Size
Lipocalin
2
CAGAAGGCAGCTTTACGATG CCTGGAGCTTGGAACAAATG 134
SFRP TACCACGGAAGCCTCTAAGC CTCGCTTGCACAGAGATGTT 100
CTGF CCACCCGAGTTACCAATGAC GACAGGCTTGGCGATTTTAG 146
IGF-I GTGGACCGAGGGGCTTTTACTT TTTGCAGCTTCGTTTTCTTGTTTG 246
Lumican TGCTCGAGCTTGATCTCTCC CAGTGGTCCCAGGATCTTACA 156
Integrin
10
CTGAGGCTGGTTCACAATGA CGGGAGGCTTCATTCAGTAG 138
DMP1 AAAGTCAAGCTAGCCCAGAGG CCGGTCCCCGTACTCTTAG 129
SGCK GATGGGCCTGAACGATTTTA GAGGAGAGGGGTTAGCGTTC 111
GAPDH TGAGGCCGGTGCTGAGTATGTCG CCACAGTCTTCTGGGTGGCAGTG 302
3.5 Results
3.5.1 Microarray Analysis
Quality control analysis revealed that all RNA samples were of a suitable quality for
hybridisation to the Affymetrix gene chip. Analysis in GeneSpring 6.0 software
demonstrated that from a total of 45101 probe sets, 614 genes were changed by 1.5-
fold or more (Figure 3.2). Significance testing of these genes with student’s t-test
ANOVA analysis then identified 96 genes whose expression was significantly
changed by 1.5-fold or more with Dex treatment (Table 3.1A and B, and Appendix 1Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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for full details of gene ontologies). 82.2% of these genes were significantly up-
regulated with Dex treatment, leaving 17.7% of down-regulated genes in response to
Dex. A distribution of fold differences between Control and Dex samples showed
that the majority of gene expression changes did not exceed 1.5-fold.
Figure 3.2 Scatterplot of Affymetrix micorarray results from GeneSpring
analysis. Analysis in GeneSpring 6.0 software demonstrated that from a total of
45101 probe sets, 614 genes were changed by 1.5-fold or more. Genes to the left of
the outer blue line are up-regulated by 1.5-fold or more, and genes to the right of the
outer blue line are down-regulated by 1.5-fold or more.Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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Table 3.2A Genes significantly up-regulated by 1.5-fold or more with Dex treatment.
Affymetrix
ID
Fold Change Gene Name Assoc. with Bone
Growth/Remodelling
Assoc. with GCs
1427747_a_at 14.53 lipocalin 2 * *
1448550_at 7.98 lipopolysaccharide binding protein *
1428942_at 5.064 metallothionein 2 *
1416125_at 3.877 FK506 binding protein 5
1442025_a_at 3.839 similar to promyelotic leukaemia zfp
1434202_a_at 3.607 hypothetical protein MCG58343
1418187_at 3.583 calcitonin receptor activity modifying
protein
*
1448881_at 3.44 haptoglobin acute phase response *
1416953_at 3.324 connective tissue growth factor *
1425281_a_at 3.19 delta sleep inducing peptide
1423233_at 3.131 CCAAT/enhancer binding protein
delta
*
1449851_at 3.035 chemokine ligand 2
1419874_x_at 2.983 promyelotic leukaemia zinc finger
protein
1420772_a_at 2.893 delta sleep inducing peptide
1422557_s_at 2.847 metallothionein 1 *
1418091_at 2.731 transcription factor CP2 like 1
1440235_at 2.69 Integrin alpha 10 *
1422878_at 2.591 synaptotagmin 12
1416041_at 2.56 serum/glucocorticoid regulated
kinase
* *
1428471_at 2.53 sorbin and SH3 domain containing 1
1450826_a_at 2.508 serum amyloid A 3
1455048_at 2.475 immunoglobulin superfamily
member 2
1423274_at 2.365 DEAD-H
1443745_s_at 2.332 dentin matrix protein 1 *
1426236_a_at 2.32 glutamate ammonia ligase
1422573_at 2.108 AMP deaminase 3
1449254_at 2.02 sectreted phosphoprotein 1
1418269_at 2.005 lysyl oxidase-like 3
1448830_at 2.003 dual specificity phosphatase 1
1417507_at 1.999 cytochrome b-561
1434203_at 1.973 hypothetical protein MCG58343
1438953_at 1.935 c-fos induced growth factor
1435943_at 1.905 dipeptidase 1
1434642_at 1.9 dehydrogenase/reductase member 8
1448842_at 1.894 Cysteine dioxygenase 1
1439755_at 1.837 signal-induced proliferation-
associated 1 like 1
1416383_a_at 1.835 pyruvate carboxylase
1451596_a_at 1.834 sphingosine kinase 1
1424051_at 1.823 procollagen type IV *
1436789_at 1.818 similar to FLJ14166 protein
1460011_at 1.793 cytochrome p450Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
105
Table 3.2A Continued
Affymetrix
ID
Fold Change Gene Name Assoc. with Bone
Growth/Remodelling
Assoc. with
GCs
1452141_a_at 1.788 selenoprotein P
1433832_at 1.782 expressed sequence AI551766
1418932_at 1.768 Interleukin 3
1426195_a_at 1.756 Cystatin C
1422620_s_at 1.736 phosphatidic acid phosphatase 2a *
1422478_a_at 1.668 acetyl coenzyme A synthetase 2
1417936_at 1.666 chemokine ligand 9
1454675_at 1.665 nuclear receptor subfamily 1 group D
1449731_s_at 1.657 nuclear factor of kappa light chain
gene enhancer
1448489_at 1.651 platelet activating factor 2
1447602_x_at 1.646 sulfatase 2 metbolism
1424671_at 1.645 pleckstrin homology domain
containing F
1437820_at 1.642 forkhead-like 18
1451939_a_at 1.635 sushi-repeat containing protein
1435254_at 1.627 plexin B1
1456312_x_at 1.62 Gelsolin
1454849_x_at 1.619 Clusterin
1441926_x_at 1.616 transmembrane inner ear
1430388_a_at 1.615 sulfatase 2 metbolism
1459978_x_at 1.6 similar to FLJ14166 protein
1448321_at 1.6 SPARC related modular calcium
binding 1
1455078_at 1.593 protein pdb:1LBG
1416825_at 1.579 synotrophin acidic 1
1450678_at 1.565 Integrin beta 2 *
1425894_at 1.565 cDNA sequence BC019711
1452296_at 1.554 slit homolog 3
1426947_x_at 1.553 procollagen type IV alpha 2
1417872_at 1.544 Sprouty homolog 1
1428164_at 1.531 nudix type motif 9
1415874_at 1.525 period homolog 1
1420834_at 1.522 vesicle-associated membrane protein
2
1455768_at 1.516 Niemann pick type C2
1437865_at 1.507 spermatogenesis associated 13
1455158_at 1.504 Integrin alpha 3 *
1427038_at 1.501 preproenkephalin 1
1421037_at 1.5 neuronal PAS domain protein 2
1421921_at 1.498 Cysteine protease inhibitorChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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Table 3.2B Genes significantly down-regulated by 1.5-fold or more with Dex treatment
Affymetrix
ID
Fold
Change
Gene Name Assoc. with Bone
Growth/Remodelling
Assoc. with
GCs
1418174_at 2.681 D site albumin promoter binding
protein
1423607_at 2.232 lumican *
1451191_at 1.984 cellular retinoic acid binding protein
II
1423294_at 1.923 CPG2_Human coatomer gamma 2
subunit
1449855_s_at 1.887 ubiquitin thiolesterase
1449486_at 1.876 carboxylesterase 1
1448201_at 1.718 sectreted frizzled-related sequence
protein 2
*
1450243_a_at 1.692 down syndrome critical region gene 1
1428950_s_at 1.664 nucleolar protein 8
1454888_at 1.639 prefoldin 4
1425357_a_at 1.618 cysteine knot superfamily1
1450756_s_at 1.61 cullin 3
1425806_a_at 1.546 SRB7
1417394_at 1.531 Kruppel-like factor 4 (gut)
1431056_a_at 1.529 lipoprotein lipase
1436993_x_at 1.524 four and a half LIM domains1
1437401_at 1.506 IGF-1 * *
3.5.2 Identification of Trends in Gene Expression
The enrichment score tells users how important a specific gene annotation is in terms
of the results obtained from an individual microarray, and therefore, higher
enrichment scores mean that particular gene annotations are biologically more in
mportant. The enrichment score of a gene group is determined from the minus log
transformation on the geometric mean of p-values from the annotation terms
associating with one or more of the gene group members. Of 79 genes up-regulated
in the presence of Dex, 23% were involved in extracellular signalling (Table 3.2A;
Figure 3.3A), and a relatively high enrichment score of 5.1 displayed that extracellular
matrix proteins are important following GC exposure in chondrocytes
Unsurprisingly, 5% of genes were associated with bone formation and remodelling.
An enrichment score of 2.4 confirmed that these genes played an important role in the
cell’s response to GCs. 7% of genes had links with cell-matrix communicationChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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(enrichment score = 2.4), and 5% of genes were associated with cell motility and
adhesion. A number of genes involved in differentiation (12%) and proliferation
(5.5%) were also up-regulated (enrichment scores: 1.9 and 1.4, respectively), as were
genes associated with ion binding (13%; 1.2 enrichment) and membrane proteins
(13%; 1.1 enrichment). Interestingly, a number of genes involved in apoptosis were
also up-regulated (6.8%, 1.1 enrichment) (Figure 3.3A). As a smaller number of
genes were down-regulated with Dex treatment, only 4 gene ontologies were
associated with the gene list produced. Again, extracellular signalling was the most
important ontology after Dex treatment, with 24% of down-regulated genes having
some extracellular signalling association (enrichment score: 1.3) (Figure 3.3B; Table
3.2B). Interestingly, 24% of down-regulated genes had some known enzyme actions
(enrichment score = 1.1), and genes associated with cell metabolism were also
important (34%, enrichment score: 0.7). A number of genes involved in the
development process were also down-regulated (17%), although this ontology was the
least important (enrichment score: 0.25).Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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Figure 3.3 Functional Annotation of up-regulated (A) and downregulated (B)
genes in ATDC5 cells following Dex treatment. In both groups, extracellular
signalling seems to be the most important gene ontology following Dex treatment.Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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Table 3.3A Functional Annotation clustering and enrichment scores for the gene ontology
of genes significantly up-regulated with Dex treatment
Gene Ontology Enrichment Affymetrix ID Gene Name
Extracellular signalling 5.1 1443745_s_at dentin matrix protein 1
1450678_at integrin beta 2
1435254_at plexin b1
1451939_a_at sushi-repeat-containing protein
1423274_at dead/h (asp-glu-ala-asp/his) box polypeptide 26
1427747_a_at lipocalin 2
1448321_at sparc related modular calcium binding 1
1422620_s_at hydrogen peroxide inducible protein 53
1417936_at chemokine (c-c motif) ligand 9
1455768_at niemann pick type c2
1424051_at procollagen, type iv, alpha 2
1430388_a_at sulfatase 2
1418269_at lysyl oxidase-like 3
1448881_at haptoglobin
1455158_at integrin alpha 3
1450826_a_at serum amyloid a 3
1425894_at mas-related gpr, member f
1427038_at preproenkephalin 1
1449254_at osteopontin
1456312_x_at gelsolin
1426195_a_at cystatin c
1454849_x_at clusterin
1438953_at c-fos induced growth factor
1448489_at platelet-activating factor acetylhydrolase 2
1452296_at slit homolog 3 (drosophila)
1416953_at connective tissue growth factor
1426947_x_at procollagen, type vi, alpha 2
1435943_at dipeptidase 1 (renal)
1418187_at receptor calcitonin activity modifying protein 2
1452141_a_at selenoprotein p, plasma, 1
1441926_x_at transmembrane inner ear
Bone formation 2.4 1443745_s_at dentin matrix protein 1
1450678_at integrin beta 2
1448321_at sparc related modular calcium binding 1
1449254_at osteopontin
1416953_at connective tissue growth factor
1424051_at procollagen, type iv, alpha 2
1440235_at integrin, alpha 10
1426947_x_at procollagen, type vi, alpha 2
1428471_at sorbin and sh3 domain containing 1
1438953_at c-fos induced growth factor
1455158_at integrin alpha 3
Cell/ECMcommunication 2.4 1443745_s_at dentin matrix protein 1
1449254_at osteopontin
1452296_at slit homolog 3 (drosophila)
1416953_at connective tissue growth factor
1452141_a_at selenoprotein p, plasma, 1
1438953_at c-fos induced growth factor
1441926_x_at transmembrane inner earChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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Table 3.3A continued
Gene Ontology Enrichment Affymetrix ID Gene Name
Cell motility and
adhesion
2.1 1450678_at integrin beta 2
1452296_at slit homolog 3 (drosophila)
1449254_at secreted phosphoprotein 1
1416953_at connective tissue growth factor
1424051_at procollagen, type iv, alpha 2
1440235_at integrin, alpha 10
1426947_x_at procollagen, type vi, alpha 2
Proliferation 1.4 1451596_a_at sphingosine kinase 1
1450678_at integrin beta 2
1435254_at plexin b1
1422620_s_at hydrogen peroxide inducible protein 53
1449254_at secreted phosphoprotein 1
1419874_x_at, zinc finger and btb domain containing 16
1438953_at c-fos induced growth factor
1449731_s_at nuclear factor of kappa light chain gene enhancer in
b-cells inhibitor, alpha
Differentiation 1.9 1460011_at cytochrome p450, family 26, subfamily b,
polypeptide 1
1443745_s_at dentin matrix protein 1
1450678_at integrin beta 2
1435254_at plexin b1
1449254_at secreted phosphoprotein 1
1419874_x_at, zinc finger and btb domain containing 16
1415874_at sprouty homolog 1 (drosophila)
1438953_at c-fos induced growth factor
1449731_s_at nuclear factor of kappa light chain gene enhancer in
b-cells inhibitor, alpha
1451596_a_at sphingosine kinase 1
1416825_at syntrophin, acidic 1
1452296_at slit homolog 3 (drosophila)
1416953_at connective tissue growth factor
1417872_at four and a half lim domains 1
1454675_at thyroid hormone receptor alpha
1452141_a_at selenoprotein p, plasma, 1
1455158_at integrin alpha 3
1441926_x_at transmembrane inner ear
Ion binding 1.2 1460011_at cytochrome p450, family 26, subfamily b,
polypeptide 1
1416383_a_at pyruvate carboxylase
1448842_at cysteine dioxygenase 1, cytosolic
1419874_x_at, zinc finger and btb domain containing 16
1456312_x_at gelsolin
1423274_at dead/h (asp-glu-ala-asp/his) box polypeptide 26
1424671_at pleckstrin homology domain containing, family f
(with fyve domain) member 1
1451596_a_at sphingosine kinase 1
1448321_at sparc related modular calcium binding 1
1452296_at slit homolog 3 (drosophila)
1416825_at syntrophin, acidic 1
1428164_at nudix (nucleoside diphosphate linked moiety x)-
type motif 9Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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Table 3.3A continued
Gene Ontology Enrichment Affymetrix ID Gene Name
Ion binding (cont.) 1.2 1417507_at cytochrome b-561
1435943_at dipeptidase 1 (renal)
1418269_at lysyl oxidase-like 3
1417872_at four and a half lim domains 1
1422557_s_at metallothionein 1
1428942_at metallothionein 2
1450678_at integrin beta 2
Membrane protiens 1.1 1425894_at mas-related gpr, member f
1435254_at plexin b1
1449254_at secreted phosphoprotein 1
1419874_x_at zinc finger and btb domain containing 16
1456312_x_at gelsolin
1455078_at slingshot homolog 2 (drosophila)
1437820_at forkhead-like 18 (drosophila)
1440235_at integrin, alpha 10
1448489_at platelet-activating factor acetylhydrolase 2
1422620_s_at hydrogen peroxide inducible protein 53
1416953_at connective tissue growth factor
1424051_at procollagen, type iv, alpha 2
1426947_x_at procollagen, type vi, alpha 2
1418187_at receptor (calcitonin) activity modifying protein 2
1418269_at lysyl oxidase-like 3
1428471_at sorbin and sh3 domain containing 1
1454675_at thyroid hormone receptor alpha
1418091_at transcription factor CP2-like 1
1455158_at integrin alpha 3
1451596_a_at sphingosine kinase 1
Apoptosis 1.1 1435254_at plexin b1
1422620_s_at hydrogen peroxide inducible protein 53
1449254_at osteopontin
1419874_x_at, zinc finger and btb domain containing 16
1454849_x_at clusterin
1420772_a_at tsc22 domain family 3
1449731_s_at nuclear factor of kappa light chain gene enhancer
in b-cells inhibitor, alpha
1424671_at pleckstrin homology domain containing, family f
(with fyve domain) member 1
1416041_at serum/glucocorticoid regulated kinaseChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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Table 3.3B Functional Annotation clustering and enrichment scores for the gene ontology of
genes significantly down-regulated with Dex treatment
Gene Ontology Enrichment Affymetrix ID Gene Name
Extracellular signalling 1.3 1423607_at lumican
1437401_at insulin-like growth factor 1
1431056_a_at lipoprotein lipase
1423294_at mesoderm specific transcript
1449486_at carboxylesterase 1
1448201_at secreted frizzled-related sequence protein 2
1425357_a_at gremlin 1
Enzyme action 1.1 1436993_x_at profilin 2
1425806_a_at suppressor of RNA polymerase B
1431056_a_at lipoprotein lipase
1423294_at mesoderm specific transcript
1449486_at carboxylesterase 1
1449855_s_at ubiquitin thioloesterase
Cell metabolism 0.7 1454888_at prefoldin 4
1431056_a_at lipoprotein lipase
1425806_a_at suppressor of RNA polymerase B
1451191_at cellular retinoic acid binding protein ii
1423294_at mesoderm specific transcript
1450756_s_at cullin 3
1417394_at kruppel-like factor 4 (gut)
1418174_at d site albumin promoter binding protein
1449855_s_at ubiquitin thioloesterase
Development 0.25 1437401_at insulin-like growth factor 1
1450243_a_at down syndrome critical region gene 1-like 1
1451191_at cellular retinoic acid binding protein ii
1448201_at secreted frizzled-related sequence protein 2
1425357_a_at gremlin 1
3.5.3 Validation of Microarray Expression Data
From a list of 96 genes, a short-list of 8 genes were chosen for further analysis. The
choice of candidates from the short-list that were initially prioritised for future study
were based on reviews of function, likely relationship to GC action and association
with chondrocytes and bone growth (Figure 3.4). Lipocalin 2 was chosen for the
exceptionally large fold change (14-fold) compared to other genes, and for the fact
that it has previously been shown to be expressed in chondrocytes (Ulivi et al., 2006).
Serum GC-regulated kinase (SGCK) was chosen as it is known to be an important
signalling molecule in growth factor and insulin dependent signalling pathways, and
has previously been shown to be up-regulated in osteoblasts in response to DexChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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(Leclerc et al., 2002). Connective tissue growth factor (CTGF), Lumican, Integrin
α10, and dentin matrix protein 1 (DMP-1) were chosen for their links with growth
plate chondrogenesis, and IGF-I and secreted frizzled-related protein (SFRP) are both
important signalling molecules at the level of the growth plate and in GC actions.
Figure 3.4 GC-responsive chondrocyte genes as determined by Affymetrix microarray
analysis. A short list of 8 genes were chosen for further analysis based on reviews of
function, likely relationship to GC action and association with chondrocytes and bone
growth.
To validate microarray data using independent methods, the genes were analysed for
changes in expression with qPCR. Gene expression patterns for Lipocalin 2, SGCK,
CTGF, IGF-I, Integrin α10, and DMP-1 all mirrored expression patterns observed in
the microarray, with significant fold changes of 42-fold, 2.5-fold, 4.2-fold, -6.5-fold,
4.2-fold and 4.8-fold, respectively (p<0.01) (Figure 3.5). Interestingly, the fold
changes obtained for qPCR analysis were notably higher than those obtained in the
microarray. The expression of Lumican and SFRP were not changed when analysed
by qPCR.Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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Figure 3.5 Validation of microarray results with qPCR analysis. Gene expression
patterns for lipocalin 2, SGCK, CTGF, IGF-I, Integrin α10, and DMP-1 all mirrored
expression patterns observed in the microarray, although the fold-changes in
expression were notably larger with qPCR analysis. All data are expressed as mean 
SEM (n=3 replicates each run in triplicate; ***p<0.001 vs. control samples; **p<0.01
vs. control samples;
N/Snot significant.
3.6 Discussion
Glucocorticoids are the most effective anti-inflammatory agents known. However, in
children, their long-term use leads to growth retardation through a combination of
systemic effects through the GH/IGF axis, and direct effects on the growth plate
(Baron et al., 1992; Ahmed and Mushtaq, 2002). The exact mechanisms by which
GCs exert their effects at the growth plate are still unclear, but may be related to a
reduction in chondrocyte proliferation combined with an increase in apoptosis, in
addition to alterations in IGF-I signalling mechanisms (Mushtaq et al., 2004, Chrysis
et al., 2005). Murine in vivo studies have demonstrated that after one week of Dex
treatment, the total width of the growth plate in 3-week-old mice is significantly
decreased due to a decrease in the width of the proliferative zone (Smink et al., 2003;
Owen et al., unpublished). In addition the murine chondrogenic ATDC5 cell line hasChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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previously been used to show that, in vitro, Dex causes a significant reduction
chondrocyte proliferation and an increase in ALP activity, a known marker of
terminally differentiating chondrocytes (Mushtaq et al., 2002; Owen et al., 2007).
This study provides an extensive profile of the alterations in gene expression that
occur in GC-treated chondrocytes. While some of the disclosed genes have
previously been described as GC-responsive in chondrocytes (IGF-I, SGCK, CTGF),
the response of many others, such as lipocalin 2, SFRP2 and DMP-1 are described
here for the first time.
Microarrays are a powerful method for the global analysis of gene or protein content
and expression, however, due to the fact that the technology is so sensitive to change,
and the fact that such large data sets are produced, it is critical that all steps of the
process are accurately and consistently performed, to maximise the reliability and
significance of results. In addition, the experimental design must take into account
the biological question under study, and should include statistical input to permit the
required level of statistical significance to be obtained. Consequently, experiments
should be well controlled and replicated. In this study, two control replicates and two
Dex replicates were used to identify differentially expressed genes in Dex-treated
ATDC5 cells. Although increasing the replicate number or pooling samples may have
improved the statistical power of the results obtained, changes in gene expression
were confirmed by qPCR, suggesting that the results did not contain a large number of
false positives. However, there is a possiblilty that some interesting genes were
overlooked due to the occurrence of false negatives.Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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In any gene expression analysis, technological problems and biological variation can
make it difficult to distinguish signal from noise (Vingron et al., 2001). A major
caveat of microarray analysis is the generation of large data sets, and the
quantification of expression levels observed for any given chip (Barash et al., 2004).
There are large variations in PM and MM intensities for a probe set (2.8.1), and the
MM is an extremely complex measure of unspecific hybridisation. In addition,
GeneChips can display expression level independent effects at the probe level.
Therefore, it is important that expression levels are scaled before comparing
expression data between GeneChips and between probes on the same chip. Selecting
the correct normalisation algorithm is critical in obtaining robust data, however,
unfortunately, a consensus has yet to be reached regarding the selection of optimal
normalisation algorithms, and there are many different normalisation algorithms
available. The RMA algorithm (2.8.2) is commonly used to normalise Affymetrix
data, and uses the PM value only, ignoring the expression value obtained for the MM
probe. RMA normalisation is an effective method for normalising microarray data,
as, by ignoring the MM value, less ‘noise’ is produced, therefore reducing the chance
of false positives. In this study, data was normalised with the RMA algorithm using
the microarray data analysis programme GeneSpring, and was then filtered for
significant changes in expression of 1.5-fold or more. Higher stringency
normalisation and filtering reduces the frequency of false positives, but can also limit
the amount of meaningful data obtained. It is therefore important to establish a
balance between excluding biologically meaningful data by using restrictive analysis
criteria and using permissive parameters, which could also reduce the biological value
of the data by increasing the number of artefacts. Consequently, although a two-
sample t-test was carried out to determine significant changes in gene expressionChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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compared to baseline values in this study, both the cross-gene error model and
multiple testing corrections were considered too stringent and were not used.
From this analysis, a list of 76 up-regulated and 19 down-regulated genes were then
annotated and clustered according to function. Traditional microarray analysis
methods are useful for the identification of probe sets exhibiting transcriptional
responses to Dex-treatment, but are limited in certain capacities. Alternate statistical
methods such as student’s t-tests produce transcript lists that, while effectively
reducing the dimensionality or sample size of the data set, can increase the rate of
false negatives. In addition, Gene Ontology annotations alone are not always
sufficiently robust to detect differences in the representation of specific molecular
categories. Accordingly, it can be difficult to grasp a clear concept of the central
pathways and biological categories affected by Dex treatment. Functional annotation
clustering is an algorithm that is designed to effectively evaluate the effect of a
specific experimental condition on known biological pathways and functional
categories. These analyses show whether a given treatment (e.g. Dex stimulation)
results in enrichment of genes sets involved in the regulation of a specific phenotype.
Enriched gene sets were identified for both up- and down-regulated transcripts.
The highest correlation for both the up- and down-regulated Dex phenotype was
extracellular signalling, which contained 32 and 7 genes, respectively. Interestingly, a
recent paper studying the effect of irradiation on the expression of genes within the
growth plate has also found that extracellular signalling genes are up-regulated in both
the proliferative and hypertrophic zones following irradiation (Zhang et al., 2007).
The authors hypothesise that this is due to the premature terminal differentiation ofChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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proliferating chondrocytes following irradiation, and results in increased matrix
production. The theory that GCs cause premature differentiation of chondrocytes has
previously been postulated (Mushtaq et al., 2002), and would explain the reduction in
proliferation and increase in alkaline phosphatase activity commonly observed in GC-
treated chondrocytes (Mushtaq et al., 2002; Owen et al., 2007). The finding that a
large number of up-regulated genes were also associated with differentiation also
supports this hypothesis. Not surprisingly, genes involved in bone formation and
remodelling were important in the response to Dex-treatment, and a large number of
genes involved in apoptosis were also up-regulated. A number of previous studies
have shown that GCs increase chondrocyte apoptosis in vitro and in vivo, although
this response seems to vary between cell types. In the HCS2-8 cell line, Dex
increased apoptosis partly by suppression of the Akt-(PI3K) signalling pathway
(Chrysis et al., 2004), and in ATDC5 cells in the terminally differentiated phenotype,
Dex increased apoptosis, although no increases were observed during the proliferative
phase (Mushtaq et al., 2002). In pre-pubertal mice treated daily with Dex for 7 days,
TUNEL staining displayed a significant increase in apoptotic hypertrophic
chondrocytes (Smink et al., 2003). Although functional annotation clustering is a
useful method for extracting meaningful data from microarrays, it does have some
limitations. The enrichment score obtained in functional annotation clustering is a
measure of the importance of a particular annotation term within a gene group,
however, due to the complexity of biological systems, this score is only a guideline
and should be used in combination with the expected biology for the samples in
question.Chapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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Following data analysis, a short-list of 8 genes were chosen for further study based on
links with bone tissue or GC action. The Wnt-antagonist SFRP-2, the proteoglycan
Lumican, and IGF-I were all down-regulated by Dex, although only IGF-I was
confirmed as being down-regulated after qPCR analysis. Variations in results
between microarray and qPCR analysis have been widely reported and is caused by a
number of factors including the microarray normalisation technique used,
measurement of spot intensity in the microarray, and tissue preparation between
experiments (Morey et al., 2006). The IGF-I signalling system is one of the major
regulators of endochondral ossification, and previous studies have shown that GCs
reduce IGF-I mRNA in growth plate chondrocytes (Luo et al., 1989), and inhibit basal
and IGF-I induced DNA synthesis (Itagane et al., 1991). It has been suggested that
some skeletal effects of GCs may be mediated via decreased IGF-I expression, with
reduced expression of IGF-I, IGF-I receptor and growth hormone receptor in GC-
treated chondrocytes (Jux et al., 1998, Klaus et al., 2000). Interestingly however,
work at the Roslin Institute previously shown that IGF-I ameliorates Dex-induced
growth retardation in murine metatarsal cultures (Mushtaq et al., 2004), suggesting
that IGF-I may in fact have a protective role against GC in the growth plate.
Up-regulated genes included CTGF, integrin α10, lipocalin 2, SGCK, and DMP1.
CTGF is a secreted, extracellular matrix-associated protein that regulates diverse
cellular functions in different cell types, and is a critical growth factor for chondrocyte
proliferation and differentiation. Endogenous overexpression of CTGF in human
chondrocytic HCS-2/8 cells, achieved by using recombinant adenoviruses that
generated CTGF mRNA, resulted in enhanced cellular proliferation and expression of
aggrecan and type X collagen (Nakanishi et al., 2000). It also increased theChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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proteoglycan synthesis and gene expressions of aggrecan and collagen type II, in
maturing HCS-2/8 cells. Furthermore, CTGF overexpression effectively stimulated
the gene expression of collagen type X, a marker of chondrocyte hypertrophy, in RGC
cells in over-confluent culture where the cells were in the prehypertrophic stage
(Nakanishi et al., 2000). Moreover, the CTGF overexpressing HCS-2/8 cells
stimulated ALP activity, a marker of calcification, and indeed induced matrix
calcification of HCS-2/8 cells in culture (Nishida et al., 2002). In another study,
during the healing of experimental bone fracture, CTGF was expressed in periosteal
cells and hypertrophic chondrocytes (Kanaan et al., 2006). These results indicate that
CTGF directly promotes the proliferation and differentiation of growth cartilage cells
toward endochondral ossification. Interestingly, in this study, CTGF expression was
increased with Dex, which is a known inhibitor of chondrocyte proliferation both in
vitro and in vivo, a finding which contradicts the hypothesis that CTGF is a promoter
of chondrocyte proliferation. However, CTGF has previously been shown to be
upregulated by Dex in both the chondrocytic HCS-2.8 cell line (Kubota et al., 2003),
and in primary chondrocytes (James et al., 2007), and interestingly, a recent study has
shown that CTGF is upregulated in growth plate chondrocytes undergoing recovery
following irradiation (Wang et al., 2007). This finding, along with the fact that both
Dex and irradiation cause an increase in the expression of other ECM components,
suggests that both treatments are working in a similar way to cause growth retardation
at the level of the growth plate.
Chondrocyte function crucially depends on the interaction of chondrocytes with the
surrounding ECM. These interactions are primarily mediated by members of the
integrin family of cell surface receptors. The up-regulation of integrin α10 suggestsChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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that these receptors in particular are important in the chondrocyte response to GCs.
Expression of integrin alpha10 is initiated at the beginning of chondrogenesis and
continues throughout cartilage development in adult cartilage (Wenke et al., 2006). It
has recently been shown that Integrin 10 null mice display growth retardation due to
increased apoptosis of growth plate chondrocytes (Bengtsson et al., 2005). The
finding that Dex induces Integrin 10 expression has previously been unreported, and
provides a novel target for investigation in GC-induced effects.
Closer examination of the genes contributing to the enrichment scores for the
extracellular signalling gene set revealed that DMP1 was the top ranking gene.
DMP1 belongs to the SIBLING family of matrix molecules and has been linked to
chondrocyte differentiation. A study analysing the skeletal phenotype of DMP(-/-)
mice found that their long bones were shorter and wider, with highly expanded
growth plates (Ye et al., 2005). This phenotype appeared to be due to increased cell
proliferation in the proliferating zone and reduced apoptosis in the hypertrophic zone.
Interestingly, a recent paper documenting an Affymetrix microarray of GC-treated
primary chondrocytes also found that DMP-1 was the top ranking gene when
analysing gene enrichment for extracellular signalling (James et al., 2007), suggesting
that DMP1 plays an important role in GC-induced growth retardation.
SGCK is a serine kinase that has a catalytic domain homologous to that of Akt, and
can be activated by PI3 Kinase, making it an important signalling molecule in growth
factor and insulin dependent signalling pathways. SGCK has been shown to play an
important role in the maintenance of cells within the cell cycle, by phosphorylating
and consequently inhibiting the activation of Foxo3a, a member of the ForkheadChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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family of transcription factors (Brunet et al., 2001). Under normal circumstances,
Foxo3a targets the activation of the CDKI p27, causing cells to exit the cell cycle and
progress towards terminal differentiation and apoptosis. By inhibiting Foxo3a
activity, SGCK causes the cells to continue proliferating, indicating that SGCK is a
regulator of cell survival (Tessier et al., 2006). The role of SGCK as a stress response
protein has been widely reported. A variety of environmental stresses such as UV
irradiation, heat shock, oxidative stress, and hyper-osmotic stress induce SGCK
protein levels through the p38/MAPK pathway and SGCK phosphorylation through
the PI3K pathway in non-tumourigenic mammary epithelial cells (Leong et al., 2003).
SGCK has previously been shown to be upregulated in osteoblasts in response to Dex
(Leclerc et al., 2004), however, there have been no previous reports of SGCK
expression within the growth plate. The fact that SGCK expression is increased in
response to environmental and toxicological stresses, and inactivates proteins
involved in the exit from the cell cycle, suggests that SGCK may be acting as a
survival factor in response to Dex in this study.
From a list of 79 genes up-regulated following Dex treatment, lipocalin 2 expression
was increased by the greatest amount in this study (14-fold microarray response and
40-fold qPCR response). Lipocalin 2, also known as Neutrophil-associated gelatinase
lipocalin (NGAL), was originally identified as a 25kDa protein which binds to small
lipophillic substances such as bacteria-derived lipopolysaccharide (LPS), and is
thought to act as a modulator of inflammation. It has been shown to be expressed in
the liver, spleen, lung, muscle, heart and tibia of embryonic mice (Garay-Rojas et al.,
1996; Ulivi et al., 2006). Within the tibia of embryonic rats, the rat homologue of
lipocalin 2, neu-related lipocalin (NRL) is localised to the prehypertophicChapter 3 Identification of Novel GC-Responsive Chondrocyte Genes
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chondrocytes (Zerega et al., 2000). Differences in lipocalin 2 expression between
adult and foetal tissue have previously been described (Garay-Rojas et al., 1996) and,
as lipocalin 2 is known to induce the differentiation of mesenchymal cells to epithelial
cells (Yang et al., 2002), a role for lipocalin 2 in the control of cellular differentiation
has been proposed (Ulivi et al., 2006).
3.7 Conclusions
As previously mentioned, it has been hypothesised that Dex may cause growth
retardation by causing premature differentiation of proliferative chondrocytes within
the growth plate. This hypothesis is supported by the finding that Dex causes an
increase in the expression of ECM genes, such as CTGF and DMP1, and an increase
in ALP activity (Mushtaq et al., 2002; Owen et al., 2007). The fact that lipocalin 2 is
known to induce differentiation and reduce proliferation (Yang et al., 2002;
Devireddy et al., 2001) suggests that increased lipocalin 2 expression is a possible
mechanism for GC-induced growth retardation. The expression of lipocalin 2 in
response to Dex, and the effect of lipocalin 2 on chondrocyte dynamics requires
further study.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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4.1 Introduction
The mechanisms by which GCs exert control over chondrocyte dynamics are
presently unclear. It is likely that GCs affect a wide range of complex regulatory and
signalling networks involving cell-matrix and intercellular interactions to mediate
chondrocyte proliferation and differentiation. In Chapter 3, Affymetrix Microarray
gene expression profiling of ATDC5 cells was used to identify novel glucocorticoid-
responsive chondrocyte genes in an attempt to further our understanding of the
processes involved in GC-induced growth retardation. It was confirmed that CTGF,
Integrin 10, DMP-1, SGCK, and lipocalin 2 were upregulated by Dex in ATDC5
cells. One gene in particular, lipocalin 2, stood out due to the fact that it was up-
regulated by 40-fold in the presence of Dex, and was therefore selected for further
analysis.
Lipocalin 2 was originally identified as an acute phase protein released in the immune
response, and is a member of the lipocalin family of binding proteins. Members of
this family are typically small secreted proteins which are characterised by a range of
different molecular-recognition properties: their ability to bind small, principally
hydrophobic molecules (such as retinol); their binding to specific cell-surface
receptors and their formation of macromolecular complexes. The lipocalins are a large
and ever-expanding group of proteins exhibiting great structural and functional
diversity, both within and between species. Although they have, in the past, been
classified primarily as transport proteins, it is now clear that members of the lipocalin
family fulfil a variety of different functions (Table 4.1) These include roles in retinol
transport, olfaction, pheromone transport, immune responses and the enzymaticChapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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synthesis of prostaglandins. In addition the lipocalins have also been implicated in
the regulation of the immune response and the mediation of cell homoeostasis.
Table 4.1 Lipocalin protein family members and known functions
Name Abbreviation Common Names and
Acronyms
Known Functions References
Extracellular
fatty acid-
binding lipocalin
Ex-FABP Ch21, P20K, quiescence-
specific protein
Mediator of cell cycle
regulation
Bedard et al., 1989;
Flower 1994
Retinol-binding
protein
RBP serum retinol binding
protein
Sole retinol transporter in
plasma from liver to
peripheral tissues
Blomhoff et al.,
1990
β-Lactoglobulin  Βlg  BLG  Major component of whey 
from milk, may be a carrier of
insoluble molecules from
mother to child
Said et al., 1989;
Hambling et al.,
1992
Glycodelin Glc pregnancy protein 14,
human pregnancy-
associated endometrial
protein, α2-globulin, α-
uterine protein
Major component of rat urine;
pheromone transporter
Roy et al., 1966;
Roy et al., 1983
Apoplipoprotein
D
apoD apocrine secretion
odour-binding protein
(ASOB2)
Cholesterol metabolism;
mediator of proliferation and
differentiation
Francone et al.,
1989; Lopez-
Boado et al., 1994
Epididymal
retinoic acid-
binding protein
E-RABP B/C protein, epididymal
secretory protein (ESP1),
lipocalin 5
Sperm maturation, epididymal
function
Ong et al., 2000;
Fouchecourt et al.,
2003
Odourant
binding protein
OBP frog Bowman's gland
protein
Odour molecule transporter Lee et al., 1987;
Cavaggionni et al.,
1987; Snyder et al.,
1988
Tear prealbumin TP protein migrating faster
than albumin, specific
tearalbumin, tear
lipocalin, lipocalin 1,
LCN1
Scavenger of hydrophobic
harmful molecules and
bacterial growth inhibitor;
present in tears
Fluckinger et al.,
2004
Probasin PB pM-40 Cell cycle regulation Matuo et al., 1984;
Spence et al., 1989
Prostaglandin D
synthase
PGDS β-trace Synthesises prostaglandin D2
(major neuromodulator) in the
brain
Urade et al., 1989;
Nagata et al., 1991
Neutrophil
gelatinase-
associated
lipocalin
NGAL SIP24, 24p3,
uterocalin, Neu-related
lipocalin, lipocalin 2
Acute phase protein released
in the immune response and
after partuition
Hraba-Renevey et
al., 1989; Meheus
et al., 1993; Lui et
al., 1995Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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Despite common characteristics and common functions, the lipocalin family has been
defined largely on the basis of structure and sequence. In contrast with their low
conservation at the sequence level, analysis of available lipocalin crystal structures
shows that the overall folding pattern common to the lipocalins is highly conserved
(Figure 4.1). The lipocalin fold is a highly symmetrical all-β protein dominated by a
single eight-stranded antiparallel β-sheet closed back on itself to form a continuously
hydrogen-bonded β-barrel, which, in cross-section, has a flattened or elliptical shape
and encloses an internal ligand-binding site (Goetz et al., 2000). The eight β-strands
of the barrel are linked by a succession of loops. These seven loops, are all typical of
short β-hairpins, except loop L1 which is a large Ω loop which forms a lid folded back
to partially close the internal ligand-binding site found inside the closed barrel (Figure
4.2).
Figure 4.1 Crystal structure of the human homologue of lipocalin 2, neutrophil
gelatinase associated lipocalin (NGAL). The crystal structure of NGAL displays a
single eight-stranded continuously hydrogen-bonded antiparallel β-barrel, which
encloses an internal ligand-binding site. β-strands are shown as smoothly curving
arrows, and α-helices are shown as spiral ribbons. Fatty acid ligand molecules are
shown using a coloured all-atom representation. From Goetz et al., 2000Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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Figure 4.2 Characteristic features of the lipocalin fold. An unwound view of the
lipocalin fold orthogonal to the axis of the barrel. The eight β-strands of the
antiparallel β-sheet are shown as arrows and labelled A-H. The N-terminal helix (N)
and C-terminal α-helix (labelled A1) are also marked. The hydrogen-bonded
connection of two strands is indicated by a pair of dotted lines between them.
Connecting loops are shown as solid lines and labelled L1-L7. The two ends of the β-
barrel are topologically distinct. One end has four β-hairpins (L1, L3, L5 and L7) and
is called the ‘open end’ as the internal ligand-binding site is located here. The other
has three β-hairpin loops (L2, L4 and L6). At this section, the N-terminal polypeptide
chain crosses the end of the barrel to close it, and is therefore termed the closed end of
the molecule. Adapted from Flower et al., 1996.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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Lipocalin 2 is a secreted glycoprotein that was identified and characterised in
quiescent Balb/c3T3 cells in the late 1980’s. Originally known as superinducible
protein 24 (SIP24), its expression can be induced by a number of factors including
serum, FGF, prostaglandin F2a, phorbol ester, and Dex. It is also a major secretory
protein of cultured mouse macrophages which have been stimulated with
lipopolysaccharide (LPS) (Meheus et al., 1993). Lipocalin 2 is the protein product
of the murine gene named 24p3, whose cDNA was originally cloned from mouse
kidney primary cell cultures (Hraba-Renevey et al., 1989). The role of Lipocalin 2 in
inflammation was further hypothesised when it was discovered that lipocalin 2 knock-
out mice had increased susceptibility to infection (Berger et al., 2006) and as lipocalin
2 is known to induce the differentiation of mesenchymal cells to epithelial cells (Yang
et al., 2002), a role for lipocalin in the control of cellular differentiation has also been
proposed (Ulivi et al., 2006).
The tissue expression of lipocalin 2 has been well documented, and it has been shown
to be expressed in the liver, spleen, lung, muscle, heart and tibia of embryonic mice
(Garay-Rojas et al., 1996; Ulivi et al., 2006). Within the tibia of embryonic rats, the
rat homologue of lipocalin 2, neu-related lipocalin (NRL), is localised to the
prehypertophic chondrocytes (Zerega et al., 2000), and in cultured MC615
chondrocytes, lipocalin 2 expression is detected in hypertrophic chondrocytes only
(Ulivi et al., 2006). Lipocalin 2 has previously been shown to be regulated by Dex in
a number of cell types (Garay-Rojas et al., 1996; Vizzardelli et al., 2006), however,
it’s stimulation in ATDC5 cells has not previously been reported, and may provide a
novel mechanism for GC-induced growth retardation in chondrocytes.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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4.2 Hypothesis
The hypothesis of this study was that the acute-phase binding protein lipocalin 2 could
mediate the effects of Dex on growth plate chondrocytes, therefore providing a
potential novel mechanism for GC-induced growth retardation.
.
4.3 Aims
I. Characterise lipocalin 2 expression in ATDC5 cells and primary
chondrocytes through timecourse and dose response experiments.
II. Confirm increases in lipocalin 2 expression are GR dependent and do not
involve the synthesis of other proteins.
III. Investigate the involvement of the p38 and NFκB signalling pathways in 
Dex-induced lipocalin 2 expression.
IV. Analyse the effect of lipocalin 2 over-expression on chondrocyte dynamics
through stable transfection of ATDC5 cells.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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4.4 Materials and Methods
4.4.1 Cell Culture
The ATDC5 chondrocyte cell line was maintained and differentiated as previously
described (Section 2.2.3) for 8 days, at which point Dex (final concentration 10
-6M)
was added to the cells for the stated period. Control cells received vehicle only. Total
RNA was extracted from chondrocytes as previously described (2.5.2). The protein
synthesis blocker, cycloheximide (CHX; 8g/ml), and the GC-receptor antagonist
RU486 (10
-5M) were added to ATDC5 cells to investigate the mechanisms involved
in Dex-induced lipocalin 2 expression, and the involvement of the p38/NFB pathway
was assessed using specific inhibitors of p38 (SB203580; 20M; Calbiochem, CA,
UAS) and NFB (TLCK; 0.5 - 50M (Sigma); SN50; 18μM, Calbiochem).
Recombinant lipocalin 2 was added to the cells at a range of concentrations (5-
20g/ml; R&D Systems, Abingdon, UK) to analyze the effect of lipocalin 2 on cell
proliferation.
4.4.2 QPCR
QPCR was used to confirm changes in the expression of selected genes. ATDC5 cells
at day 8 of culture were incubated with 10
-6M Dex for 1h to 7-days and RNA
extracted as previously described (2.5.2). RNA samples or blanks (containing
nuclease-free water in place of RNA) were reverse transcribed in 20µl reactions with
200ng random hexamers and 200U Superscript II reverse transcriptase using the
Superscript preamplification protocol as previously described (2.5.4) (Invitrogen).
qPCR was performed using the Stratagene Mx3000P real-time QPCR system as
previously described (2.5.6) (Stratagene, California, USA). Primers were designed
using the software programe Primer3 (Whitehead Institute for Biomedical Research),Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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and were made to span at least one intron to identify any amplification from
contaminating genomic DNA by semi-quantitive PCR (See Appendix 5). cDNA (10ng)
derived from each of 3 control and 3 Dex treated cultures at each time point was
amplified in triplicate using the Platinum SYBR Green qPCR SuperMix (Invitrogen,
Paisley, UK) under the following conditions: cDNA was denatured for 2 minutes at
95
oC, followed by 40 cycles consisting of 15 s at 95
oC and 30 s at 60
oC and 1 cycle
consisting of 1 min at 95
oC and 30 s at 60
oC. Each reaction contained 10l cDNA,
25l Platinum SYBR Green qPCR Super-Mix, 1l ROX Reference Dye, and 250nM
primer in a total volume of 50l. A dilution series of both gene of interest and external
control (GAPDH) were carried out and subjected to an identical PCR to allow estimation
of PCR efficiency, and fold changes normalised for the expression of GAPDH, were
calculated using the comparative method (Livak et al., 2001).
4.4.3 p38 MAP Kinase Assay
The nonradioactive p38 MAPK assay (Cell Signalling Technology, Boston, USA)
was used to determine the level of active p38 in SB203580 treated ATDC5 cells
according to the manufacturer’s instructions. Briefly, treated cells were lysed and p38
MAPK was immunoprecipitated from the lysate using beads coated with phospho-p38
MAPK (Thr-180/Tyr-182) monoclonal antibody overnight at 4
oC with constant
agitation. After washing in the lysis buffer and kinase buffer provided, the
immunoprecipitated p38 MAPK was incubated for 30min at 30
oC in kinase buffer
containing 200M ATP and 2g of GST-ATF-2 fusion protein as substrate. The
reaction was terminated by adding 2x Laemmli buffer and heating the samples to
95
oC for 5min. The samples were separated on a 4-12% SDS-PAGE gel andChapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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immunoblotted for phosphorylated ATF-2 and total p38 MAPK (Cell Signalling
Technology).
4.4.4 Western Blotting
Cells were lysed in RIPA buffer as previously described and amount of protein
quantified using the Bradford assay as previously described (2.7.1). Protein lysates
(15g) were loaded onto 10% Bis-Tris Gels, fractionated and electroblotted onto
nitrocellulose membranes (2.7.2). After blocking with 5% non-fat milk powder and
0.1% Tween, the membranes were incubated overnight with Anti-Lipocalin 2 primary
antibody (1:500; R&D Systems) at 4
oC, washed and incubated at room temperature
for 1h with rabbit anti-goat peroxidase labelled secondary antibody (1:2000; DAKO,
Cambridge, UK). Beta-actin expression was also measured as a loading control (anti
beta-actin clone AC15; Sigma A5441; 1:5000) on membranes stripped with Stripping
Reagent (Pierce, IL, USA) for 1.5h at RT. The immune complexes were then
visualised by enhanced chemiluminescence (ECL) (GE Healthcare, Buckinghamshire,
UK) (2.7.3).
4.4.5 Histological Analysis of Lipocalin 2 Expression in the Growth Plate
Tibiae were dissected from 10-day-old and 5-week-old saline and Dex treated mice
(5mg/kg Dex daily for 7 days), that had been euthanised by cervical dislocation.
Metatarsals were dissected from 17-day-old normal foetal mice euthanised by cervical
dislocation. The tissues were then processed as previously described (2.4.1), and
sections cut at 6μm. For histological analysis, sections were dewaxed and demasked
for 30min in 10mM citrate buffer, and immunohistochemistry carried out (2.4.3) with
an overnight incubation at 4
oC of 2μg/ml goat anti-lipocalin 2 (R & D systems)Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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followed by rabbit anti-goat IgG peroxidase (1:100 dilution; DAKO) for 60 min.
Specific background staining was inhibited by incubating control sections with
0.2mg/ml Goat IgG (concentration if IgG content in primary antibody) in place of
goat anti-lipocalin 2 under the same conditions. Ideally, specific background staining
should also be blocked by the adsorption of a primary antibody with the purified
antigen prior to use, however, at this time, no purified lipocalin 2 antigen was
available. Another useful negative control in this study would have been growth
plates from lipocalin 2 null mice, however, again, these mice were not readily
available and so could not be used.
4.4.6 Isolation of Primary Murine Chondrocytes
Primary cultures of chondrocytes from rib growth plates of 1-day-old mice were
prepared using the isolation procedure and culture system developed by Lefebvre et
al. (1994), as detailed in section 2.2.2. Chondrocytes were seeded in 6-well plates at a
density of 100,000 cells per well in DMEM with antibiotics, ascorbic acid, and 10%
FBS, and were grown for 24h, at which point Dex was added (10
-6M; 6h, 24h, or 72h
incubation).
4.4.7 Production of a Lipocalin 2 Expression Construct
Lipocalin 2 cDNA (see Appendix 3 for sequence details) was first ligated into the
pGEM-T Easy vector (Promega, WI, USA) for cloning as detailed in sections 2.6.5-
2.6.12, inclusive (see Appendix 2 for vector details). The digested pGEM-Lipocalin 2
clone was run on a 1.5% agarose gel, and the lipocalin 2 fragment purified using the
Qiagen QiaQuick gel extraction kit as outlined in 2.6.7. Amplified lipocalin 2 cDNA
was then inserted into the EcoRI site of the pWGB10 overexpression vectorChapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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(Appendix 2) as described in sections 2.6.5 – 2.6.12 (a kind gift from Dr. Wei Cui,
Imperial College, London). pWGB10 contains a phosphoglycerate kinase (PGK)
promoter, which drives recombinant protein expression, and a simian virus 40 (SV40)
small t intro/polyA, and SV40/Puromycin to allow cell selection. To stop re-
circularisation of the empty vector, the pWGB10 plasmid was first dephosphorylated
with shrimp alkaline phosphatase (SAP) in a reaction containing 100ng vector DNA,
2 units SAP (Roche), and 1x reaction buffer for 10mins at 37
oC. This was then heat
killed at 70
oC for 15mins. Following lipocalin 2 ligation into the linearised pWGB10
vector, the ligation reaction was used to transform SURE2 competent cells as
described in 2.6.9. Liquid cultures and plasmid minipreparations of individual clones
were subsequently carried out (2.6.10 and 2.6.11, respectively). The clones were then
analysed by multiple restriction digestions with enzymes EcoRI, NcoI and PstI to
assess insert orientation. A clone containing the insert in the correct orientation (in
respoect to the PGK promoter) was then purified as detailed in 2.6.12.
4.4.8 Generation of ATDC5 Stable Transfections
1g of pWGB10/Lipocalin2 was transfected into 80% confluent ATDC5 cells using
FuGene6 according to the manufacturer’s instructions (Roche Diagnostics, Basel,
Switzerland). Control cell lines were generated using the same procedure after
transfection of an empty pWGB10 vector. After 48 hours, cells were selected in
media containing 2g/ml puromycin, and after 2 weeks, when no sign of cellular
death was evident, clones were isolated and lipocalin 2 expression evaluated by PCR
and Western blotting (2.5.4 and 2.7.3).Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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4.4.9 Effect of Lipocalin 2 Overexpression on Chondrocyte Proliferation and
Differentiation
To understand more fully the functional effects of lipocalin 2 overexpression on
chondrocyte function, chondrocyte proliferation ([
3H]thymidine uptake) and
chondrocyte differentiation (Coll X expression) was assessed as previously described
(2.9.1 and 2.5.5, respectively) . Additional experiments determined if the response of
ATDC5 cells to Dex treatment (10
-6M for 48h) was modified in the presence of
lipocalin 2 overexpression.
4.4.9 Statistical Analysis
Analysis of variance (ANOVA) was performed to determine the significance of a
given result. General Linear Model analysis incorporating pair-wise comparisons
using Tukeys test was used to compare groups within the ANOVA models. All data
are expressed as the mean +/- SEM. Statistical analysis was performed using Minitab
14. Statistical significance was accepted at p<0.05.
4.5 Results
4.5.1 Characterisation of Dex-induced Lipocalin 2 Expression in Chondrocytes
The temporal effect of 10
-6M Dex on lipocalin 2 expression was studied, and although
no effect was seen at 1h, Dex significantly (p<0.001) increased lipocalin 2 expression
at all other time points studied (6-168h), with an apparent plateau at 48h (75-fold)
(Figure 4.3; Ct values in Table 4.2). Consequently, 48h Dex incubation was used for
all future ATDC5 experiments. Dex-induced lipocalin 2 expression in ATDC5 cells
was also found to be concentration-dependent (Figure 4.4A-C). At 10
-6M Dex,
lipocalin 2 expression was 71-fold higher than control samples. This response wasChapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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reduced to 44-fold and 13-fold at 10
-7 and 10
-8 Dex, respectively (p<0.001), whereas
no response was observed with 10
-9M Dex (Ct values in Table 4.3) Western blotting
confirmed that 10
-6M Dex increased lipocalin 2 protein expression at 48h in ATDC5
cells (Figure 4.5). Primary chondrocytes also expressed lipocalin 2 and this expression
was increased with 10
-6M Dex treatment (3-fold at 6h, P<0.001), and this increased
expression was maintained for up to 72h (Figure 4.3C). Taken together, the results
indicate that Dex regulates chondrocyte lipocalin 2 expression at both the mRNA and
protein level and that the regulation of gene expression is both time and concentration
dependent.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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Table 4.2 Ct values and corresponding fold change in expression of Lipocalin 2
following exposure to 10
-6M Dex for varying timecourses
Sample Lipocalin 2 Ct GAPDH Ct Change in Ct 2
change in Ct Fold
Change
Control 1h 33.47 15.2 -18.27 3.16E-06
Dex 1h 32.1 14.9 -17.2 6.64E-06 2.1 ± 0.24
Control 6h 32.29 15.34 -16.95 7.90E-06
Dex 6h 26.85 15.29 -11.56 3.31E-04 41.8 ± 1.45
Control 24h 32.12 15.06 -17.06 7.32E-06
Dex 24h 26.25 14.55 -11.7 3.01E-04 41.1 ± 1.67
Control 48h 32,19 14.62 -17.57 5.14E-06
Dex 48h 26.58 15.24 -11.34 3.86E-04 75.1 ± 3.1
Control 96h 31.41 15.01 -16.4 1.16E-05
Dex 96h 25.5 15.46 -10.04 9.50E-04 81.9 ± 2.7
Control 168h 29.33 16.19 -13.14 1.11E-04
Dex 168h 24.2 17.19 -7.01 7.76E-03 69.9 ± 1.78
Figure 4.3 Lipocalin 2 Expression following Dex exposure over time A) Lipocalin 2
amplification in ATDC5 cells treated with 10
-6M Dex for 1-168h (1h control, blue circles,
Dex, purple open squares; 6h control, green triangles, Dex, grey diamonds; 24h control,
purple open squares, Dex, blue open diamonds; 48h control, red squares, Dex, orange inverted
triangles; 96h, control, blue crosses, Dex, red triangles; 168h control, green open triangles,
Dex, grey circles). C) GADPH amplification in ATDC5 cells treated with 10
-6M Dex for 1-
168h. D) Fold change in lipocalin 2 expression with Dex (10
-6M) over time (data are
expressed as mean  SEM). For all data, n=3 cell culture replicates run in triplicate.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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Table 4.3 Ct values and corresponding fold change in expression of Lipocalin 2
following exposure to varying concentrations of Dex for 48h.
Sample Lipocalin 2 Ct GAPDH Ct Change in Ct 2
change in Ct Fold
Change
Control 32.38 16.61 -15.77 1.79E-05
Dex
-6M 27.32 17.68 -9.64 1.25E-03 69.8 ± 5.5
Dex
-7M 28.34 17.99 -10.35 7.66E-04 42.7 ± 6.7
Dex
-8M 30.29 18.21 -12.08 2.31E-04 12.9 ± 1.27
Dex
-9M 32.03 17.54 -14.49 4.35E-05 2.4 ± 0.25
Figure 4.4 Dose-responsive change in lipocalin 2 expression in ATDC5 cells with
Dex over 48h. A) Amplification of lipocalin 2 treated with 10
-6M (red closed
squares), 10
-7M (green closed triangles), 10
-8M (grey diamonds) and 10
-9M (blue
circles) Dex for 48h (controls = yellow asterisk). B) Amplification of GAPDH
following exposure to Dex (10-6M-10-9M) for 48h. C) Dose-responsive change in
lipocalin 2 expression following exposure to Dex (data are expressed as mean 
SEM). For all data, n=3 cell culture replicates run in triplicate.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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Figure 4.5 Lipocalin 2 Expression in Chondrocytes A) Primary murine
chondrocytes treated with 10
-6M Dex for 6, 24 or 72h. B) Lipocalin 2 protein
expression in ATDC5 cells as analysed by Western blotting, after exposure to 10
-6M
Dex for 48h.
4.5.2 Immunolocalisation of Lipocalin 2 Expression in the Murine Growth Plate
Immunohistochemistry revealed that in metatarsals from 17-day old foetal mice,
lipocalin 2 was poorly expressed in both the proliferating and mineralising
chondrocytes, situated on either side of the strongly positive staining
prehypertrophic/hypertrophic chondrocytes (Figure 4.6A). The pattern of lipocalin
distribution appeared to change in the post-natal growth plate. In the 10-day-old
epiphysis, greater lipocalin 2 expression was localised to the proliferating
chondrocytes (Figure 4.6B) and this was more clearly seen in the 5-week-old growth
plate where intense lipocalin 2 staining was observed in both the proliferating and
hypertrophic zones (Figure 4.6C). No obvious difference in lipocalin 2 localisation or
staining intensity was observed between the growth plates of 5-week-old Dex-treated
and control mice (data not shown). High levels of expression were also observed in
the articular chondrocytes, and within the hypertrophic chondrocytes of the
developing secondary ossification centre (Figure 4.6D) of the 10-day-old tibias. All
control sections incubated with pre-immune serum were negative (Figure 4.6E). The
immunolocalisation results clearly show that lipocalin 2 is expressed by murineChapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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growth plate chondrocytes and this confirms our qPCR data (Figure 4.5A). In the
epiphyses from older animals lipocalin 2 appears to be present in all growth plate
maturational zones whereas in the younger growth plates it is more restricted to the
maturing hypertrophic cells.
Figure 4.6 Lipocalin 2 localisation in the murine proximal tibia and metatarsal.
(A) In metatarsals from 17-day old foetal mice, lipocalin 2 is poorly expressed in the
proliferating and mineralising chondrocytes (arrowheads), however strong positive
staining is present in the prehypertrophic and hypertrophic chondrocytes (arrows)
(scale bar = 400m) . (B) In the 10-day-old lipocalin 2 expression is localised to the
proliferating chondrocytes and this can also be seen in the 5-week-old growth plate
(scale bar = 200m) (arrows) (C), where intense lipocalin 2 staining is present in both
the proliferating and hypertrophic zones (arrows). (D) Lipocalin is also present in the
chondrocytes of the developing secondary ossification centre (*) (scale bar = 200m).
(E) All control sections incubated with Goat IgG are negative.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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4.5.3 Mechanism of Dex-induced Lipocalin 2 Expression in Chondrocytes
Incubating ATDC5 cells with CHX did not block Dex-induced lipocalin expression
(Figure 4.7A), but instead caused a further significant increase in lipocalin 2
expression. RU486 caused lipocalin 2 expression to return to basal levels in the
presence of Dex (Figure 4.7B) (13-fold change in the presence of RU486 and Dex
compared to 39-fold change with Dex alone; p<0.01). As with most steroidal
competitive antagonists, RU486 exhibits partial agonist properties under certain
conditions (Leonhardt and Edwards, 2002), and this could explain the small 13-fold
increase in lipocalin 2 expression with RU486 alone (Figure 4.7B).
Figure 4.7 Involvement of the GR in GC-induced Lipocalin 2 expression in
ATDC5 cells. (A) Lipocalin 2 expression with Dex plus the protein synthesis blocker
CHX. ATDC5 cells were incubated with 10
-6M Dex for 6h, with CHX (8g/ml)
added 30mins before the addition of Dex. (B) Lipocalin 2 expression with Dex plus
the GR antagonist, RU486. ATDC5 cells were incubated with 10
-6M Dex plus
RU486 (10
-5M) for 48h. All data are expressed as mean  SEM (n=3 cell culture
replicates run in triplicate; ***p<0.001 vs. control;
p<0.05 vs. Dex).Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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4.5.4 Involvement of the NFkB and p38 pathways in Dex-induced Lipocalin 2
Expression
The addition of SB203580 blocked p38 activity but did not block the increase in
lipocalin 2 expression observed with Dex (Figures 4.8A and 4.8B). However, TLCK
caused a concentration-dependent reduction in lipocalin 2 expression compared to
Dex alone (Figures 4.9A and 4.9B). Both 5 and 50M TLCK significantly reduced
Dex induced lipocalin 2 expression but only 50M TLCK brought lipocalin 2
expression back to non-induced levels (Figure 4.9B). It was next determined if TLCK
could, in part, inhibit the antiproliferative effects of Dex on ATDC5 proliferation
(Mushtaq et al 2002; Owen et al. 2007). Dex (10
-6M) caused a significant reduction
(46.5%; p<0.001) which was partly reversed by co-incubation with 50M TLCK
(Figure 4.7C). Co-incubation, however, only increased proliferation by 20% (p<0.05)
compared to cells incubated with Dex alone, and this proliferation remained
significantly lower (p<0.001) lower than control cells. These data indicate that the
Dex effects on lipocalin 2 expression are not dependent on protein synthesis or p38
activity. The transcription factor, NFB, however appeared to mediate the Dex
effects on chondrocyte lipocalin 2 expression. To confirm that this was, in fact the
case, a specific peptide inhibitor for NFB, SN50, was also incubated in the presence
of Dex in ATDC5 cells. Interestingly, this inhibitor had no effect on Dex-induced
lipocalin 2 expression, suggesting that the inhibitory effects seen with TLCK were not
specific to NFB (Figure 4.9D).Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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Figure 4.8 The p38 signalling pathway and GC-induced Lipocalin 2 expression.
(A) Lipocalin 2 expression with Dex (10
-6M) and the p38 inhibitor SB203580
(20μM). ATDC5 cells were incubated with SB203580 for 2h, before the addition of
Dex for the remaining 48h. All data are expressed as mean  SEM (n=3 separate cell
culture replicates run in triplicate; ***p<0.001 vs. control. (B) p38 activity in
SB203580 treated ATDC5 cells. A kinase assay for p38 MAPK activity was carried
out using ATF-2 fusion protein as phosphorylation substrate. Total p38 protein was
determined by Western blotting.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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Figure 4.9 The NFkB signalling pathway and GC-induced Lipocalin 2
expression. The NFkB inhibitor TLCK (50μM) TLCK was incubated with ATDC5
cells for an initial period of 4h before the addition of Dex for another 48h. (B)
Lipocalin expression with varying concentrations of TLCK. ATDC5 cells were
incubated with 50, 5 or 0.5μM TLCK for 4h before the addition of 10
-6M Dex for the
remaining 48h. (C) Proliferation of ATDC5 cells treated with TLCK (50μM) and/or
Dex (10
-6M) for 48h. (D) Lipocalin 2 expression with Dex (10
-6M) and the selective
NFB inhibitor SN50 (18μM). ATDC5 cells were incubated with SN50 for 2h,
before the addition of Dex for the remaining 48h. All data are expressed as mean 
SEM (n=3 separate cell culture replicates run in triplicate; ***p<0.001 vs. control;
p<0.05 vs. Dex,
p<0.01 vs. TLCK).Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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4.5.5 Functional Effects of Lipocalin 2 on ATDC5 Cell Dynamics
To identify the possible physiological effect of Dex-induced lipocalin 2 expression on
chondrocyte dynamics, in initial studies, the effects of both lipocalin 2 overexpression
(Figure 4.10A) and recombinant lipocalin 2 on ATDC5 proliferation was analysed.
Proliferation was significantly reduced (p<0.001) in overexpressing cells (Figure
4.10B) and those treated with recombinant lipocalin 2 (Figure 4.10C). The reduction
in proliferation by recombinant lipocalin 2 was modest (23.1% at 10g/ml) and
similar at all concentrations tested, whereas a more dramatic effect (49.1%) was noted
in the overexpressing cells. This difference is likely to be due to the unstable nature
of synthetic recombinant proteins, and therefore over-expressing cells were used for
further analysis.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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Figure 4.10 The effect of increased lipocalin 2 expression on chondrocyte
dynamics. (A) Lipocalin 2 over-expression in ATDC5 cells was confirmed by (I)
PCR of Lipocalin 2, puromycin resistance gene, and GAPDH; and (II) Western
blotting for lipocalin 2 and beta-actin loading control. (OE = Lipocalin over-
expressing; C = Control cells containing empty vector only). (B) Proliferation of
lipocalin 2 over-expressing cells as measured by [
3H]-thymidine incorporation.
Transfected ATDC5 cells were incubated with or without 10
-6M Dex for 24h. (n=3
cell culture replicates; ***p<0.001 vs. control; **p<0.01 vs. control;
p<0.05 vs. Dex,
p<0.01 vs. Lipocalin). (C) ATDC5 proliferation as measured by [
3H]thymidine
incorporation following 48h incubation with recombinant lipocalin 2 protein (5-
20g/ml; R&D systems) (n = 6 cell culture replicates; ***p<0.001 vs. control).
4.5.6 The Combined Effect of Lipocalin 2 and Dex on ATDC5 Cells
Lipocalin-2 overexpression caused an increase in collagen type-X expression (4-fold,
p<0.001; Figure 4.11A). The effects of lipocalin-2 overexpression on chondrocyte
proliferation (64% reduction vs. control cells, p<0.001) and collagen type-XChapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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expression (8-fold increase vs. control, p<0.001) were further amplified by the
addition of 10
-6M Dex (Figures 4.11A and 4.11). This apparent synergistic effect of
Dex and lipocalin 2 on proliferation and collagen type X expression may be in
response to the further increase in lipocalin 2 expression (140-fold, p<0.001) noted in
the Dex treated overexpressing cells (Figure 4.11B).
Figure 4.11 The combined effect of lipocalin 2 and Dex on ATDC5 cells. (A)
Type X collagen expression in lipocalin 2 over-expressing ATDC5 cells incubated
with or without 10
-6M Dex for 48h. (B) Effect of Dex on lipocalin 2 expression in
ATDC5 cells over-expressing lipocalin 2. Cells were incubated with 10
-6M Dex for
48h, and lipocalin 2 expression was measured by qPCR (n=3-6 cell culture replicates
run in triplicate; ***p<0.001 vs. control;
p<0.05 vs. Dex Empty;
p<0.05 vs.
lipocalin only). All data are expressed as mean  SEM.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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4.6 Discussion
Lipocalin 2, also known as Neutrophil-associated gelatinase lipocalin (NGAL), was
originally identified as a 25kDa protein which binds to small lipophillic substances
such as bacteria-derived lipopolysaccharide (LPS). Since then, the known actions of
lipocalin 2 have sprialled, and lipocalin 2 has now been linked with a wide range of
different functions, including partuition, inflammation, differentiation, apoptosis and
acute phase immunity. Originally termed SIP24 (Superinducible-protein 24),
lipocalin 2 is known to be induced by a number of factors and conditions, such as
LPS, CHX, serum, FGF2, prostaglandin F2α, oxidative stress, partuition, and, of
course, Dex (Meheus et al., 1993; Lui et al., 1995).
In this study, it has been shown that lipocalin 2 expression is significantly increased
with Dex treatment in murine chondrogenic ATDC5 cells. This increased expression
was Dex-concentration dependent, and reached a plateau after 48h Dex. In primary
murine costochondral chondrocytes isolated from the rib cages of 2-day-old mice, an
increase in lipocalin 2 expression was also observed, and although significant, this
increase was smaller than seen in ATDC5 cells. ATDC5 cells were originally isolated
from a differentiating culture of AT805 teratocarcinoma cells, which display a
fibroblast-like phenotype until the addition of insulin, which promotes their
differentiation into chondrocytes (Atsumi et al., 1990). These cells are a useful model
for studying chondrogenesis due to the fact that their temporal sequence of maturation
directly mirrors the maturational phases within the growth plate. In addition, the cell
population differentiates collectively, so that all the cells are at the same stage of
differentiation at the same time. However, because of this, they cannot be compared
directly to primary costochondral chondrocytes, which are isolated as a population ofChapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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chondrocytes at all stages of differentiation. The fact that ATDC5 cells and primary
costochondral chondrocytes comprise of 2 different phenotypes could explain the
differences in the magnitude of lipocalin 2 expression observed in this study.
The expression of lipocalin 2 in primary chondrocytes was supported by the finding
that lipocalin 2 was expressed in the metatarsals of embryonic mice. Lipocalin 2 has
previously shown to be expressed in the liver, spleen, lung, muscle, heart and tibia of
embryonic mice (Garay-Rojas et al., 1996; Ulivi et al., 2006), and within the tibia of
embryonic rats, the rat homologue of lipocalin 2 neu-related lipocalin (NRL) is
localised to the prehypertophic chondrocytes (Zerega et al., 2000), supporting the
findings of this study. It has previously been found that ALP has a similar pattern of
localisation within the growth plate (Maio and Scutt, 2002; Mushtaq et al., 2004),
suggesting that, like ALP, lipocalin 2 may be a marker for chondrocyte
differentiation. Interestingly, in 10-day-old and 5-week-old mice in this study, it has
been shown that lipocalin 2 is more prominent in the proliferative chondrocytes,
suggesting the localisation of lipocalin 2 expression within the growth plate is age-
dependent. Differences in lipocalin 2 expression between adult and foetal tissue have
previously been described, with a general decline in expression in conjunction with
ageing (Garay-Rojas et al., 1996). This, together with similarities in expression to
ALP, and previous studies showing the pro-differentiating effects of lipocalin 2 in
epithelial cells (Yang et al., 2002), further supports the hypothesis that lipocalin 2
may have a role in the regulation of chondrocyte differentiation. Interestingly, it has
been shown that lipocalin 2 knock-out mice have no skeletal defects, the only obvious
phenotype being an increased susceptibility to infection (Berger et al., 2006). To
date, there have been no studies documenting skeletal growth in these mice followingChapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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Dex treatment, and, it is possible that growth retardation in these mice could be
reduced.
In an attempt to identifiy some of the mechanisms involved in Dex-induced lipocalin
2 expression, the GR antagonist RU486 was incubated alone or with Dex in ATDC5
cells. Results showed that, in the presence of RU486 alone, lipocalin 2 expression
was increased to some extent. RU486 is a competitive antagonist for the GR, and, by
nature, such antagonists often display some agonist activity at the receptor they
competitively bind to, accounting for the increases in lipocalin 2 expression observed
here. When RU486 and Dex were incubated together, lipocalin 2 expression could no
longer be induced with Dex. Analysis of the lipocalin 2 sequence with ‘MatInspector’
(www.genomatix.de) confirmed previous reports of two GC response elements (GRE)
in the 5’ regulatory region of the lipocalin 2 promoter (Garay Rojas et al., 1996;
Cartharius et al., 2005) (Figure 4.11). The presence of GRE in the promoter region of
lipocalin 2 suggested that this gene could be a direct target of the GR complex. This
was supported by the fact that the Dex-induced increase in lipocalin 2 mRNA levels
was not inhibited by CHX, a protein synthesis inhibitor. Interestingly, CHX in fact
caused a further increase in lipocalin 2 expression. This finding has been previously
reported (Davis et al., 1991) and could be due to CHX blocking the synthesis of a
lipocalin 2 or Dex repressor.Chapter 4 Lipocalin 2 and GC-Induced Growth Retardation
152
Figure 4.12 The Lipocalin 2 Promoter Analysis of the lipocalin 2 promoter
sequence with ‘MatInspector’ (www.genomatix.de) confirmed previous reports of two
GC response elements (GREs), suggesting that this gene could be a direct target of the
GR complex. Other interesting binding sites include the estrogen reponse element
(ERE), an NFκB binding site, Vitamin D receptor site, and binding sites for the pro-
inflammatory transcription factors STAT1 and STAT3.
In addition to several GRE’s, the lipocalin 2 promoter region also contains a number
of NFkB binding sites. Previous studies have reported IL-1-induced lipocalin 2
expression through NFkB signalling (Cowland et al., 2006), and the presence of an
NFB binding site on the lipocalin 2 promoter supports a putitative role for NFB in
this study (Figure 4.10). The NFkB/p38 pathway is suggested to be involved in LPS-
induced lipocalin 2 expression in chondrocytes (Ulivi et al., 2006), and is also
involved in chondrocyte differentiation (Wen et al., 2006), and in an attempt to
further define the mechanisms by which Dex induces lipocalin 2 expression, the role
of the p38/NFkB pathway was examined. The p38 inhibitor SB203580 had no effect
on lipocalin 2 expression, although its activity was confirmed by a p38 MAPK assay,
suggesting that p38 had no role in lipocalin 2 induction in this study. The NFB
inhibitor TLCK, a serine protease inhibitor, blocked Dex-induced lipocalin 2
expression and partly blocked the Dex effects on ATDC5 proliferation, initiallyChapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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suggesting that NFB was involved in the Dex effects on lipocalin 2. To confirm this
result, the experiment was repeated using another NFB inhbitor, SN50, a peptide
inhibitor which selectively inhibits the translocation of NFB to the nucleus. Results
using this inhibitor showed that blocking NFB activity had no effect on lipocalin 2
expression, suggesting that the initial results obtained with TLCK were due to the
inhibition of other factors such as protein kinase C (PKC) (Solomon et al., 1985), or
cell cycle regulators such as pp70s6k (Grammer et al., 1996). Consequently, the
exact mechanisms by which Dex increases lipocalin 2 expression in ATDC5 cells are
still unknown.
Interestingly, a recent study has found that there is a marked increase in lipocalin 2 in
obese humans (Wang et al., 2006). In addition, this study displayed a significant
positive correlation between lipocalin 2 expression and several variables associated
with obesity-related metabolic disorders, including hyperinsulinemia and fasting
glucose concentrations. It is known that at pharmacological doses, Dex can cause an
increase in fasting glucose concentrations, and due to the fact that lipocalin 2
expression is increased following exposure to insulin-resistance-inducing and
inflammatory adipokines such as TNFα, IL6 and resistin (Berg et al., 2005; Wellen et
al., 2005), it is possible that Dex is increasing lipocalin 2 expression through
alterations the gluconeogenesis pathway.
The importance of lipocalin 2 in GC-induced growth retardation was further
supported with the finding that its overexpression caused a reduction in ATDC5
proliferation and an increase in differentiation, an effect which is similar to that seen
with GC-treated ATDC5 cells (Mushtaq et al., 2002; Owen et al., 2007). The effectsChapter 4 Lipocalin 2 and GC-Induced Growth Retardation
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on proliferation were also reproduced with the addition of lipocalin 2 recombinant
protein, supporting the hypothesis that lipocalin 2 is influencing chondrocyte
dynamics in a similar way to GCs. Interestingly, the effects of lipocalin 2
overexpression on proliferation and differentiation were exacerbated with Dex, and
lipocalin 2 expression in transfected cells was increased more than would be expected
from the additive effects of Dex and lipocalin 2 expression alone. The synergistic
effect of Dex and LPS on lipocalin 2 expression has previously been described
(Vizzardelli et al., 2006), however, these findings suggest that lipocalin 2 itself may
play a role in mediating the effects of Dex. It is therefore possible that lipocalin 2
could be exacerbating Dex-induced growth retardation by interacting directly with
Dex to inhibit chondrocyte proliferation and increase differentiation. As previously
discussed, it has been reported that lipocalin 2 contains 2 GREs on the promoter. Due
to this fact, it would be interesting to study the behaviour of Dex-treated ATDC5 cells
transfected with a lipocalin 2 promoter, constructed with a GRE knock-out element.
4.7 Conclusions
Lipocalin 2 has previously been shown to be regulated by Dex in dendritic cells
(Vizzardelli et al., 2006) and fibroblast-derived murine L-cells (Garay-Rojas et al.,
1996), however, it’s stimulation in chondrocytes has not previously been reported.
This study has shown that the acute-phase binding protein lipocalin 2 is markedly
increased in chondrocytes in response to Dex, and that lipocalin 2 may mediate Dex
effects on chondrocytes. This finding provides a potential novel mechanism for GC-
induced growth retardation.Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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5.1 Introduction
Despite recent advances in the understanding of how GCs regulate growth and
differentiation in a number of target tissues, the molecular mechanisms by which they
exert these profound effects on bone growth and development have remained a
mystery. It is generally accepted that proliferation and differentiation are mutually
exclusive biological processes; therefore, a required step in the progression towards
terminal differentiation is the withdrawal of a cell from the cell proliferation cycle. A
growing body of evidence suggests that GCs may exert their effects on cell growth
and differentiation in chondrocytes partly through regulation of this cell cycle
(Robson et al., 1998; Sanchez and He 2002; Mushtaq et al., 2002; Siebler et al., 2002;
Schrier et al., 2006).
Progression of the cell cycle is controlled primarily by cyclin dependent kinases
(CDKs), and their repressors, the cyclin dependent kinase inhibitors (CDKIs). In
mammals, there are two families of CDKIs; the CIP/KIP family composed of
p21
WAF1/CIP1, p27
KIP1, and p57
KIP1, which bind to and inhibit G1 CDKs, and the INK4
proteins p16
INK4A, p15
INK4B, p18
INK4Cand p19
INK4D, which inhibit CDK4 and to a lesser extent
CDK6. The Cip/Kip family can act on most cyclin/CDK complexes and are essential
for G1 progression and S1 entry (Johnson and Walker 1999). Increasing evidenceChapter 5 The Role of p21 in GC-Induced Growth Retardation
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from murine gene knockout experiments, analysis of human dyschondroplasias, and
in vitro studies suggest that these CDKIs play an important role in the control of bone
growth at the level of the growth plate.
Disruption of the p57 gene has been shown to cause delayed chondrocyte
differentiation, resulting in skeletal deformations and shortened limbs (Yan et al.,
1997; Zhang et al., 1997). In these studies, chondrocytes showed increased
proliferation and reduced expression of Coll X, suggesting that p57 may be required
for chondrocyte differentiation. In contrast, however, mice deficient for p27 or p21
do not show any obvious skeletal phenotypes. However, p27-null mice are larger than
wild-type mice (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996), and
this increase in size appears to affect growth of all organs, suggesting that some
growth plate effects are likely. p21 deficient mice do not display any developmental
defects, although isolated cells do show altered cell cycle kinetics (Deng et al., 1995;
Missero et al., 1996). Expression of p21 in differentiating rat growth plate
chondrocytes has been examined in cells cultured as three-dimensional pellets
(Ballock et al., 2000), and has also been detected in rat costochondral growth plate
chondrocytes and articular chondrocytes in pellet culture (Stewart et al., 1997) (Figure
5.1). In addition, upregulation of Coll X and ALP activity in hypertrophic
chondrocytes has been associated with increased expression of p21 but not p27
(Stewart et al., 1997).Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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Figure 5.1 Immunohistochemical localisation of p21 in the rat growth plate.
Sections (5 µm) were incubated with polyclonal, rodent-specific rabbit antibody to
p21 (A), or to an equal concentration of ammonium acetate-precipitated rabbit non-
immune serum (B). Reactive cells are dark red. Although staining is evident in a few
proliferative cells, expression of p21 appears substantially increased in cells at the
transition between the proliferative and hypertrophic zones, in hypertrophic cells, and
in cells adjacent the epiphyseal ossification front. E = epiphyseal ossification front, P
= proliferative zone, H = hypertrophic zone. From Stewart et al., 1997.
Other studies have also suggested that p21 may play a role in the regulation of growth
plate chondrocyte proliferation and differentiation. Increased expression of p21 in
cartilage has been demonstrated in thanatophoric dysplasia human embryos (a form of
short-limbed dwarfism that usually causes death within the first few hours after birth)
(Su et al., 1997). In addition, in ATDC5 cells, p21 expression increases as the cells
progress towards terminal differentiation, and this expression is blocked by p38 and
MAPK inhibitors, suggesting that, in chondrocytes, p21 expression is p38/MAPK
dependent (Negishi et al., 2001; Nakajima et al., 2004).
p21 expression is usually controlled at the transcriptional level by both p53-dependent
and –independent mechanisms. The p53 tumour suppressor protein is a transcription
factor required for the activation of a number of genes involved in growth control, and
results from the γ-irradiation of p53-knockout and wild-type mice suggested that p53 Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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dependent regulation of p21 is critical for the response to DNA damage (Macleod et
al., 1995). However, a variety of agents that promote differentiation activate p21
transcription by p53-independent mechanisms, primarily through transcription factors
which bind to specific cis-acting elements located within the p21 promoter. Dex has
been shown to induce the expression of p21 by acting through the CCAAT/enhancer
binding protein-α (C/EBPα) transcription factor, which regulates p21 expression at the
transcriptional level (Timchenko et al., 1996; Cha et al., 1998; Cram et al., 1998). In
osteoblasts, pharmacological concentrations of Dex induce p21 expression (Leclerc et
al., 2004), resulting in reduced osteoblast development. In addition, studies using rat
hepatoma cells have shown that Dex causes a p53-independent increase in p21 mRNA
and protein expression, whereas the expression of other CDKIs such as p27 remain
unchanged (Cha et al., 1998).Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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5.2 Hypothesis
In Chapter 3, microarray analysis suggested that Dex may cause growth retardation by
causing premature differentiation of proliferative chondrocytes within the growth
plate. Due to the previous finding that increased p21 expression is linked with
chondrocyte differentiation, it is possible that Dex may promote p21 expression to
cause a reduced proliferation in growth plate chondrocytes.
5.3 Aims
I. Confirm p21 expression is increased in terminally differentiating ATDC5
cells through Western Blotting and qPCR.
II. Analyse the effect of Dex on p21 expression in ATDC5 cells by Western
Blotting and qPCR.
III. Develop an effective in vivo protocol for measuring GC-induced growth
retardation in mice.
IV. Analyse the role of p21 in GC-induced growth retardation with p21
-/- mice
using physiological and histological measures of bone growth.Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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5.4 Materials and Methods
5.4.1 In Vitro Studies
5.4.1.1 Cell Culture
For experiments measuring the role of p21 in chondrocyte differentiation, the ATDC5
chondrocyte cell line was maintained and differentiated as previously described
(Section 2.2.3) for up to 15 days. For studies examining p21 expression with GCs,
Dex (final concentration 10
-6M) was added to both chondrogenic and terminally
differentiating cells for 6, 12, or 24h. Control cells received differentiation medium
only.
5.4.1.2 Cell Counting
In order to measure the growth of ATDC5 cells progressing towards terminal
differentiation, cells were trypsinised and counted on days 0, 3, 7, 11, 14, and 18 of
differentiation as described in section 2.2.3. Six replicates were used for each
timepoint.
5.4.1.3 PCR
To measure the expression of CDKIs during ATDC5 differentiation, RNA was
isolated from the cells at days 0, 2, 4, 7, 9, 11 and 15, and extracted as previously
described (2.5.1). For analysis of p21 expression following Dex treatment, RNA was
isolated by the same method. All samples were then reverse transcribed (2.5.3), and
both qPCR and Endpoint-PCR reactions were carried out as detailed in sections 2.5.4
and 2.5.5, respectively. The primers for the endpoint PCR analysis of different
CDKIs and chondrocyte marker genes during ATDC5 differentiation were as detailed
in Table 5.1. The cycling reaction for all primers was as follows: 1 cycle of 92
oC forChapter 5 The Role of p21 in GC-Induced Growth Retardation
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2mins, 55
oC for 1min and 72
oC for 1min, followed by 30 cycles of 92
oC for 1min,
55
oC for 1min and 72
oC for 1min.
Table 5.1 Primer Sequences and product sizes for CDKIs and chondrocyte marker
genes analysed by PCR
Gene Name Primer Sequences (5’ – 3’) Product Size
(bp)
p21 F AATCCTGGTGATGTCCGACC
R TTGCAGAAGACCAATCTGCG
460
p27 F TATGGAAGAAGCGAGTCAGC
R GCGAAGAAGAATCTTCTGCAG
334
p57 F GGATTGTGGAGGCTTTCTCC
R CTTGGCGATCATGTCCTCAAAG
309
p18 F GGACACTGTACAGGCTTTGC
R TTCCATAGAACCTGGCCAAG
197
p19 F GCGACGTGCAAGAGGTCCG
R GCTGACCACGGAGCTATGGC
318
Coll X F AGGCAAGCCAGGCTATGGAA
R GCTGTCCTGGAAAGCCGTTT
583
Aggrecan F CGAGAATGACACCTGCTAGG
R AAGAAGACAGGACCAGGAAGG
218
18S Unknown, purchased from Ambion 488
p21 qPCR F TTGCACTCTGGTGTCTGAGC R
F TCTGCGCTTGGAGTGATAGA R
112
Coll II qPCR F GCCAAGACCTGAAACTCTGC R
F GGTTGGGGTAGACGCAAGTC R
123
5.4.1.4 Western Blotting
For analysis of p21 protein expression, ATDC5 cells were scraped at days 0, 2, 4, 7,
9, 11 and 15, or after 6h Dex treatment (10
-6M) in PBS containing 1.6 mg/ml of
Complete
® protease inhibitor cocktail, and protein concentration measured as
previously described (2.7.1). Proteins were then separated on a 4-12% Bis-Tris Gel
(Invitrogen) by SDS-PAGE (2.7.2), and Western blotting carried out as previously
described (2.7.3). For analysis of p21 expression, monoclonal mouse anti-p21 (BD
Pharmingen; Appendix 4) was used at a 1:250 dilution, and this was detected with a
goat anti-mouse IgG peroxidase secondary antibody, at a dilution of 1:8000 (Sigma;Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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Appendix 4). Beta-actin expression was also measured as a loading control (Anti
beta-actin clone AC15; Sigma; 1:5000 dilution).
5.4.2 In Vivo Studies
5.4.2.1 p21 Null Mice Genotyping
Genotyping for transgenic mice was carried out on tail clippings from mice no
younger than 3 weeks of age, as detailed in section 2.6.2. Heterozygous p21 null mice
were identified by bands at 872bp and 700bp, wildtype mice by one band at 700bp,
and mice homozygous for the p21
-/- allele by one band at 872bp (Figure 5.2)
Figure 5.2 Genotyping of p21 null homozygous and heterozygous mice.
Heterozygous p21 null mice were identified by bands at 872bp and 700bp, wildtype
mice by one band at 700bp, and mice homozygous for the p21
-/- allele by one band at
872bp. Amplified products were loaded onto a 1.5% tris-acetate gel.
5.4.2.2 In Vivo Treatment of Mice with Dex
For all GC-growth retardation studies, 4-week-old mice underwent an injection
regime of 5mg/kg subcutaneous (sc) Dex daily for 7 days (water soluble Dex; Sigma
lot 105K1411; dissolved in 0.9% saline (NaCl)). Control mice received an equal
volume of 0.9% NaCl. In addition, all mice received a single intra-peritoneal (ip)
injection of calcein (10mg/kg in sodium bicarbonate (NaHCO3)) on day 1, and BrdU
(25mg/kg in NaCl; sc) exactly 1h before being culled. Although double calcein
labelling (with one injection of calcein at the start of an experiment, and another justChapter 5 The Role of p21 in GC-Induced Growth Retardation
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before culling) is more common when measuring mineral apposition in skeletal tissue
this was not necessary in this study due to the obvious demarcation of the chondro-
osseous junction at the distal end of the growth plate. During the 7-day treatment
period, mice were weighed daily, and crown-rump body lengths measured on days 1
and 7. Mice involved in the p21
-/- study also received x-rays at days 0, 3, and 6 of
Dex treatment. In order to take the x-rays, the mice where placed into a Vet-Tech box
where they where given Halothane gas. Once anaesthetised sufficiently, the mice
were placed under the x-ray beam, and the x-ray taken at a setting of 5.0mas and
50Kv. All mice were culled by cervical dislocation at the end of the experiment.
5.4.2.3 Measurement of Organ Weights and Lengths
Directly following culling, left and right tibia were dissected, weighed, and measured
using digital calipers. In addition, the spleen, heart, kidneys, and liver were also
removed and weighed to analyse the effect of Dex.
5.4.2.4 Tissue Processing
As described above, both the left and right proximal tibiae were dissected from each
mouse. The left tibia was decalcified and processed for embedding in paraffin wax
and sectioned as described in section 2.4.1. The right tibia was left undecalcified, and
frozen in a hexane freezing bath, before sections were cut using the CryoJane tape
transfer system as previously described (2.4.2.1 – 2.4.2.4).
5.4.2.5 Toluidine Blue Analysis of Growth Plate Morphology
Paraffin sections of the proximal tibia were dewaxed through graded alcohol solutions
as described in section 2.4.3, and stained for Toluidine blue as described in sectionChapter 5 The Role of p21 in GC-Induced Growth Retardation
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2.4.4. Stained sections were then examined under a Nikon Eclispe TE300
microscope, and the lengths of the proliferating and hypertrophic zones measured at
10 different sites along the length of the growth plate. The identification of sections
were hidden with masking tape during analysis to avoid bias. However, it should be
noted that this type of analysis is dependent on the angle at which tissues are
embedded into the paraffin wax, as variations in the angle at which sections are cut
can significantly alter the observed growth plate width. Consequently, when
embedding, care was taken to ensure all tissues were embedded and cut at
approximately the same angle.
5.4.2.6 Analysis of X-rays
X-rays of p21
-/- and wildype mice were taken at days 0, 3, and 6 of Dex treatment as
previously described (5.4.6). X-rays were scanned using the Kodak LS-75 film
scanner, and images converted from DICOM to TIFF files using the programme
IrfanView (www.irfanview.com). ImageJ was then used to measure the lengths of
tibiae, femur, and tails from the TIFF x-ray files.
5.4.2.7 Measurement of Mineral Apposition Rate (MAR) with Calcein Labelling
Calcein labelling was used to measure the rate of bone formation in control and Dex
treated mice during the 7-day treatment period. Mice were injected with a single dose
of 10mg/kg Calcein fluorochrome on day 1 of Dex treatment as previously described
(5.4.2.2). Tibia were dissected and frozen sections cut as previously described
(2.4.2.1-2.4.2.4), and sections were examined for fluorescence using the Nikon
Eclispse TE300 microscope. The distance between the chondro-osseous junction at
the distal end of the growth plate and the fluorescing mineralisation front wasChapter 5 The Role of p21 in GC-Induced Growth Retardation
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measured at 10 different points along the section, and an average taken. This was
then divided by the number of days of treatment, to obtain a MAR for each section.
Four sections per tibia were measured from 6 mice per treatment.
5.4.2.8 Laser Capture Microscopy
In an attempt to measure p21 gene expression within the proliferative and
hypertrophic zones of the growth plate, sections (10µm) from undecalcified frozen
proximal tibiae were cut using the CryoJane tape transfer system (2.4.2.6), and
chondrocytes from both the proliferative and hypertrophic zones of 12 sections per
mouse were isolated using LCM as previously described (2.4.2.7) (Figure 5.3). RNA
was pooled, extracted from the chondrocytes (2.5.2), and amplified using the
MessageAmp RNA amplification kit (2.5.3). The aRNA was then reverse transcribed,
and qPCR for chondrocyte marker genes aggrecan and Coll II, and p21 carried out as
previously described (2.5.4 and 2.5.6; primer details section 5.4.1.3).
Figure 5.3 Laser Capture Microscopy (LCM) of proliferating and hypertrophic
chondrocytes. (A) Proximal tibia growth plate section before LCM highlighting the
proliferative (P) and hypertrophic (H) zones. (B) Proximal tibia growth plate section
after LCM highlighting the removal of both zones, with only the prehypertrophic
chondrocytes remaining.Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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5.5 Results
5.5.1 In Vitro Studies
5.5.1.1 Analysis of p21 Expression During ATDC5 Differentiation
During the 15 days of ATDC5 differentiation, expression of the hypertrophic
chondrocyte marker gene aggrecan increase, as expected (Figure 5.4A). Of all the
CDKIs analysed, only the expression of p21 increased as the cells progressed towards
differentiation. The expression of p27, p27, p15 and p19 remained unchanged (Figure
5.4A). The increase in p21 expression during differentiation was confirmed by qPCR,
with a 4-fold increase in expression by day 11 (p<0.01; Figure 5.4B). p21 protein
expression was also increased in ATDC5 cells at days 9 and 15 of differentiation
(Figure 5.4C), at which point cell proliferation had ceased (Figure 5.4D).Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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Figure 5.4 Expression of CDKIs during ATDC5 differentiation. (A) Of the
CDKIs tested, only p21 expression increased as the cells progressed towards terminal
differentiation. Expression of the chondrocyte marker gene, aggrecan, also increased.
Samples were run on a 1.5% Tris-acetate gel. (B) p21 fold change in differentiating
ATDC5 cells as measured by qPCR. (**p<0.01; *p<0.05 n = 3 separate cell replicates
run in triplicate; all data are expressed as mean  SEM). (C) p21 protein expression
in ATDC5 cells. β-actin was used as a loading control. (D) Proliferation in ATDC5
cells as measured by directly counting in a haemocytometer chamber.
5.5.1.2 p21 Expression in ATDC5 Cells Following Dex Treatment
Both p21 gene and protein expression were increased in ATDC5 cells following 1h
and 6h Dex treatment, as measured by qPCR and Western Blotting, respectively
(Figures 5.5A and B). qPCR revealed a 3.8-fold and 2-fold increase in p21 expression
with 1h and 6h Dex treatment, respectively (p<0.01; Figure 5.5A), although no
change in expression was observed at 24h.Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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Figure 5.5 p21 expression with Dex treatment in ATDC5 cells. (A) qPCR analysis
revealed a significant increase in p21 expression at 1h, and 6h Dex treatment. No
change in expression was observed at 24h. (***p<0.001; **p<0.01; n = 3 cell
replicates run in triplicate; all data are expressed as mean  SEM). (B) p21 protein
expression was also increased following 1h and 6h Dex treatment, but not at 24h.
Expression of β-actin loading control remained unchanged.
5.5.2 In Vivo Studies
5.5.2.1 Growth in Dex-Treated Mice
In order to establish a dosing regime for future in vivo experiments, saline and Dex-
treated mice were weighed daily for 7 days and crown-rump lengths measured. Dex-
treated mice were significantly lighter than control mice from day 3 of treatment
(14.5g and 17g, respectively; p<0.001; Figure 5.6A), and by day 7, the body lengths
of Dex-treated mice were also significantly shorter than control mice (7.6cm and
8.2cm, respectively; p<0.001; Figure 5.6B)Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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Figure 5.6 Skeletal growth in Dex-treated mice (A) 4-week-old mice were
injected daily for 7 days with 5mg/kg Dex or 0.9% NaCl, and weighed each day.
Dex-treated mice were significantly smaller from day 3 of treatment. (B) Dex-treated
and control mice were measured from crown to rump at days 1 and 7 of treatment.
The body lengths of Dex-treated mice were significantly shorter after 7 days
(***p<0.001; n = 8 mice; all data are expressed as mean  SEM).
5.5.2.2 Effect of Dex on Organ Weight
Organ weights were first normalised to the overall body weight for each mouse, and
multiplied by 1000 for ease of data analysis. The weight of the liver and spleen were
significantly reduced in Dex-treated mice compared to their control littermates
(p<0.01; Figure 5.7). Tibiae were also dissected from control and Dex-treated mice,
and when weighed, the weights of Dex-tibiae were significantly reduced (39mg forChapter 5 The Role of p21 in GC-Induced Growth Retardation
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Dex-treated mice compared to 50mg for control mice; p<0.05; Figure 5.7). Dex had
no effect on the weight of the kidney or heart compared to control mice.
Figure 5.7 Effect of Dex on mouse organ weights. Organs were dissected,
weighed, and normalised to the overall body weight for each mouse. Weights of the
spleen, liver and tibia were significantly reduced with Dex treatment, whilst weights
of the kidney and heart were unaffected (***p<0.01; **p<0.01; *p<0.05; n = 8
organs; all data are expressed as mean  SEM).
5.5.2.3 Effect of Dex on Growth Plate Morphology
To analyse the effect of Dex on the growth plate, proximal tibia growth plate sections
from control and Dex-treated mice were stained for Toluidine blue (Figure 5.8A and
B, respectively). Dex significantly reduced the overall width of the growth plate, due
to a reduction in the width of both the proliferative and hypertrophic zones (p<0.001;
Figure 5.8C).Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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Figure 5.8 Toluidine Blue staining of the Growth Plate in Dex-treated mice
Proximal tibia growth plate sections from control (A) and Dex-treated (B) mice were
stained with toluidine blue for analysis of growth plate morphology and zone width.
Scale bar = 200µm (C) The widths of both the proliferating and hypertrophic zones
were significantly reduced in Dex-treated mice, resulting in a reduction in the overall
growth plate width. (PZ = proliferating zone; HZ = hypertrophic zone) (***p<0.01
versus control; n = 8; all data are expressed as mean  SEM).
5.5.2.4 Analysis of p21 Expression in the Growth Plate
Due to the fact that p21 has previously been shown to be expressed at high levels in
the hypertrophic zone of the growth plate (Stewart et al., 1997), numerous attempts
were made to confirm these findings, and to analyse the expression of p21 in the
growth plate of Dex-treated mice. However, despite using various different
antibodies against p21, I failed to show staining that was consistent with previous
studies. Consequently, an attempt was made to compare the relative expression of
p21 in the proliferative and hypertrophic zones in Dex-treated mice by qPCR.
Chondrocytes were isolated from each zone by LCM, and the RNA was extracted andChapter 5 The Role of p21 in GC-Induced Growth Retardation
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amplified as described previously (5.4.2.8). Although chondrocytes were successfully
isolated from each zone (Figure 5.3), the RNA obtained was of very poor quality, with
260/280 ratios varying between 0.29 and 2.42, and average total RNA yields of 20ng.
In order for amplification to perform effectively, it is vital that the RNA is of good
quality. Consequently, when amplification was carried out, although some samples
were amplified successfully, others were not, making it impossible to analyse the
expression of chondrocyte marker genes or p21 by endpoint or qPCR.
5.5.2.5 Growth in Dex-treated p21
-/- Mice
In order to study the role of p21 in GC-induced growth retardation, mice lacking the
p21 gene were injected daily for 7 days with 5mg/kg Dex or 0.9% NaCl as previously
described (5.4.2.2). Wildtype mice received identical treatments. By day 4, the
growth of both p21
-/- and wildtype mice undergoing Dex treatment was significantly
reduced compared to their control littermates (p<0.001; Figure 5.9). This growth
retardation was maintained until day 7.Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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Figure 5.9 Growth in p21
-/- Dex-treated mice p21
-/- and wildtype mice were treated
with 5mg/kg Dex for 7 days, and weighed daily. By day 4, the weights of both null
and wildtype mice treated with Dex were significantly reduced compared to NaCl
controls. (***p<0.01; n = 8; all data are expressed as mean  SEM).
5.5.2.6 Skeletal Growth of Dex-treated p21
-/- mice – X-ray Analysis
X-rays of p21-/- and wildtype mice treated with 5mg/kg Dex were taken on days 0, 3
and 6 as described previously (5.4.2.2; Figure 5.10A). Lengths of the tibiae, femurs
and tails for each day were measured with ImageJ (5.4.2.6). Tibia lengths in Dex-
treated null and wildtype mice were slightly shorter than their respective controls,
however this was not a significant change (Figure 5.10B). Similarly, when the
lengths of the tibiae, femurs, and tails from each of the groups were combined, there
did seem to be a reduction in bone growth in Dex-treated null and wildtype mice.
However, this reduction was not significantly different (Figure 5.10C).Chapter 5 The Role of p21 in GC-Induced Growth Retardation
175
Figure 5.10 Skeletal growth of Dex-treated p21 null mice (A) Representative x-
rays from (I) wildtype control, (II) wildtype Dex-treated, (III) p21
-/- control and (IV)
p21
-/- Dex-treated mice on day 6. Scale bar = 2cm. (B) Percentage tibial growth
from day 0 for p21
-/- and wildtype mice treated with or without Dex (C) Percentage
growth of combined values from tibiae, femurs and tails of Dex-treated p21 null and
wildtype mice (n = 8; all data are expressed as mean  SEM).
5.5.2.7 Growth Plate Morphology in Dex-treated p21 Null Mice
As before, Dex significantly reduced the width of the growth plate in wildtype mice,
due to a reduction in the width of both the proliferative and hypertrophic zones
(p<0.001; Figure 5.11A I and II; Figure 5.11B). A similar response to Dex was
observed in the growth plates of p21
-/- mice, with a significant reduction in the width
of the proliferating and hypertrophic zones, leading to a reduction in overall growth
plate width (p<0.001; Figure 5.11A III and IV; Figure 5.11B). Interestingly, the
hypertrophic zone in p21
-/- control mice was also significantly smaller than theChapter 5 The Role of p21 in GC-Induced Growth Retardation
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hypertrophic zone in control wildtypes (p<0.05; Figure 5.11A I and III; Figure
5.11B).
Figure 5.11 Toluidine Blue staining of growth plates from Dex-treated p21 null
mice. (A) Proximal tibia growth plate sections from control wildtype (I), Dex-treated
wildtype (II), p21 null control (III) and Dex-treated p21 null (IV) mice stained with
toluidine blue for analysis of growth plate morphology and zone width. Scale bar =
200µm (B) The widths of both the proliferating and hypertrophic zones were
significantly reduced in Dex-treated mice from both wildtype and p21 null strains,
resulting in a reduction in the overall growth plate width. (PZ = proliferating zone;
HZ = hypertrophic zone) (***p<0.001 versus respective control group; *p<0.05
versus respective control group;
αp<0.05 versus wildtype control HZ; n = 8; all data
are expressed as mean  SEM).Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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5.5.2.8 Effect of Dex on Mineral Apposition in p21
-/- Mice
The daily rate of mineral formation (MAR) was measured using a Calcein
fluorochrome label as previously described (5.4.2.7). The MAR in proximal tibiae
from Dex-treated wildtype and null mice was significantly reduced compared to
control mice (51% and 27% reduction, respectively; p<0.05; Figure 5.12A and B).
Interestingly, the MAR in p21-/- control mice was also significantly reduced
compared to wildtype controls (38%; p<0.05; Figure 5.12A).Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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Figure 5.12 Calcein labelling in Dex-treated p21-/- mice (A) Proximal tibia
sections from control wildtype (I), Dex-treated wildtype (II), p21 null control (III) and
Dex-treated p21 null (IV) mice examined under fluorescence for analysis of the
mineral apposition rate. The MAR was calculated by measuring the distance between
the distal end of the growth plate and the mineralisation front (green fluorescence),
and dividing this by the number of treatment days. Scale bar = 500µm (B) MAR in
wildtype and p21 null mice treated with Dex. The MAR was significantly reduced
with Dex treatment in both wildtype and null mice (***p<0.01, *p<0.05 vs. WT
control;
αp<0.05 vs. p21
-/- control; all data are expressed as mean  SEM).Chapter 5 The Role of p21 in GC-Induced Growth Retardation
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5.6 Discussion
Previous findings by us, and others, have suggested that GCs may act to inhibit bone
growth by causing premature differentiation of growth plate chondrocytes (Mushtaq
et al., 2002; James et al., 2007; Chapters 3 and 4). p21 is a CDKI that has previously
been shown to increase in expression in differentiating chondrocytes (Negishi et al.,
2001; Stewart et al., 1997), a finding that has been supported in this study. In ATDC5
cells, p21 gene and protein expression increased throughout the differentiation
process, whereas the expression of all other CDKIs tested remained unchanged. As a
CDKI, p21 controls the cell cycle by blocking the formation of Cyclin/CDK
complexes which promote cell cycle progression through the phosphorylation of
pocket proteins pRb (Retinoblastoma protein), p107 and p130. Once phosphorylated,
these pocket proteins form complexes with E2F transcription factors, leading to the
transcription of genes necessary for cell cycle progression and DNA replication.
Consequently, it is thought that the main function of p21 is the inhibition of cell
proliferation and promotion of differentiation (Harper et al., 1995). At high
concentrations, p21 also acts as an inhibitor of proliferating cell nuclear antigen
(PCNA) activity, a characteristic which is unique to p21, distinguishing it from other
CDKIs (Luo et al., 1995). A number of studies have correlated the expression of p21
with cell cycle arrest and/or differentiation in many cell types after treatment with
extracellular growth regulators, exposure to particular environmental conditions, or by
ectopic expression of intracellular modulators of the cell cycle (Sherr 1995; Harper
and Elledge 1996). p21 is under transcriptional control by the p53 tumour suppressor
gene, and the p21 promoter contains two p53 binding sites that are conserved in
several species. For p53-dependent activation, at least one of these sites must beChapter 5 The Role of p21 in GC-Induced Growth Retardation
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functioning (El-Deiry et al., 1995). p53 dependent activation of p21 has been shown
to be critical in response to DNA damage, although during development, p21
expression is normal in p53
-/- mice. p21 activation can also occur independently of
p53, and there are many factors involved in the activation of p21 at the transcriptional
level. These include vitamin D receptor (Liu et al., 1996), retinoic acid receptor (Liu
et al., 1996), TGF-β1 and the AP2 (Zeng et al., 1997), E2A (Prabhu et al., 1997), Sp1,
Sp3 and STAT1 transcription factors through their respective response elements on
the p21 promoter (Figure 5.13) (El-Deiry et al., 1993, 1994, 1995; Michieli et al.,
1994). Other factors include nerve growth factor (Erhardt et al., 1998), platelet-
derived-growth factor (Michieli et al., 1994), progesterone (Owen et al., 1998), and
steroid hormones (Jiang et al., 1994). In specific osteosarcoma and fibroblast cell
lines, GCs have been shown to increase p21 expression through unknown
mechanisms. GC inhibition of L929 mouse fibroblast proliferation was associated
with an induction of p21 expression (Ramalingam et al., 1997), and GCs were also
shown to inhibit the entry of alveolar epithelial cells into the S-phase by inducing p21
expression (Corroyer et al., 1997).
In this study, Dex significantly increased p21 gene and protein expression after 1 and
6 hours in ATDC5 cells. The rapid response in p21 expression with Dex is not
surprising, as it has previously been shown that GCs stimulate p21 promoter activity.
Although no GREs have been detected on the p21 promoter, it is thought that Dex
acts through the C/EBPα transcription factor to directly increase p21 transcription
(Figure 5.13) (Cha et al., 1998; Cram et al., 1998). It is possible that this increase in
p21 expression with Dex-treatment could contribute to GC-induced growth
retardation. In order to test this hypothesis, the effect of Dex on skeletal growth wasChapter 5 The Role of p21 in GC-Induced Growth Retardation
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analysed in mice lacking the p21 gene. Before this, however, it was necessary to
develop a Dex dosing regime that effectively caused growth retardation in 4-week-old
mice.
Figure 5.13 Factors acting on the p21 promoter A number of factors act to
transcriptionally activate or repress p21 expression. The two p53 binding sites at
positions 2301 and 1324 are critical for p21 expression during DNA damage and
irradiation. Dex increases p21 expression through the transcription factor C/EBP at
position 1263. Figure adapted from Gartel et al., 1999.
Injecting mice with 5mg/kg Dex daily for 7 days caused a significant reduction in
growth by day 3 of treatment. The weights of the tibia, liver and spleen were
significantly reduced in Dex treated mice, a finding that has previously been reported
(Smink et al., 2003a; Van Buul-Offers et al., 2005). The reduction in spleen weight is
most likely due to its known role in the immune response, and the effects on the liver
may be due to its roles in drug metabolism. The reduction in weight of the tibia
suggests that tibial growth was reduced, possibly due to a reduction in the width of theChapter 5 The Role of p21 in GC-Induced Growth Retardation
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proliferative and hypertrophic zones within the growth plate. This effect on the
growth plate has been widely reported, (Smink et al., 2003a; Smink et al., 2003b; Van
Buul-Offers et al., 2005) and is probably due to a reduction in chondrocyte
proliferation, as shown in Chapter 4, and by previous studies (Robson et al., 1998;
Klaus et al., 2000; Mushtaq et al., 2002; Owen et al., 2007), in addition to an increase
in chondrocyte apoptosis, and possibly a reduction in IGF-I expression (Smink et al,
2003).
When this dosing regime was implemented in 4-week old mice lacking the p21 gene,
significant growth retardation was still observed. As previously reported, p21
-/- mice
have no obvious skeletal phenotype (Deng et al., 1995), an interesting finding which
has also been shown in mice lacking the p27 gene (Emons et al., 2006). Although
p21
-/- generally seemed smaller than their wildtype littermates, the width of the
proliferating and hypertrophic zones within the growth plate were not significantly
different. Interestingly, however, the MAR in p21
-/- control tibiae was significantly
lower than wildtypes, suggesting that p21 may act on other factors involved in
mineralisation. These findings suggest that p21 alone does not play a major role in
longitudinal bone growth and endochondral ossification. It is possible that there may
be considerable redundancy between the CDKIs, and that a number of CDKIs may act
together to control chondrocyte dynamics in the growth plate. It would therefore be
interesting to study skeletal growth in mice with numerous CDKI null mutations, such
as p27
-/-and p21
-/- together.
When treated with Dex, the growth plate widths of p21-/- mice were significantly
reduced, due to a reduction in the width of both the proliferative and hypertrophicChapter 5 The Role of p21 in GC-Induced Growth Retardation
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zones, as observed in wildtype mice. Interestingly, when measuring longitudinal bone
growth by x-rays throughout the treatment period, no significant changes in growth
were observed in either mouse strain with Dex treatment. Previous studies have
suggested that obvious skeletal differences are only observed after long-term GC
treatment of up to 1 month (Smink et al., 2003), although morphological cell changes
within the growth plate are observed much earlier. Due to the size of the mice and the
x-ray, it was difficult to accurately determine the beginning and end of the bone in
question. Measuring skeletal growth using x-ray technology is also limited due to the
large amount of varation in results that can arise from the distance between the mouse
and the x-ray apparatus, differences in exposure between days, and similarly,
differences in experimental procedure between the staff of the small animal unit
between different days. An alternative measurement of skeletal growth during Dex
treatment, such as tail length, may have highlighted changes between treatment
groups, due to the large number of long bones, and hence growth plates present in
murine tails. The mineral apposition rate was also reduced in Dex-treated mice from
wildtype and p21
-/- groups, which is unsurprising when the reduction in growth plate
width is taken into account. This finding has previously been shown (Fritz et al.,
1998), and an additional contributing factor is likely to be increased osteoblast
apoptosis and increased survival of osteoblasts (Kim et al., 2006).
5.7 Conclusions
The role of p21 in GC-induced growth retardation was studied due to the findings
from this, and previous studies that p21 expression is increased in chondrocyte
differentiation, and that p21 expression is increased with Dex. Findings from this
study suggest that, although p21 seems to play a role in GC effects in ATDC5 cells, itChapter 5 The Role of p21 in GC-Induced Growth Retardation
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does not seem to be important in GC-induced growth retardation in vivo. A number
of other cell cycle regulators have also been shown to be important in chondrocyte
growth in vitro, such as p57 and p27, although their effects on skeletal growth in vivo
are minimal. Although the cell cycle does play some role in the control of
endochondral ossification, it is clear that a number of other factors are involved.Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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6.1 Introduction
Glucocorticoids (GC) are commonly used as anti-inflammatory or
immunosuppressive treatments, and it has been estimated that 5-10% of children may
require some form of GC therapy at some time in childhood (Warner 1995). Since the
introduction of GCs in the treatment of rheumatoid arthritis over 50 years ago, the
therapeutic applications of these drugs have greatly broadened to encompass a large
number of non-endocrine and endocrine diseases (Hench et al., 1949). Despite
intense efforts in optimising therapy, adverse effects of GC medication are still
common with growth impairment being one of the commonest in childhood (Mushtaq
and Ahmed 2002).
Over the last several decades, attempts to improve the therapeutic window of GCs
have focused on methods of limiting systemic exposure. These include the
development of topical or inhaled agents such as budesonide, or the development of
"antedrugs" such as fluticasone propionate that act at the site of administration but are
transformed to inactive metabolites upon entry to the systemic circulation. Much
effort has also been spent on modifying the steroid backbone of GCs in an attempt to
reduce the side effect profile; however, these efforts have been met with little success.
Deflazacort, a D-ring-substituted steroid otherwise similar to cortisol, was originally
hyped as a powerful anti-inflammatory molecule exhibiting more selective activity,
and therefore reduced adverse effects on bone and glucose metabolism. Initially,
clinical data supported this notion (Markham et al., 1995; Canalis et al., 1992).
However, subsequent trials that adjusted the steroid dose to maintain equivalent anti-
inflammatory efficacy needed higher doses of Deflazacort that resulted in the re-
occurrence of side effects (Markham et al., 1995).Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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It has only been in the last 5-10 years, however, that an understanding of the
molecular mechanism by which GCs elicit their biological effects has led to the
development of structurally novel small molecule GR modulators that differentiate the
anti-inflammatory properties from the metabolic side effects of GCs. The field was
re-energised by the discovery that the likely mechanism of GR-mediated repression of
pro-inflammatory genes involved the receptor binding directly to specific
transcription factors (AP-1 and NFκB) involved in up-regulating inflammatory genes.  
This mechanism was genetically separable from transcriptional activation and lead to
the search of ligands that could induce transcriptional repression but impede
transcriptional activation. In 1997, the first compounds that separated transactivation
from transrepression were reported (Vayssiere et al., 1997). These compounds
(RU24858, RU40066 and RU24782) were steroidal in nature, were very efficient
inhibitors of both AP-1 and NFκB-mediated gene induction, and were strong anti-
inflammatory agents in vivo. However, subsequent in vivo studies revealed that,
despite their promising in vitro profile, no therapeutic advantage could be
demonstrated for these molecules. It was found that they were no better than Pred
when side effects such as body weight, thymic involution and inhibitory effects at the
growth plate of the femoral head were measured (Belvisi et al., 2001).
The activation-repression hypothesis has also been used as an approach to discovering
selective GR modulators. One such ligand discovered in this way was a compound
created during a collaborative effort between Abbott Laboratories and Ligand
Pharmaceuticals, named AL-438 (Abbott-Ligand 438) (Coghlan et al., 2003). This
ligand was shown to be a specific, non-steroidal ligand for the GR that exhibited a
unique profile both in vitro and in vivo.Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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Although AL-438 possesses a tetracyclic core similar to classic GCs, there are several
key structural differences that alter its functional activity. These include: the lack of
a C-11-hydroxyl group mandatory for function in steroidal GR ligands; the absence of
a C-3 ketone typically found in corticosteroids; the addition of a secondary amine
function in AL-438 and the presence of a methoxy group in needed for GR selectivity
and functional activity (Zhi et al., 1998). These structural differences significantly
alter the functional activity of AL-438 compared to other GCs such as Dex, allowing
the activational properties to be separated from repression (Figure 6.1).
Figure 6.1 Structural differences between AL-438 and Dexamethasone Although
AL-438 possesses a tetracyclic core similar to classic GCs, there are several key
structural differences that alter its functional activity. (1) The lack of a C-11-hydroxyl
group mandatory for function in steroidal GR ligands; (2) the absence of a C-3 ketone
typically found in corticosteroids; (3) the addition of a secondary amine function in
AL-438 and (4) the presence of a methoxy group in needed for GR selectivity and
functional activity
AL-438 displayed similar affinity to Pred at the GR (Ki = 2.5nM and 2.4nM,
respectively), and was fully efficacious when repressing E-selectin activity compared
to Dex (94% repression of activity compared to Dex). AL-438 is fully efficacious at
the transcriptional repression of certain genes related to the anti-inflammatory aspect
of GC activity (E-selectin and interleukin-6 (IL-6)), but is weaker (a partial agonist)
for the transcriptional activation of certain genes linked to adverse side effects. ThisChapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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activity seems to be cell-type specific, as, using other promoters in different cell
backgrounds, AL-438 becomes more active as a transcriptional activator In animal
models, AL-438 was as efficacious as Pred at inhibiting inflammation, and
importantly, AL-438 exhibited significantly reduced impact on fasting glucose levels
compared with Pred, suggesting that this compound might not cause the diabetogenic
effects of steroidal GCs (Coghlan et al., 2003). Studies with AL-438 using the
carrageenan-induced paw edema assay and the adjuvant arthritis models in rats have
shown that it retains full anti-inflammatory efficacy but has reduced negative effects
on bone compared to those elicited by Pred (Elmore et al., 2001; Coghlan et al., 2003,
6.2 Hypothesis
Due to the bone-sparing properties of AL-438 in osteoblasts, it is hypothesised that
AL-438 will have reduced deleterious effects on growth plate chondrocyte dynamics
compared with the effects of other commonly used GCs such as Dex and Pred.
6.3 Aims
I. Compare the effect of AL-438 on chondrocyte proliferation and differentiation
in ATDC5 cells with the commonly used GCs, Dex and Pred.
II. Analyse the effect of AL-438 on longitudinal bone growth in vitro compared
to Dex using the foetal mouse metatarsal culture model.
III. Determine the anti-inflammatory efficacy of AL-438 in ATDC5 cells
compared to Dex.Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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6.4 Materials and Methods
6.4.1 ATDC5 Proliferation in AL-438 Treated Cells
ATDC5 cells were maintained as previously described (2.2.3). Dex, Pred, AL-438 or
0.01% dimethyl sulphoxide (DMSO) (10
-6M, 10
-7M or 10
-8M) were added to the cells
during both chondrogenesis (day 6) and terminal differentiation (day 13), and were
incubated for 24h. Chondrocyte proliferation was measured using the [
3H]thymidine
incorporation assay as previously described (2.9.1).
6.4.2 Effect of AL-438 on Proteoglycan production in ATDC5 cells
Dex, Pred and AL-438 (10
-6M) or 0.01% DMSO were added to ATDC5 cells at day 6
or day 13 for 96h. For analysis of proteoglycan production, ATDC5 cells were
measured for alcian blue incorporation onto the monolayer as previously described
(2.9.2).
6.4.3 Effect of AL-438 on Alkaline Phosphatase Activity
Dex, Pred and AL-438 (10
-6M) or 0.01% DMSO were added to ATDC5 cells at day 6
or day 13 for 96h. To measure ALP activity, cells were scraped and the supernatant
was assayed for protein content and ALP activity as previously described (2.9.3).
6.4.4 Expression of Chondrocyte Marker Genes with AL-438
In order to study and compare the effects of AL-438 on chondrocyte marker gene
expression, Dex, Pred and AL-438 were added to the cells during both
chondrogenesis (day 6) and terminal differentiation phases (day 13) at a final
concentration of 10
-6M in 0.01% (DMSO). Control cultures contained 0.01% DMSO
only. Cells were grown in the presence of the compounds for 4 days, at which pointChapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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RNA was extracted, reverse transcribed and analysed for aggrecan gene expression by
qPCR as previously described (2.5.5). Primers for aggrecan were obtained from
SuperArray Bioscience (Maryland, USA; sequence unknown) and primers for GAPDH
were designed using the software programme Primer3 (Whitehead Institute for
Biomedical Research) (forward 5’ TGAGGCCGGTGCTGAGTATGTCG 3’, reverse
5’CCACAGTCTTCTGGGTGGCAGTG 3’). Briefly, cDNA (5ng) was amplified in
triplicate using the Platinum SYBR Green qPCR SuperMix (Invitrogen, Paisley, UK)
under the following conditions: cDNA was denatured for 2 minutes at 95
oC,
followed by 40 cycles consisting of 15 s at 95
oC and 30 s at 60
oC and 1 cycle
consisting of 1 min at 95
oC and 30 s at 60
oC. Each reaction contained 10l cDNA,
25l Platinum SYBR Green qPCR Super-Mix, 1l ROX Reference Dye, and 250nM
primer in a total volume of 40l. Fold changes, normalised for the expression of
GAPDH, were calculated using the comparative method as previously described
(2.5.5) (Livak et al., 2001).
6.4.5 Apoptosis in AL-438 Treated ATDC5 Cells
Dex, Pred and AL-438 (10
-6M) were added to ATDC5 cells in a 6-well plate during
chondrogenesis or terminal differentiation periods for 24h. As a positive control, cells
were incubated as above with 10ng/ml TNFα (Autogen Bioclear, Wiltshire, UK).
Apoptosis was then measured using the Caspase-3 Apoptosis assay, which was used
according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN,
USA). Caspase-3 is a cysteine protease that exists as a proenzyme, and is activated
during apoptosis. Briefly, cells were scraped in their own medium and transferred to
Eppendorfs. The cells were then centrifuged at 17,900 x g for 2mins, the supernatant
removed and 75l of lysis buffer added to the pellet. This was incubated for 10minsChapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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at 4
oC, and centrifuged again at 10000g for 1min. The supernatant was then
transferred to a fresh Eppendorf and kept on ice. 50l of this supernatant was added
to wells in duplicate in a 96-well plate, along with 50l reaction buffer plus DTT
(10l) per 1ml reaction buffer), and 5l substrate. The 96-well plate was then
incubated for 2h at 37
oC and read at 405nm. Following this, the protein content of
the cell lysates was measured as previously described (2.7.1).
6.4.6 Determination of Anti-inflammatory Efficacy of AL-438 in ATDC5 Cells
ATDC5 cells were grown in 10µg/ml LPS (Lot 104K4036; from EColi 0127:B8;
Sigma) with or without Dex or AL-438 (10
-6M) for 24h. The medium was removed
and analysed for levels of IL-1, IL-6 and TNF-α by Luminex technology (assay
completed by Dr Alistair Gracie, Division of Immunology, Infection and
Inflammation, University of Glasgow). Luminex technology utilises patented pre-
dyed microsphere bead sets allowing up to 100 cytokines to be measured
simultaneously in the one biological sample. By utilising the theory of a sandwich
ELISA, a specific antibody against a cytokine of choice is coupled to an individual
bead set. Combinations of these bead sets are then incubated with the sample and
thereafter a cocktail of detection antibodies are labelled with a reporter fluorochrome.
Detection of the beads and quantification of cytokines was then performed using a
Multiplex system and Bio-Plex software (Bio-Rad Laboratories, Inc., Hemel
Hempstead, Herts, UK). This technique has the advantage of allowing detection of
multiple cytokines from a single small sample volume (typically 50μl). In addition,
unlike a standard ELISA which gives one optical density value for each sample,
Luminex will give the average value of at least 100 individual measurements per
cytokine in each sample. All samples were assayed in duplicate and values determinedChapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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by comparison to standard curves run in parallel. Analysis was carried out as per
manufacturer’s instruction using preconfigured multiplex cytokine kits (Biosource,
Nivelles, Belgium).
6.4.7 Foetal Metatarsal Organ Culture
The middle three metatarsals were aseptically dissected from 18-day-old embryonic
Swiss mice that had been killed by decapitation (2.3.6). The experimental protocol
was approved by Roslin Institute’s Animal Users Committee and the animals were
maintained in accordance with Home Office guidelines for the care and use of
laboratory animals. Bones were individually cultured at 37°C in a humidified
atmosphere in the conditions described in section 2.3.6. Dex or AL-438 were added
at a final concentration of 10
-6M in 0.01% DMSO to the bones and the medium was
changed every second or third day. The control groups (0.01% DMSO only) and
experimental groups contained 6 metatarsals each.
Figure 6.2 Murine foetal metatarsal culture model. (A) Metatarsals were dissected
from the hind legs of 18-day-old foetal mice, and cultured for up to 10 days in the
presence of Dex or AL-438. (B) Metatarsal after 10 days of culture (Scale bar =
1mm).
A
B
A
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6.4.8 Morphometric Analysis
Images were taken of the metatarsals every second or third day of culture using a
digital camera attached to a Nikon TE300 microscope. The total length of the bone
was determined using Image Tool (Image Tool version 3.00, University of Texas
Health Life Science Centre, San Antonio, TX). All results are expressed as a
percentage change from harvesting length, which was regarded as baseline to
demonstrate the rate of growth over time. For the determination of the size (in the
direction of longitudinal growth) within the growth region of the distinct chondrocyte
maturational zones, the 12-day-old metatarsals were fixed in 70% ethanol,
dehydrated, and embedded in paraffin wax (Mushtaq et al., 2004). Wax sections
(10µm in thickness) were reacted for ALP activity for the demarcation of the
hypertrophic and proliferating zones. Sections were also stained with von Kossa and
haematoxylin and eosin using standard protocols to identify the zone of cartilage
mineralisation (Mushtaq et al., 2004). Images of the stained metatarsals were
captured and the size of the ALP-negative proliferating zone was determined
(proliferating zone = total length – (hypertrophic zone + mineralising zone). The size
of the hypertrophic zone was determined by subtracting the von Kossa stained
mineralising zone from the ALP-positive zone, and the size of the mineralising zone
was determined directly from the von Kossa-stained sections.
6.4.9 Histological Assessment of Bromodeoxyuridine (BrdU) Uptake
BrdU was added to the culture medium of the metatarsals at a final concentration of
1mg/ml for the last 6h of culture on day 12. At the end of the incubation period, the
tissue was washed in PBS and fixed in 70% ethanol, dehydrated, and embedded in
paraffin wax. Sections 10µm in thickness were cut along the longitudinal axis, andChapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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chondrocyte nuclei with incorporated BrdU were detected as described in section
2.4.5. To determine the proliferation index, the total number of BrdU positive cells
was divided by the total area of the metatarsal section. Three sections from each of
six bones from each treatment group were examined to obtain an aggregate value.
6.4.10 Statistical Analysis
Data were analysed by one-way analysis of variance. All data are expressed as the
mean ± S.E.M of at least 6 replicates within each experiment, and statistical analysis
was performed using Minitab (Minitab 14; PA, USA). P<0.05 was considered to be
significant.
6.5 Results
6.5.1 Effect of AL-438 on ATDC5 Cell Number and Proliferation
During chondrogenesis exposure to Dex or Pred for 24h led to a concentration-
dependent reduction in [
3H]-thymidine incorporation (54.5% and 29.2%, respectively,
at 10
-6M (p<0.05)), whereas exposure to AL-438 had no significant effect at any
concentration tested (Figure 6.3A and 6.3B). Therefore, based on these data and
previous observations that the affinity of AL-438 and Pred for the GC-receptor is
similar (Elmore et al., 2001), a saturating dose of 10
-6M was used for all compounds
in future experiments. Counting the cells directly in a haemocytometer chamber
supported these results, with Dex and Pred causing a significant reduction in cell
number at 10
-6M (36.2% and 36.8% respectively (p<0.05)), and AL-438 having no
significant effect (Figure 6.3C). During the terminal differentiation phase (days 13-
17), no compounds significantly altered chondrocyte proliferation or cell number
(data not shown).Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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Figure 6.3 Effect of Dex, Pred and AL-438 on cell proliferation as assessed by
[
3H]-thymidine uptake. (A) Dex (and solid line) and Pred ( and dashed lines)
caused a dose-dependent decrease in ATDC5 chondrocyte proliferation, whereas AL-
438 (▲ and solid line) had no effect.  (B) ATDC5 proliferation with 10
-6M Dex, Pred
and AL-438. (C) Cell proliferation as measured by counting the cells directly in a
haemocytometer. Data are expressed as means ± SEM. (n = 6 separate cell culture
replicates). ***p< 0.001 compared with control treated cells.Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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6.5.2 Differentiation in AL-438-treated Chondrocytes
In comparison with control cultures during the chondrogenesis period, exposure to
10
-6M Dex and Pred for 96h caused a significant reduction in proteoglycan synthesis,
as measured by Alcian Blue staining of the ATDC5 cell monolayer (56% and 54%,
respectively; p<0.001), whereas exposure to AL-438 had no significant effect (Figure
6.4A). No significant differences between treatments were noted during terminal
differentiation (data not shown). The effect of AL-438 on terminal chondrocyte
differentiation was assessed by ALP activity. During chondrogenesis, ALP activity
was significantly increased after exposure to Dex, Pred and AL-438 (p<0.001) (Figure
6.4B), but no significant differences were observed during terminal differentiation
(data not shown).
Figure 6.4 Effect of AL-438 on ATDC5 differentiation. A) Effect of Dex, Pred and
AL-438 (all 10
-6M) on proteoglycan production as assessed by Alcian Blue staining in
ATDC5 cells during chondrogenesis. Data are expressed as means ± SEM (n = 6 cell
culture replicates). ***p<0.001 compared with control and AL-438 treated cells. B)
Effect of Dex, Pred and AL-438 (all 10
-6M) on ALP activity in ATDC5 cells during
chondrogenesis. Data are expressed as means ± SEM (n = 6). ***p<0.001 compared with
control treated cells.Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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6.5.3 Effect of AL-438 on Apoptosis in ATDC5 Cells
Caspase-3 activity was unchanged in Dex, Pred and AL-438 treated cells compared to
controls during both chondrogenesis and terminal differentiation, but TNF- led to a
significant increase in Caspase-3 activity, as expected (93% increase in Caspase-3
activity compared to control samples; p<0.001) (Figure 6.5).
Figure 6.5 Effect of AL-438 on apoptosis in ATDC5 cells during chondrogenesis.
Dex, Pred, AL-438 (10
-6M) and TNF (10ng/ml) were added to ATDC5 cells for 24h
and Caspase-3 activity measured at 405nm. Absorbances were then normalised to
amount of protein per sample. Data are expressed as means ± SEM (n = 6 cell culture
replicates). *P<0.001 compared with control and AL-438 treated cells.Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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6.5.4 Chondrocyte Marker Gene Expression in AL-438 treated ATDC5 Cells
Endpoint PCR of ATDC5 cDNA from Dex, Pred, and AL-438 treated cells revealed
that the expression of chondrocyte marker genes Coll II, Coll X and aggrecan was
reduced by Dex. Pred caused a small reduction in aggrecan expression, but no
changes in expression were observed in AL-438 treated cells. Analysis by qPCR
confirmed a significant reduction in aggrecan expression with Dex (3.5-fold
reduction; p<0.001), and with Pred (1.36-fold; p<0.001), but no effect on aggrecan
expression by AL-438 (Figure 6.6).
Figure 6.6 Chondrocyte marker gene expression in ATDC5 cells. A) RT-PCR
of Coll II, Coll X, and aggrecan in ATDC5 cells treated with Dex, Pred or AL-438
(10
-6M) for 96h. (B) qRT-PCR of aggrecan gene expression in ATDC5 cells treated
with Dex, Pred or AL-438 (10
-6M) for 96h. All data are shown as the mean relative
gene expression ± SEM (n=6 cell culture replicates run in triplicate) and normalised to
GAPDH mRNA levels. ***p<0.001; **p<0.01 compared with control treated cells.Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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6.5.5 Anti-inflammatory Efficacy of AL-438 in ATDC5 Cells
LPS induced IL-6 production in ATDC5 cells and this induction was reduced by the
co-incubation of Dex or AL-438 by 58.1% and 55.4%, respectively. These results
were significantly different from IL-6 levels in LPS-only treated cells (p<0.001), but
not significantly different from each other (Figure 6.7). Interestingly, levels of IL-1β
and TNF- were undetected in control and test samples (data not shown). These
results demonstrate that AL-438 has a similar anti-inflammatory efficacy to Dex in
ATDC5 cells.
Figure 6.7 LPS-induced IL-6 production in ATDC5 cells. ATDC5 cells were
grown in 10µg/ml lipopolysaccharide (LPS) (Lot 104K4036; from EColi 0127:B8;
Sigma) with or without Dex or AL-438 (10
-6M) for 24h. The medium was removed
and analysed for levels of IL-1, IL-6 and TNF-α by Luminex technology. Data are
expressed as means ±S.E.M. (n = 6). ***p < 0.001 compared with LPS treated cells.Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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6.5.6 Longitudinal Bone Growth and Assessment of Maturational Zones
Until day 7 of culture, foetal mouse metatarsals treated with Dex or AL-438 grew at a
similar rate to controls. After day 7, Dex treated metatarsals were significantly shorter
than controls (18.5% shorter at day 10 (p<0.05) and 22.2% shorter at day 12
(p<0.01)), whereas the growth of the AL-438 treated metatarsals continued to parallel
the growth of the controls (Figure 6.8A). The lengths of the proliferating,
hypertrophic and mineralising zones were measured on histological sections of 12-
day-old metatarsals (Table 6.1), using Von Kossa staining to identify mineralisation,
and ALP staining to identify the hypertrophic and proliferating regions (Figure 6.8B
and C). The lengths of the proliferating and hypertrophic zones did not significantly
change between treatments, however, Dex significantly reduced the length of the
mineralising zone (57% of control; p<0.05).Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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Figure 6.8 Effect of AL-438 on the growth of murine metatarsals (A) Effect of
Dex or AL-438 (10
-6M) on the growth of metatarsals isolated from the hind legs of
18-day old foetal Swiss mice and cultured over a 12-day period ( = Control; ♦ = 
AL-438; ■ = Dex) Data are expressed as mean ± SEM (n = 6). **p<0.01 compared
with controls; *p<0.05 compared with controls. (B) The mineralisation zone was
measured by Von Kossa staining of 12-day old metatarsal sections. (C) The length of
the hypertrophic and mineralising zone was defined by ALP staining, and the
proliferating zone was deduced by subtracting the total length of ALP staining from
the entire length of the bone (Scale bars = 200µm).
Treatment Mineralising zone Hypertrophic zone Proliferating zone
Control 1.29 +/- 0.08 0.68 +/- 0.09 0.84 +/- 0.02
Dexamethasone 0.74 +/- 0.19 * 0.77 +/- 0.12 0.71 +/- 0.05
a
AL-438 1.30 +/- 0.07 0.56 +/- 0.06 0.80 +/- 0.03
Table 6.1 – Lengths of the proliferating, mineralising and hypertrophic zones in
murine metatarsals treated with Dex or AL-438. Data are expressed in mm ± SEM
(n = 6). *P<0.05 compared with controls;
aP = 0.06 compared with controls.Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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6.5.7 Effect of AL-438 on Chondrocyte Proliferation in Metatarsals
To study the effect of AL-438 on chondrocyte proliferation on a more physiological
level, the number of proliferating cells in murine metatarsals was determined by BrdU
incorporation analysis (Figure 6.9) The proliferation index in control metatarsals was
significantly higher than metatarsals treated with either Dex (76%; p<0.001) or AL-
438 (80%; p<0.001).
Figure 6.9 Histological assessment of chondrocyte proliferation in metatarsals
treated with Dex or AL-438 BrdU-labeled cells in control, Dex-treated and AL-438-
treated metatarsals cultured for 12d. Note the decreased number of proliferating cells
in the Dex- and AL-438 treated metatarsals. The proliferation Index was calculated
by dividing the total number of BrdU positive cells by the total section area in mm
2.
***p<0.001 compared with controls.
6.6 Discussion
Glucocorticoids are the most effective anti-inflammatory agents known. However, in
children, their long-term use leads to growth retardation through a combination of
GC-mediated effects on the systemic GH/IGF-1 axis as well as direct effects on the
growth plate (Ahmed & Mushtaq, 2002). Infusion of GC directly into the growth
plate results in a decrease in the ipsilateral tibial growth rate with no effects on the
contralateral limb, suggest the possibility of a mechanism intrinsic to the epiphyseal
growth plate (Baron et al., 1992).Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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The search for a novel GC that has the anti-inflammatory properties of conventional
steroids without one or more of the side-effects has been a long-standing goal.
Previous efforts have concentrated primarily on modifying the steroid backbone,
albeit with little success. Deflazacort, a D-ring substituted steroid, was originally
hailed as a powerful anti-inflammatory molecule exhibiting reduced activity in bone
and glucose metabolism (Miner 2002). Although, initial clinical data supported this
notion (Canalis et al, 1992), subsequent trials that adjusted the steroid dose to
maintain equivalent anti-inflammatory efficacy resulted in the need for higher levels
of deflazacort at which the advantages of deflazacort disappeared (Markham et al.,
1995). The discovery of specific transcription factors (NFB and AP-1) that bind to
the GR and which can up- or down-regulate specific inflammatory genes initiated the
search for ligands that could induce selective transcription (Diamond et al., 1990;
Jonat et al., 1990).
AL-438 is a specific, non-steroidal ligand for the GR that exhibits a unique profile,
both in vivo and in vitro. It retains full anti-inflammatory activity but has reduced
negative effects on osteoblasts compared to Pred (Miner 2002; Coghlan et al., 2003;
Rosen and Miner, 2005). In this study, incubating ATDC5 cells with AL-438 had no
effect on cell proliferation, cell number or proteoglycan synthesis, whereas, as found
in previous studies, these factors were significantly reduced by both Dex and Pred
(Mushtaq et al., 2002; Fujita et al., 2004). The finding that Dex and Pred promoted
ALP activity is in concordance with the pro differentiating effects of Dex and Pred,
and has previously been reported by us (Mushtaq et al., 2002). The increase in ALP
activity observed with AL-438 suggests that the bone-sparing effects seen with AL-Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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438 are not due to direct effects on chondrocyte differentiation, but may be due to
reduced effects on chondrocyte proliferation compared to Dex and Pred. The lack of
effect of Dex on ATDC5 apoptosis is in agreement with previous studies (Mushtaq et
al., 2002) but at variance with other chondrocyte studies (Chrysis et al., 2005),
suggesting a cell type dependent effect. Studies measuring the bone turnover marker
osteocalcin in the human osteoblast-like cell line MG-63 have shown that AL-438 is
unable to inhibit osteocalcin expression as efficiently as Pred (Coxam et al., 1996). In
addition, AL-438 has been shown to exhibit a weak inhibition of osteoprotegerin in
MG-63 cells compared to other GCs (Coghlan et al., 2003). The differential effect on
ATDC5 cell progression between AL-438 and Dex and Pred may be due to the fact
that AL-438 is qualitatively different in terms of its ability to activate or repress gene
expression. Interestingly, none of the compounds had an effect on ATDC5
maturation in terms of proliferation, ALP activity or proteoglycan production during
the terminal differentiation period, a finding that has been reported previously
(Mushtaq et al., 2002).
There are at least three distinct mechanisms by which GCs can regulate gene
transcription. Firstly, GCs can bind to a cytosolic GR which translocates to the
nucleus and, in the case of positive regulation, transactivates through cis-activating
palindromic glucocorticoid response elements (GREs) located in the promoter region
of responsive genes. Secondly, GCs are able to bind to negative GREs resulting in the
repression of gene transcription. However, GCs decrease the transcription of genes
involved in the inflammatory process that have no identifiable GREs in their promoter
regions, suggesting that an alternative mechanism must mediate this inhibitory effect.
There is now evidence to suggest that GCs may control inflammation predominantlyChapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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through the trans-repression of transcription factors that regulate inflammatory gene
repression, such as activator protein-1 (AP-1), NFĸB, and nuclear factor of activated 
T-cells (NF-AT) (Belvisi et al., 2001).
There is now increasing acceptance of the hypothesis that the side effects of steroids
are likely to be due to the transactivation of genes (such as those involved in lipid and
muscle metabolism) through binding of the GR dimers to DNA, whereas the anti-
inflammatory effects may be due to the binding of a single GR to transcription factors
or corepressors, resulting in the repression of pro-inflammatory genes such as IL-1,
IL-6 and TNF-α (Figure 6.9). The proposed mechanism of action of AL-438 is based
on this hypothesis, and is thought to result from changes in the interaction of the GR
with gene-specific transcriptional cofactors.
Upon binding to the GR, AL-438 induces a unique change to its structural
conformation, which is completely different than those induced by steroids such as
Pred or Dex (Coghlan et al., 2003). These structural changes lead to a reduction in
co-factor interactions between the GR and co-factors such as PGC-1, which is
involved in hepatic glucose production (Herzig et al., 2001; Yoon et al., 2001), but do
not change the interactions between GR and GRIP-1, a co-factor which plays a role in
the repression of pro-inflammatory genes (Rogastsky et al., 2001; Coghlan et al.,
2003) (Figure 6.9). This hypothesis may explain the reported maintenance of anti-
inflammatory activity with AL-438 but also its reduced effects on ATDC5 cells as
found in this study.Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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Figure 6.9 Proposed mechanism of action of AL-438 Upon binding to the GR,
AL-438 induces a unique change to its structural conformation, which is different than
that induced by Dex. These structural changes lead to a reduction in co-factor
interactions between the GR and co-factors such as PGC-1, which is involved in
hepatic glucose production, but do not change the interactions between the GR and
cofactors involved in the inflammatory response, such as GRIP-1, a co-factor which
plays a role in the repression of pro-inflammatory genes.
The proposed mechanism of action of AL-438 is also supported by the finding that as
opposed to Dex, AL-438 does not have a detrimental effect on metatarsal bone
growth. This finding confirms bone-sparing results from previous studies which used
calcein and tetracycline labelling in rats to show that AL-438 treatment was not
associated with the level of reduction in bone formation that was associated with PredChapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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(Coghlan et al., 2003). This study also measured the expression of bone formation
markers osteocalcin and osteoprotegerin, and found that these genes were not, or only
weakly repressed by AL-438 compared to Pred. The fact that the length of the
mineralising zone, but not the proliferating or hypertrophic zones, was significantly
shorter in Dex treated bones suggests that Dex is acting directly on the terminally
differentiated chondrocytes to reduce overall bone length. A similar finding has
previously been found by our group (Mushtaq et al., 2004) and others (Picherit et al.,
2000), and may be caused by Dex interfering with genes involved in the
mineralisation process.
The finding that AL-438 maintains a similar anti-inflammatory efficacy to Dex in
ATDC5 cells was important, as it proved that AL-438 was still fully efficacious as an
anti-inflammatory agent in chondrocytes despite the fact that it was much less harmful
than Dex or Pred. The anti-inflammatory efficacy of AL-438 has previously been
demonstrated both in vivo using the rat carrageenan-induced paw edema assay and the
adjuvant arthritis model in rats, and in vitro in HepG2 cells and human skin
fibroblasts (Coghlan et al., 2003). In these studies, AL-438 and Pred were equally
effective at inhibiting an inflammatory response, although Pred was slightly more
potent, with an ED50 of 1mg/kg compared to 9mg/kg for AL-438 in the adjuvant
arthritis model.
To compensate for the fact that AL-438 is slightly less potent than Pred, a saturating
dose of 10
-6M was used for all compounds in this study. In addition, this
pharmacological concentration of Dex and Pred is similar to that found in chronic GC
therapy and has been shown previously by us, and others, to inhibit both chondrocyteChapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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proliferation and longitudinal bone growth (Mushtaq et al., 2002 and 2004). At 10
-
6M the compounds fully occupied the receptor (Elmore et al., 2001; Coghlan et al.,
2003), therefore, allowing their full efficacy as anti-inflammatory agents to be
measured. Although AL-438 has been shown to have similar affinity for the GC-
receptor across a wide array of tested cell types (Elmore et al., 2001; Coghlan et al.,
2003; plus unpublished data) it also exhibits some affinity for the mineralocorticoid
receptor at this concentration. This affinity is comparable to that of 10
-6M Pred, and
when tested against a variety of other nuclear and non-nuclear receptors, kinases and
enzymes, AL-438 displayed no affinity up to a concentration of 10M (Coghlan et al.,
unpublished). In addition to interactions with its receptor, GCs are also known to
have non–genomic effects that are not mediated by the GC-receptor (Song et al.,
2005). Although all indications are that AL-438 acts exclusively through the GC-
receptor (Coghlan et al., 2003), further studies are required to establish the precise
cellular events involved in AL-438 actions. Nevertheless, the data from this study
suggest that, when studied at a concentration (10
-6M) that fully occupies the GC-
receptor, allowing its full efficacy as a GC-receptor agonist, AL-438 may separate
anti-inflammatory activity from a number of bone growth-related side effects,
including chondrocyte proliferation and longitudinal bone growth.
6.7 Conclusions
This study has used a well-established model of longitudinal bone growth to show
that the non-steroidal anti-inflammatory agent, AL-438 is less detrimental to
chondrocyte proliferation and bone growth at the level of the growth plate.
Importantly, it has also been shown that AL-438 maintains a similar anti-
inflammatory efficacy to Dex, thereby confirming that a non-steroidal anti-Chapter 6 The Growth Plate Sparing Effects of the Novel GR Ligand, AL-438
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inflammatory agent is capable of selectively maintaining its anti-inflammatory effects
without negatively affecting bone growth. The reduced skeletal side-effect profile of
this novel ligand could prove important in the search for new anti-inflammatory
treatments for children, however, it should be emphasised that these studies are based
on in vitro analysis in mouse, and it still remains to be shown whether these results
will translate into the human.Chapter 7 General Discussion and Future Directions
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7.1 General Discussion
GCs have been used in the treatment of inflammatory and autoimmune conditions for
over 50 years. However, their use is limited by the wide range of side effects
associated with long term therapy. These can include hyperglycaemia, behavioural
changes, weight redistribution, osteoporosis, and, in children, growth retardation. The
precise mechanisms by which GCs cause growth retardation in the developing
skeleton are still unclear, however, it is thought that they may act directly upon the
chondrocytes of the epiphyseal growth plate to delay the process of endochondral
ossification (Baron et al., 1994), and consequently longitudinal bone growth.
The work within this thesis has attempted to further our understanding of the
mechanisms by which GCs alter chondrocyte dynamics within the growth plate,
through a range of in vitro and in vivo studies. Microarray analysis of the murine
chondrogenic ATDC5 cell line treated with Dex highlighted the importance of ECM
genes in the chondrocyte response to GCs. An interesting finding was the
upregulation of SGCK following Dex treatment. SGCK has been shown to play an
important role in the maintenance of cells within the cell cycle, by phosphorylating
and consequently inhibiting the activation of Foxo3a, a member of the Forkhead
family of transcription factors (Brunet et al., 2001). Under normal circumstances,
Foxo3a targets the activation of the CDKI p27, causing cells to exit the cell cycle and
progress towards terminal differentiation and apoptosis. By inhibiting Foxo3a
activity, SGCK causes the cells to continue proliferating, indicating that SGCK is a
regulator of cell survival (Tessier et al., 2006). SGCK has previously been shown to
be upregulated in osteoblasts in response to Dex (Leclerc et al., 2004), however, there
have been no previous reports of SGCK expression within the growth plate. The factChapter 7 General Discussion and Future Directions
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that SGCK expression is increased in response to environmental and toxicological
stresses, and inactivates proteins involved in the exit from the cell cycle, suggests that
SGCK may be acting as a survival factor in response to Dex in this study.
A number of ECM genes were significantly upregulated following Dex treatment, a
finding which has previously been reported in Dex-treated primary chondrocytes
(James et al., 2007). This finding supports the recent hypothesis that GCs may be
causing premature differentiation of proliferating chondrocytes, therefore preventing
the accumulation of a sufficient proliferative pool of chondrocytes available for
differentiation and subsequent hypertrophy (Mustaq et al., 2002). The fact that
expression of the binding protein lipocalin 2 was also increased after Dex treatment
also supports this hypothesis.
In this study, lipocalin 2 expression was significantly increased in proliferating
ATDC5 cells treated with Dex. Lipocalin 2 has previously been shown to be
expressed at high levels in hypertrophic chondrocytes, and is known to be induced by
a number of factors including LPS, FGF, PGE2, and Dex (Ulivi et al., 2006). This
study confirmed that Dex was acting directly at the GRE on the lipocalin 2 promoter
to increase lipocalin 2 expression and reduce chondrocyte proliferation. These
findings, along with the fact that lipocalin 2 increased expression of the hypertrophic
chondrocyte marker Coll X, suggests that lipocalin 2 could also be causing premature
differentiation in chondrocytes. Interestingly, this effect was amplified synergistically
with the addition of Dex, indicating the possibility that Dex may be acting through
lipocalin 2 to reduce chondrocyte proliferation and cause growth retardation through
the premature differentiation of proliferative chondrocytes.Chapter 7 General Discussion and Future Directions
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The proliferation and differentiation of growth plate chondrocytes is ultimately under
control of cell cycle regulators such as cyclins and CDKs, and their inhibitors, the
CDKIs. The rate of chondrocyte proliferation and the size of the proliferative pool in
the growth plate can vary widely between species at the same stage of development,
between bones within a single animal, and even between the proximal and distal ends
of the same bone (Beier et al., 1999). In order to test the hypothesis that GCs reduced
chondrocyte proliferation by causing them to differentiate prematurely, the expression
of a number of CDKIs was analysed. Of all the CDKIs tested, only p21 expression
increased during ATDC5 differentiation, and so was chosen for further analysis. As a
CDKI, increased p21 expression causes cells to exit the cell cycle at the G1/S
checkpoint, and progress towards terminal differentiation (Negishi et al., 2001).
Consequently, if the theory was correct, Dex should have caused an increase in p21
expression. In ATDC5 cells, both p21 protein and gene expression was increased
following Dex treatment, adding further evidence to the theory that one possible
mechanism of GC-induced growth retardation is an increase in chondrocyte
differentiation. However, this hypothesis was not transferable to an in vivo model of
growth in mice lacking a functional p21 gene, and p21
-/- mice injected with Dex
experienced comparable growth retardation to their wildtype littermates. A similar
finding has previously been reported in p27
-/- mice (Emons et al., 2006), and suggests
that, although control of the cell cycle may play an important role in GC effects at the
cellular level, it is likely that many other factors are involved.
Although a number of mechanisms have been postulated for GC induced growth
retardation, there are still many questions which must be answered before novel bone-Chapter 7 General Discussion and Future Directions
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sparing therapies are clinically available. Over the last 20 years, however, an intense
effort has been made by both science and industry to develop new drugs that maintain
the efficacy of commonly used GCs such as Pred and Dex, but display reduced
adverse effects. In the late 1990’s, hopes were raised with the discovery of the steroid
Deflazacort, which displayed reduced effects on bone and glucose metabolism both in
vitro and in vivo (Canalis et al., 1992). However, when used at a dose that displayed
equal anti-inflammatory efficacy to Dex and Pred, these side-effects re-appeared.
Since then, our increased knowledge of GR pharmacology has allowed us to develop
more sophisticated ligands that are able to separate anti-inflammatory properties from
adverse side effects. AL-438 is a selective glucocorticoid receptor modulator with a
similar anti-inflammatory efficacy to Dex and Pred in vivo and in vitro, but with
reduced negative effects on glucose metabolism, bone turnover, and as found in this
study, bone growth (Coghlan et al., 2003). The growth-sparing effects of AL-438
seemed to be due to reduced effects on chondrocyte proliferation and proteoglycan
production, and were observed in both in vivo and organ culture models of bone
growth. The mechanism of action of AL-438 is based on the theory that most GCs
exert their anti-inflammatory properties through the repression of pro-inflammatory
genes such as TNF- and IL-1, and their negative properties through the activation of
genes such as PGC-1, which is involved in glucose production. AL-438 causes a
unique conformational change in the GR which permits the binding of co-repressors,
but not co-activators. Consequently, AL-438 can successfully inhibit pro-
inflammatory genes, but cannot activate many genes that are associated with the
adverse effects of other GCs.Chapter 7 General Discussion and Future Directions
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As discussed in this thesis, the effects of Dex on endochondral ossification and
growth plate dynamics are severe. Long-term therapy in juveniles can ultimately lead
to growth retardation, due to a reduction in growth plate width caused by decreased
chondrocyte proliferation and possible premature differentiation of proliferative
chondrocytes. Due to these effects, a concerted effort has been made to develop new
anti-inflammatory agents with reduced effects on bone growth. As outlined herein,
AL438, has reduced effects on bone growth compared to Dex, but maintains similar
anti-inflammatory efficacy. However, AL-438 has not yet progressed to be clinically
available, and therefore there is still a pressing need for novel ligands that maintain
anti-inflammatory efficacy but have minimal effects on growth plate dynamics and
longitudinal bone growth.
7.2 Future Directions
The results presented within this thesis suggest possible mechanisms by which GCs
cause growth retardation at the level of the growth plate. However, much further
work is necessary if these mechanisms are to be confirmed. The upregulation of ECM
genes such as DMP1 and CTGF was an interesting finding, and suggests that GCs
could inhibit skeletal growth through an increase in the differentiation of proliferative
chondrocytes. Although this finding has previously been reported at the gene
expression level (James et al., 2007), the upregulation of DMP1 and CTGF protein
has not yet been described. In addition, it is important to study the effects of
increased DMP1/CTGF expression in chondrocytes, possibly through stable
transfection techniques, and equally, the knock-down of DMP or CTGF by siRNA
could give an insight into the role of these genes in mediating GC-effects in
chondrocytes. The up-regulation of SGCK was also an interesting finding, and couldChapter 7 General Discussion and Future Directions
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warrant further investigation, particularly due to the fact that the downstream target of
SGCK, Foxo3a, has been linked to CDKI inhibition and cell survival. A potential
future study would be to analyse Foxo3a and SGCK expression in ATDC5 cells and
primary chondrocytes, both at different stages of differentiation, and following Dex
treatment. The up-regulation of SGCK should cause an inhibition in Foxo3a
expression, and provides a potential survival mechanism for chondrocytes following
Dex treatment.
The role of lipocalin 2 in GC-induced growth retardation is also an interesting issue
which requires further investigation. An obvious question is whether Dex maintains
its anti-proliferative effects in ATDC5 cells lacking a functional lipocalin 2 gene.
This could be addressed by siRNA knock-down studies, and if the hypothesis was
correct, Dex-effects would be reduced in ATDC5 cells in the absence of lipocalin 2.
Another area which should be investigated are the signalling mechanisms involved in
lipocalin 2 induction.  Work in this thesis has shown that p38 and NFκB signalling do 
not play a role in Dex-induced lipocalin 2 expression, but the finding that the serine
protease inhibitor TLCK blocks lipocalin 2 induction suggests that other signalling
pathways such as PI3-Kinase may be involved. Although lipocalin 2 seems be
important for GC effects on chondrocytes in vitro, it may also be interesting to
analyse its role in growth retardation on a more physiological level. The murine
foetal metatarsal model could be used to study the effects of recombinant lipocalin 2
on Dex-induced growth retardation, and following growth studies, histological
analysis of chondrocyte dynamics and mineralisation could be carried out. If
successful, these studies could be extended into an in vivo model of GC-induced
growth retardation in lipocalin 2
-/-mice.Chapter 7 General Discussion and Future Directions
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The lack of involvement of p21 in reduced skeletal growth was disappointing, and
suggests that there may be considerable redundancy between the CDKIs. It is
possible that a number of CDKIs and other cell cycle regulators may act together to
control chondrocyte proliferation, and it would therefore be interesting to study the
growth of mice with multiple null mutations such as p21
-/-/p27
-/-. Due to the
importance of cell cycle regulation in the control of endochondral ossification it
would be interesting to analyse the expression of other factors involved in the cell
cycle, such as CDKs, which should be down-regulated following Dex treatment in
chondrocytes.Reference List
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Appendix 1
Gene Ontology of Dex-Responsive Chondrocyte Genes
Table 1 Up-regulated Genes
Affymetrix ID Gene Name Gene Ontology Fold
Change
1427747_a_at lipocalin 2 transporter activity, binding 14.5
1448550_at lipopolysaccharide binding
protein
Transport, lipid transport, defense
response to bacterium; LPS
binding
lipid binding; extracellular space
membrane, integral to membrane
7.9
1428942_at metallothionein 2 zinc ion homeostasis, nitric oxide
mediated signal transduction,
detoxification of copper ion; zinc
ion binding, metal ion binding
5.1
1416125_at FK506 binding protein 5 protein folding; peptidyl-prolyl cis-
trans isomerase activity binding,
protein binding, isomerase activity;
cytoplasm, mitochondrial inner
membrane
3.8
1442025_a_at similar to promyelotic
leukemia zfp
3.8
1434202_a_at hypothetical protein
MCG58343 (cDNA sequence
BC055107)
3.6
1418187_at calcitonin receptor activity
modifying protein
intracellular protein transport,
regulation of G-protein coupled
receptor protein signalling
pathway; receptor activity, protein
transporter activity, coreceptor,
soluble ligand activity;
extracellular space,
integral to membrane
3.5
1448881_at haptoglobin Proteolysis, acute-phase response;
serine-type endopeptidase activity
chymotrypsin activity, trypsin
activity, hemoglobin binding;
extracellular space
3.4
1416953_at connective tissue growth
factor
cartilage condensation, ossification,
angiogenesis, regulation of cell
growth, DNA replication, cell
adhesion, cell-matrix adhesion,
integrin-mediated signalling,
pathway, fibroblast growth factor
receptor signalling pathway, cell
migration, cell differentiation;
integrin binding, protein binding,
insulin-like growth factor binding,
heparin binding; extracellular
region
proteinaceous extracellular matrix
3.3
1425281_a_at delta sleep inducing peptide
(TSC22 domain family 3)
regulation of transcription, DNA-
dependent anti-apoptosis;
transcription factor activity;
3.1
1423233_at CCAAT/enhancer binding Transcription, regulation of 3.1Appendix
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protein delta transcription, DNA-dependent;
DNA binding, transcription factor
activity
protein binding, protein
homodimerization activity
sequence-specific DNA binding
protein heterodimerization activity
protein dimerization activity;
nucleus
1449851_at chemokine ligand 2 (Period
homolog 1)
two-component signal transduction
system (phosphorelay)
transcription
regulation of transcription, DNA-
dependent signal transduction,
circadian rhythm, negative
regulation of transcription,
rhythmic process; signal transducer
activity
protein binding; nucleus
3.0
1419874_x_at promyelotic leukaemia zinc
finger protein
skeletal development, mesonephros
development, regulation of
transcription, DNA-dependent
central nervous system
development, negative regulation
of cell proliferation, embryonic
pattern specification,
anterior/posterior pattern
formation, hemopoiesis
myeloid cell differentiation,
embryonic limb morphogenesis,
leg morphogenesis, embryonic
hindlimb/forelimb morphogenesis,
positive regulation of apoptosis,
regulation of transcription, negative
regulation of myeloid cell
differentiation, negative regulation
of transcription, DNA-dependent
male germ-line stem cell division;
nucleic acid binding, DNA binding
protein binding, zinc ion binding
specific transcriptional repressor
activity, protein homodimerization
activity, metal ion binding;
intracellular, nucleus, nuclear
speck
transcriptional repressor complex
2.9
1422557_s_at metallothionein 1 zinc ion homeostasis, nitric oxide
mediated signal transduction,
detoxification of copper ion; zinc
ion binding, metal ion binding;
lysosome, cytosol
2.8
1418091_at transcription factor CP2 like 1 negative regulation of transcription,
from RNA polymerase II promoter,
cell morphogenesis, epithelial cell
maturation, regulation of
transcription, DNA-dependent
cytoplasm organization and
biogenesis, salivary gland
development determination of adult
life span positive regulation of
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growth; DNA binding, general
transcriptional repressor activity;
nucleus, transcription factor
complex, cytoplasm, membrane
1440235_at Integrin alpha 10 cell adhesion, integrin-mediated
signalling pathway; integrin
complex
2.6
1422878_at synaptotagmin 12 transport; transporter activity;
synaptic vesicle, membrane,
integral to membrane, synapse
2.5
1416041_at serum/glucocorticoid
regulated kinase
protein amino acid
phosphorylation, apoptosis,
response to DNA damage stimulus;
nucleotide binding, protein kinase
activity
protein kinase activity, protein
serine/threonine kinase activity,
protein binding, ATP binding,
kinase activity, transferase activity;
nucleus, endoplasmic reticulum
2.5
1428471_at sorbin and SH3 domain
containing 1
Transport, insulin receptor
signalling pathway, glucose
transport, stress fiber formation,
focal adhesion formation; insulin
receptor binding
protein binding, protein kinase
binding; stress fiber nucleus, cell-
cell adherens junction, cell-
substrate adherens junction,
membrane, lipid raft
2.5
1450826_a_at serum amyloid A 3 acute-phase response; lipid
transporter activity; extracellular
space
2.5
1455048_at immunoglobulin superfamily
member 2
integral to membrane 2.4
1423274_at integrator complex subunit 6 snRNA processing; nucleic acid
binding, protein binding, ATP
binding, ATP-dependent helicase
activity; extracellular space,
nucleus, integrator complex
2.3
1443745_s_at dentin matrix protein 1 Ossification, extracellular matrix
organization and biogenesis;
proteinaceous extracellular matrix,
extracellular space, nucleus
2.3
1426236_a_at glutamate ammonia ligase glutamine biosynthetic process
nitrogen compound metabolic
process; catalytic activity
glutamate-ammonia ligase activity
ligase activity; mitochondrion
2.3
1422573_at AMP deaminase 3 nucleotide metabolic process,
purine ribonucleoside,
monophosphate biosynthetic
process; AMP deaminase activity
hydrolase activity, deaminase
activity
2.1
1449254_at sectreted phosphoprotein 1 Ossification, anti-apoptosis,
inflammatory response, cell
adhesion, cell-matrix adhesion.
negative regulation of bone
mineralisation, leukocyte
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chemotaxis, T-helper 1 type
immune response, positive
regulation of T cell proliferation,
regulation of myeloid cell
differentiation, induction of
positive chemotaxis; cytokine
activity, integrin binding, protein
binding
growth factor activity; extracellular
region proteinaceous extracellular
matrix, extracellular space,
cytoplasm, apical part of cell
1418269_at lysyl oxidase-like 3 protein-lysine 6-oxidase activity,
scavenger receptor activity, copper
ion binding, oxidoreductase
activity,
metal ion binding; extracellular
space, membrane
2.0
1448830_at dual specificity phosphatase 1 protein amino acid
dephosphorylation, cell cycle
dephosphorylation; phosphoprotein
phosphatase activity protein
tyrosine phosphatase activity,
protein binding, protein
tyrosine/serine/threonine,
phosphatase activity, hydrolase
activity, phosphoric monoester,
hydrolase activity, MAP kinase
phosphatase activity;
2.0
1417507_at cytochrome b-561 electron transport; ferric-chelate
reductase activity, transporter
activity, iron ion binding, metal ion
binding; nucleus
1.9
1434203_at hypothetical protein
MCG58343 (cDNA sequence
BC055107)
1.9
1438953_at c-fos induced growth factor 1.9
1435943_at dipeptidase 1 Proteolysis; membrane dipeptidase
activity, peptidase activity,
metallopeptidase activity,
dipeptidyl-peptidase activity, zinc
ion binding, hydrolase activity,
dipeptidase activity, metal ion
binding, GPI anchor binding;
extracellular space, endoplasmic
reticulum, microsome membrane
1.9
1434642_at hydroxysteroid (17-beta)
dehydrogenase 11
steroid biosynthetic process,
metabolic process, lipid
biosynthetic process;
oxidoreductase activity;
1.9
1448842_at Cysteine dioxygenase 1 L-cysteine catabolic process to
taurine, taurine metabolic process,
L-cysteine metabolic process; iron
ion binding, electron carrier
activity
oxidoreductase activity,
oxidoreductase activity, acting on
single donors with incorporation of
molecular oxygen, incorporation of
two atoms of oxygen, cysteine
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dioxygenase activity; cytosol
1439755_at signal-induced proliferation-
associated 1 like 1
1.8
1416383_a_at pyruvate carboxylase Gluconeogenesis, metabolic
process, lipid biosynthetic process;
nucleotide binding, catalytic
activity,
pyruvate carboxylase activity, ATP
binding, biotin binding, ligase
activity, manganese ion binding;
cytoplasm, mitochondrion,
mitochondrial inner membrane
1.8
1451596_a_at sphingosine kinase 1 blood vessel development, protein
kinase C activation, intracellular
signalling cascade, brain
development, positive regulation of
cell proliferation, negative
regulation of apoptosis, sphingoid
catabolic process, positive
regulation of fibroblast
proliferation; magnesium ion
binding, DNA binding,
diacylglycerol kinase activity,
protein binding, calmodulin
binding, sphinganine kinase
activity, kinase activity, D-erythro-
sphingosine kinase activity;
membrane fraction, soluble
fraction, cytoplasm, cytosol
1.8
1424051_at procollagen type IV phosphate transport, cell adhesion,
negative regulation of
angiogenesis; structural molecule
activity, extracellular matrix
structural constituent, conferring
tensile strength; proteinaceous
extracellular matrix, collagen type
IV, baSEMent membrane,
extracellular space, cytoplasm
1.8
1436789_at cyclin J-like regulation of progression through
cell cycle; nucleus
1.8
1460011_at cytochrome p450 cell fate determination, electron
transport, male meiosis,
spermatogenesis, proximal/distal
pattern formation, embryonic limb
morphogenesis, retinoic acid
metabolic process, retinoic acid
receptor signalling pathway;
monooxygenase activity, iron ion
binding, oxidoreductase activity,
heme binding, metal ion binding;
endoplasmic reticulum, microsome,
membrane
1.7
1452141_a_at selenoprotein P selenium metabolic process, brain
development, locomotory
behaviour, post-embryonic
development, sexual reproduction
growth; selenium binding;
extracellular space
1.7
1433832_at unc-84 homolog B (C.
elegans)
nuclear membrane organization
and biogenesis; nuclear membrane
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organization and biogenesis;
nuclear chromosome, telomeric
region, nuclear chromosome,
telomeric region, condensed
nuclear chromosome, condensed
nuclear chromosome, nucleus,
nuclear envelope, nuclear envelope
membrane, integral to membrane
1418932_at nuclear factor, interleukin 3,
regulated
regulation of transcription, DNA-
dependent regulation of
transcription, DNA-dependent;
DNA binding, transcription factor
activity, sequence-specific DNA
binding, protein dimerization
activity; nucleus
1.7
1426195_a_at Cystatin C endopeptidase inhibitor activity,
cysteine protease inhibitor activity;
extracellular space;
1.7
1422620_s_at phosphatidic acid phosphatase
2a
protein amino acid
dephosphorylation, diacylglycerol
biosynthetic process, sphingosine
metabolic process, ceramide
metabolic process, signal
transduction, protein kinase C
activation, negative regulation of
cell proliferation, regulation of
lipid metabolic process, androgen
receptor signalling pathway,
phospholipid dephosphorylation;
phosphatidate phosphatase activity
hydrolase activity; membrane
fraction, plasma membrane
integral to plasma membrane
1.7
1422478_a_at acetyl coenzyme A synthetase
2
acetyl-CoA biosynthetic process,
metabolic process; catalytic
activity,
acetate-CoA ligase activity, AMP
binding, ligase activity; cytoplasm
integral to membrane
1.6
1417936_at chemokine ligand 9 Chemotaxis, immune response,
signal transduction; cytokine
activity
chemokine activity; extracellular
region, extracellular space
1.6
1454675_at thyroid hormone receptor
alpha
cartilage condensation, ossification,
regulation of transcription, DNA-
dependent regulation of heart
contraction, organ morphogenesis,
negative regulation of
transcription; DNA binding,
transcription factor activity, steroid
hormone receptor activity, receptor
activity, ligand-dependent nuclear
receptor activity,
ligand-dependent nuclear receptor
activity, thyroid hormone receptor
activity, thyroid hormone receptor
activity, protein binding, zinc ion
binding, transcriptional repressor
activity, transcription regulator
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activity, sequence-specific DNA
binding, metal ion binding; nucleus
1449731_s_at nuclear factor of kappa light
chain gene enhancer
protein import into nucleus,
translocation, lipopolysaccharide-
mediated signalling pathway,
response to lipopolysaccharide,
regulation of cell proliferation,
response to exogenous dsRNA,
negative regulation of myeloid cell
differentiation, negative regulation
of Notch signalling pathway;
protein binding, nuclear
localisation sequence binding,
ubiquitin protein ligase binding,
NF-kappaB binding; nucleus,
cytoplasm, cytosol
1.6
1448489_at platelet activating factor 2 lipid catabolic process; catalytic
activity, 1-alkyl-2-
acetylglycerophosphocholine
esterase activity, hydrolase activity;
2-acetyl-1
alkylglycerophosphocholine
esterase complex
1.6
1447602_x_at sulfatase 2 sulfur metabolic process, metabolic
process, heparan sulfate
proteoglycan metabolic process;
arylsulfatase activity, calcium ion
binding, N-acetylglucosamine-6-
sulfatase activity, sulfuric ester
hydrolase activity, hydrolase
activity
metal ion binding; extracellular
space, endoplasmic reticulum
cell surface
1.6
1424671_at pleckstrin homology domain
containing F
Apoptosis, ,induction of apoptosis,
regulation of mitochondrial,
membrane permeability; zinc ion
binding, metal ion binding; nucleus
lysosome
1.6
1437820_at forkhead-like 18 Transcription, regulation of
transcription, DNA-dependent
positive regulation of body size,
regulation of balance; DNA
binding
transcription factor activity,
sequence-specific DNA binding;
nucleus, transcription factor
complex
1.6
1451939_a_at sushi-repeat containing
protein
extracellular space 1.6
1435254_at plexin B1 multicellular organismal
development, positive regulation of
axonogenesis; receptor activity
protein binding; membrane
integral
1.6
1456312_x_at Gelsolin vesicle-mediated transport, actin
filament polymerization, actin
filament severing; actin binding
structural molecule activity,
calcium ion binding, protein
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binding; extracellular space,
cytoplasm, cytosol, cytoskeleton,
actin cytoskeleton, actin
cytoskeleton,
lamellipodium
1454849_x_at clusterin cell death; protein binding;
extracellular space
1.6
1441926_x_at transmembrane inner ear sensory perception of sound, inner
ear morphogenesis; membrane,
integral to membrane
1.6
1448321_at SPARC related modular
calcium binding 1
calcium ion binding; proteinaceous
extracellular matrix, baSEMent
membrane
1.6
1455078_at slingshot homolog 2 protein amino acid
dephosphorylation; actin binding,
phosphoprotein phosphatase
activity, protein tyrosine
phosphatase activity, protein
tyrosine/serine/threonine
phosphatase activity, hydrolase
activity, phosphoric monoester
hydrolase activity; cytoskeleton
1.6
1416825_at synotrophin acidic 1 neuromuscular junction
development; actin binding,
calcium ion binding, protein
binding,
calmodulin binding
1.6
1450678_at Integrin beta 2 cell adhesion, cell-matrix adhesion
integrin-mediated signalling,
pathway, integrin-mediated
signalling pathway, multicellular
organismal development,
neutrophil chemotaxis, cellular
extravasation
activated T cell proliferation;
1.5
1425894_at MAS-related GPR, member F signal transduction, G-protein
coupled receptor protein signalling
pathway; rhodopsin-like receptor
activity, signal transducer activity
receptor activity, G-protein coupled
receptor activity; membrane,
integral to membrane
1.5
1452296_at slit homolog 3 multicellular organismal
development, nervous system
development, axon guidance, organ
morphogenesis, organ
morphogenesis, cell differentiation;
receptor binding, calcium ion
binding, protein binding;
extracellular space
1.5
1426947_x_at procollagen type IV alpha 2 phosphate transport, cell adhesion;
structural molecule activity,
extracellular matrix structural,
constituent, protein binding
extracellular matrix structural
constituent conferring tensile
strength; proteinaceous
extracellular matrix, collagen
extracellular space, cytoplasm
1.5
1417872_at four and a half LIM domains multicellular organismal 1.5Appendix
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1 development, cell differentiation;
zinc ion binding, heme binding,
metal ion binding; nucleus
1428164_at nudix type motif 9 cation transport, ADP catabolic
process, IDP catabolic process;
magnesium ion binding, calcium
activated cation channel activity,
hydrolase activity, nucleoside-
diphosphatase activity, ADP-sugar
diphosphatase activity, manganese
ion binding, ADP-ribose
diphosphatase activity
1.5
1415874_at sprouty homolog 1 ureteric bud development,
induction of an organ, multicellular
organismal development,
regulation of signal transduction,
negative regulation of MAPK
activity, protein binding;
membrane
1.5
1420834_at vesicle-associated membrane
protein 2
membrane fusion, synaptic vesicle
exocytosis, vesicle-mediated
transport, calcium ion-dependent
exocytosis, calcium ion-dependent
exocytosis, regulation of
exocytosis; SNARE binding,
protein binding, calmodulin
binding, phospholipid binding;
synaptic vesicle membrane,
integral to membrane, integral to
membrane
synaptosome, secretory granule
synaptic vesicle membrane,
zymogen granule membrane
synapse
1.5
1455768_at Niemann pick type C2 cholesterol homeostasis; enzyme
binding; extracellular space
1.5
1437865_at spermatogenesis associated 13 intracellular signalling cascade,
regulation of Rho protein signal
transduction; guanyl-nucleotide
exchange factor activity, Rho
guanyl-nucleotide exchange factor
activity; intracellular
1.5
1455158_at Integrin alpha 3 neuron migration, cell adhesion
integrin-mediated signalling
pathway, fusion of sperm to egg,
plasma membrane memory;
receptor activity, protein binding;
integrin complex membrane,
integral to membrane, basolateral
plasma membrane, synaptosome
1.5
1427038_at preproenkephalin 1 behavioral fear response,
neuropeptide signalling pathway,
behaviour, sensory perception of
pain; opioid peptide activity
1.5
1421037_at neuronal PAS domain protein
2
two-component signal transduction
system
(phosphorelay)transcription,
regulation of transcription, DNA-
dependent signal transduction,
circadian sleep/wake cycle,
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regulation of transcription,
locomotor rhythm, rhythmic
process; two-component sensor
activity, DNA binding,
transcription factor activity, signal
transducer activity, transcription
regulator activity; nucleus
1421921_at Cysteine protease inhibitor endopeptidase inhibitor activity
serine-type endopeptidase inhibitor
activity
1.5Appendix
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Table 2 Down-Regulated Genes
Affmetrix ID Gene Name Gene Ontology Fold
Change
1418174_at D site albumin promoter
binding protein
Transcription, regulation of
transcription, DNA-dependent
regulation of transcription, DNA-
dependent, circadian rhythm,
rhythmic process; DNA binding
transcription factor activity,
sequence-specific DNA binding,
protein dimerization activity;
nucleus
2.6
1423607_at lumican protein binding, collagen binding;
proteinaceous extracellular matrix,
fibrillar collagen, extracellular
space
2.2
1451191_at cellular retinoic acid binding
protein II
Transport, embryonic forelimb
morphogenesis, retinoic acid
metabolic process; retinoic acid
binding, lipid binding, retinal
binding, cyclin binding; nucleus
cytoplasm
1.9
1423294_at mesoderm specific transcript proteolysis 1.9
1449855_s_at ubiquitin thiolesterase ubiquitin-dependent protein,
catabolic process, ubiquitin cycle,
adult walking behaviour, protein
deubiquitination, eating behaviour;
ubiquitin thiolesterase activity,
peptidase activity, cysteine-type,
peptidase activity, hydrolase
activity; intracellular
1.8
1449486_at carboxylesterase 1 catalytic activity, carboxylesterase
activity, serine esterase activity,
hydrolase activity, carboxylic ester
hydrolase activity; extracellular
space, endoplasmic reticulum
1.8
1448201_at sectreted frizzled-related
sequence protein 2
Somitogenesis, multicellular
organismal development,
multicellular organismal
development, anterior/posterior
pattern formation, Wnt receptor
signalling pathway, cell
differentiation; transmembrane
receptor activity; membrane
1.7
1450243_a_at down syndrome critical region
gene 1
calcium-mediated signalling 1.6
1428950_s_at nucleolar protein 8 nucleotide binding, nucleic acid
binding, RNA binding, protein
binding; nucleus, nucleolus
1.6
1454888_at prefoldin 4 protein folding, chaperonin-
mediated tubulin folding; protein
binding, unfolded protein binding;
cytosol, prefoldin complex
1.6
1425357_a_at gremlin 1 cell-cell signalling, organ
morphogenesis, proximal/distal
pattern formation, embryonic limb
morphogenesis; cytokine activity;
extracellular space
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1450756_s_at cullin 3 ubiquitin cycle, cell cycle; nucleus 1.6
1425806_a_at SRB7(suppressor of RNA
polymerase B)
regulation of transcription, DNA-
dependent regulation of
transcription from RNA
polymerase II promoter, positive
regulation of transcription from
RNA polymerase II promoter;
RNA polymerase II transcription
factor activity
transcription coactivator activity
DNA-directed RNA polymerase
activity, protein binding; mediator
complex, nucleus DNA-directed
RNA polymerase II, core complex
1.5
1417394_at Kruppel-like factor 4 (gut) Transcription, regulation of
transcription, DNA-dependent
negative regulation of
transcription; nucleic acid binding,
DNA binding,
transcription factor activity, zinc
ion binding, transcriptional
activator activity, transcriptional
repressor activity, metal ion
binding; intracellular, nucleus
1.5
1431056_a_at lipoprotein lipase lipid metabolic process; catalytic
activity, lipoprotein lipase activity,
lipid transporter activity, heparin
binding, hydrolase activity, GPI
anchor binding; extracellular space
membrane, chylomicron
1.5
1436993_x_at profilin 2 cytoskeleton organization and
biogenesis; actin cytoskeleton
organization and biogenesis; actin
binding, protein binding;
cytoskeleton, actin cytoskeleton
1.5
1437401_at IGF-1 Growth factor activity, hormone
activity, IGF-IR activity, protein
binding; anti-apoptosis, cell
development, glial cell
differentiation, IGF-IR pathway;
nervous system development;
organ morphogenesis; extracellular
region, extracellular space, IGF-IR
binding protein complex
1.5Appendix
259
Appendix 2 - Vector Diagrams
pGEM-T-Easy Vector (Promega)
Vector Features
T7 RNA Polymerase transcription initiation site: 1
SP6 RNA Polymerase transcription initiation site: 141
T7 RNA Polymerase promoter (-17 to +3): 2999-3
SP6 RNA Polymerase promoter (-17 to +3): 139-158
Multiple cloning region: 10-128
LacZ start codon: 180
Lac operon sequences: 2996, 166-395
Lac operator: 200-216
Beta-lactamase coding region: 1337-2197
Phage f1 region: 2380-2835
Binding site of pUC/M13 Forward Sequencing Primer: 2956-2972
Binding site of pUC/M13 Reverse Sequencing Primer: 176-192Appendix
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pWGB10/Lipocalin 2 Expression Construct
Vector Features
pWGB10 contains a phosphoglycerate kinase (PGK) promoter to drive Lipocalin 2
expression, simian virus 40 (SV40) small t intron/polyA and SV40/Puromycin to
allow cell selection. The plasmid Backbone is composed of pBluescript.Appendix
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Appendix 3 - Antibodies Used
A - Primary Antibodies
Antibody Source Catalogue ID Dilution
phospho-p38 MAPK
(Thr-180/Tyr-182)
Cell Signalling
Technology
9211 1:50 (IP)
total-p38 MAPK Cell Signalling
Technology
9212 1:1000 (WB)
Phospho-ATF2
(Thr76)
Cell Signalling
Technology
9820 1:1000 (WB)
goat anti-lipocalin 2 R & D Systems AF1857 1:500 (WB)
1:50 (IHC)
mouse anti beta-
actin
Sigma A5441 1:5000 (WB)
mouse anti-p21 BD Pharmingen 556431 1:250 (WB)
mouse anti-BrdU DAKO M0744 1:100 (IHC)
B - Secondary Antibodies
Antibody Source Catalogue ID Dilution
Rabbit anti-goat
peroxidise
DAKO P0449 1:2000 (WB)
1:100 (IHC)
goat anti-mouse IgG
peroxidise
Sigma A9917 1:8000 (WB)
goat anti-mouse IgG
FITC
Sigma F0257 1:50 (IHC)Appendix
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Appendix 4 - Primer Locations
Murine GAPDH
CCTCCCTGTTCCAGAGACGGCCGCATCTTCTTGTGCAGTGCCAGCTCGTCCCGTAGACAAAATGGTGAA
GGTCGGTGTGAACGGATTTGGCCGTATTGGGCGCCTGGTCACCAGGGCTGCCATTTGCAGTGGCAAAGT
GGAGATTGTTGCCATCAACGACCCCTTCATTGACCTCAACTACATGGTCTACATGTTCCAGTATGACTC
CACTCACGGCAAATTCAACGGCACAGTCAAGGCCGAGAATGGGAAGCTTGTCATCAACGGGAAGCCCAT
CACCATCTTCCAGGAGCGAGACCCCACTAACATCAAATGGGGTGAGGCCGGTGCTGAGTATGTCGTGGA
GTCTACTGGTGTCTTCACCACCATGGAGAAGGCCGGGGCCCACTTGAAGGGTGGAGCCAAAAGGGTCAT
CATCTCCGCCCCTTCTGCCGATGCCCCCATGTTTGTGATGGGTGTGAACCACGAGAAATATGACAACTC
ACTCAAGATTGTCAGCAATGCATCCTGCACCACCAACTGCTTAGCCCCCCTGGCCAAGGTCATCCATGA
CAACTTTGGCATTGTGGAAGGGCTCATGACCACAGTCCATGCCATCACTGCCACCCAGAAGACTGTGGA
TGGCCCCTCTGGAAAGCTGTGGCGTGATGGCCGTGGGGCTGCCCAGAACATCATCCCTGCATCCACTGG
TGCTGCCAAGGCTGTGGGCAAGGTCATCCCAGAGCTGAACGGGAAGCTCACTGGCATGGCCTTCCGTGT
TCCTACCCCCAATGTGTCCGTCGTGGATCTGACGTGCCGCCTGGAGAAACCTGCCAAGTATGATGACAT
CAAGAAGGTGGTGAAGCAGGCATCTGAGGGCCCACTGAAGGGCATCTTGGGCTACACTGAGGACCAGGT
TGTCTCCTGCGACTTCAACAGCAACTCCCACTCTTCCACCTTCGATGCCGGGGCTGGCATTGCTCTCAA
TGACAACTTTGTCAAGCTCATTTCCTGGTATGACAATGAATACGGCTACAGCAACAGGGTGGTGGACCT
CATGGCCTACATGGCCTCCAAGGAGTAAGAAACCCTGGACCACCCACCCCAGCAAGGACACTGAGCAAG
AGAGGCCCTATCCCAACTCGGCCCCCAACACTGAGCATCTCCCTCACAATTTCCATCCCAGACCCCCAT
AATAACAGGAGGGGCCTAGGGAGCCCTCCCTACTCTCTTGAATACCATCAATAAAGTTCGCTGCACCC
Accession number: NM_008084
Green highlights: Primers for qPCRs (302bp)
Yellow highlights: Location of introns 3 and 4
Lipocalin 2
CCATGGCCCTGAGTGTCATGTGTCTGGGCCTTGCCCTGCTTGGGGTCCTGCAGAGCCAGGCCCAGGACT
CACTCAGAACTTGATCCCTGCCCCATCTCTGCTCACTGTCCCCCTGCAGCCAGACTTCCGGAGCGATCA
GTTCCGGGGCAGGTGGTACGTTGTGGGCCTGGCAGGCAATGCGGTCCAGAAAAAAACAGAAGGCAGCTT
TACGATGTACAGCACCATCTATGAGCTACAAGAGAACAATAGCTACAATGTCACCTCCATCCTGGTCAG
GGACCAGGACCAGGGCTGTCGCTACTGGATCAGAACATTTGTTCCAAGCTCCAGGGCTGGCCAGTTCAC
TCTGGGAAATATGCACAGGTATCCTCAGGTACAGAGCTACAATGTGCAAGTGGCCACCACGGACTACAA
CCAGTTCGCCATGGTATTTTTCCGAAAGACTTCTGAAAACAAGCAATACTTCAAAATTACCCTGTATGG
AGAACCAAGGAGCTGTCCCCTGAACTGAAGGAACGTTTCACCCGCTTTGCCAAGTCTCTGGGCCTCAAG
GACGACAACATCATCTTCTCTGTCCCCACCGACCAATGCATTGACAACTGAATGGGTGGTGAGTGTGGC
TGACTGGGATGCGCAGAGACCCAATGGTTCAGGCGCTGCCTGTCTGTCTGCCACTCCATCTTTCCTGTT
GCCAGAGAGCCACCTGGCTGCCCCACCAGCCACCATACCAAGGAGCATCTGGAGCCTCTTCTTATTTGG
CCAGCACTCCCCATCCACCTGTCTTAACACCACCAATGGCGTCCCCTTTCTGCTGAATAAATACATGCC
CAAGCTCGAC
Red highlights: Primers for cDNA amplification for cloning (834bp)
Yellow highlights: Primers for qPCR analysis (137bp)
Green highlights: Location of intron 2-3
Accession number: X81627Appendix
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CTGF
ATGCTCGCCTCCGTCGCAGGTCCCATCAGCCTCGCCTTGGTGCTCCTCGCTCTCTGCACCCGGCCTGCT
ATGGGCCAGGACTGCAGCGCGCAATGTCAGTGCGCAGCCGAAGCAGCGCCGCACTGCCCCGCCGGCGTG
AGCCTGGTGCTGGACGGCTGCGGCTGCTGCCGCGTCTGCGCCAAGCAGCTGGGAGAACTGTGTACGGAG
CGTGACCCCTGCGACCCACACAAGGGCCTCTTCTGCGATTTCGGCTCCCCCGCCAACCGCAAGATCGGA
GTGTGCACTGCCAAAGATGGTGCACCCTGTGTCTTCGGTGGGTCGGTGTACCGCAGCGGTGAGTCCTTC
CAAAGCAGCTGCAAATACCAATGCACTTGCCTGGATGGGGCCGTGGGCTGCGTGCCCCTGTGCAGCATG
GACGTGCGCCTGCCCAGCCCTGACTGCCCCTTCCCGAGAAGGGTCAAGCTGCCTGGGAAATGCTGCGAG
GAGTGGGTGTGTGACGAGCCCAAGGACCGCACAGCAGTTGGCCCTGCCCTAGCTGCCTACCGACTGGAA
GACACATTTGGCCCAGACCCAACTATGATGCGAGCCAACTGCCTGGTCCAGACCACAGAGTGGAGCGCC
TGTTCTAAGACCTGTGGGATGGGCATCTCCACCCGAGTTACCAATGACAATACCTTCTGCAGACTGGAG
AAGCAGAGCCGCCTCTGCATGGTCAGGCCCTGCGAAGCTGACCTGGAGGAAAACATTAAGAAGGGCAAA
AAGTGCATCCGGACACCTAAAATCGCCAAGCCTGTCAAGTTTGAGCTTTCTGGCTGCACCAGTGTGAAG
ACATACAGGGCTAAGTTCTGCGGGGTGTGCACAGACGGCCGCTGCTGCACACCGCACAGAACCACCACT
CTGCCAGTGGAGTTCAAATGCCCCGATGGCGAGATCATGAAAAAGAATATGATGTTCATCAAGACCTGT
GCCTGCCATTACAACTGTCCTGGGGACAATGACATCTTTGAGTCCCTGTACTACAGGAAGATGTACGGA
GACATGGCGTAA
Yellow highlights: Primers for qPCR analysis (146bp)
Green highlights: Location of intron 4-5
Accession number: NM_010217
IGF-I
ATGACCGCACCTGCAATAAAGATACACATCATGTCGTCTTCACACCTCTTCTACCTGGCGCTCTGCTTC
TCACCTTCACCAGCTCCACCACAGCTGGACCAGAGACCCTTTGCGGGGCTGAGCTGGTGGATGCTCTTA
GTTCGTGTGTGGACCGAGGGGCTTTTACTTCAACAAGCCCACAGGCTATGGCTCCAGCATTCGGAGGA
CCTCAGACAGGCATTGTGGATGAGTGTTGCTTCCGGAGCTGTGATCTGAGGAGACTGGAGATGTACTGG
CCCCACTGAAGCCTACAAAAGCAGCCCGCTCTATCCGTGCCCAGCGCCACACTGACATGCCCAAGACTA
GAAGTCCCCGTCCCTATCGACAAACAAGAAAACGAAGCTGCAAAGGAGAAGGAAAGGTGAGCCAAAGAA
CACCCAGAAGGGGAACAGGAGGAGGTAACGGAGGCAACTCGGAAAATCAGAGGTCCCAGAGAAAAAAGC
TGGGCTAG
Yellow highlights: Primers for qPCR analysis (242bp)
Green highlights: Location of intron 3-4
Accession number: NM_010512Appendix
264
SFRP2
ATGCCGCGGGGCCCTGCCTCGCTGCTGCTGCTAGTCCTCGCCTCGCACTGCTGCCTGGGCTCGGCGCGG
GGCTCTTCCTCTTCGGCCAGCCCGACTTCTCCTACAAGCGCAGCAACTGCAAGCCCATCCCCGCCAACT
GCAGCTGTGCCACGGCATCGAGTACCAGAACATGCGGCTGCCCAACCTGCTGGGCCACGAGACCATGAG
GAGGTGCTGGAGCAGGCGGGCGCCTGGATTCCGCTGGTCATGAAGCAGTGCCACCCGGACACCAAGAAT
TCCTGTGCTCGCTCTTCGCCCCTGTCTGTCTCGACGACCTAGATGAGACCATCCAGCCGTGTCACTCGT
CTGCGTGCAGGTGAAGGACCGCTGCGCCCCGGTCATGTCCGCCTTCGGCTTCCCCTGGCCAGACATGCG
GAGTGCGACCGTTTCCCGCAGGACAACGACCTCTGCATCCCCCTCGCTAGTAGCGACCACCTCCTGCCG
CCACAGAGGAAGCTCCCAAGGTGTGTGAAGCCTGCAAAACCAAGAATGAGGACGACAACGACATCATGA
AACCCTTTGTAAAAATGACTTCGCACTGAAAATCAAAGTGAAGGAGATAACGTACATCAACAGAGACAC
AAGATCATCCTGGAGACAAAGAGCAAGACCATTTACAAGCTGAACGGCGTGTCCGAAAGGGACCTGAAA
AATCCGTGCTGTGGCTCAAAGACAGCCTGCAGTGCACCTGTGAGGAGATGAACGACATCAACGCTCCGA
TCTGGTCATGGGACAGAAGCAGGGCGGCGAGCTGGTGATCACCTCCGTGAAACGGTGGCAGAAGGGCCG
AGAGAGTTCAAGCGCATCTCCCGCAGCATCCGCAAGCTGCAATGCTAG
Yellow highlights: Primers for qPCR analysis (97bp)
Green highlights: Location of intron 1-2
Accession number: NM_009144
Lumican
ATGAATGTATGTGCGTTCTCTCTTGCCTTGGCATTAGTCGGTAGTGTCAGTGGCCAATACTACGATTAG
ACATCCCTCTCTTCATGTATGGGCAAATATCACCCAACTGTGCACCAGAATGTAACTGCCCCCACAGCA
CCCAACTGCCATGTACTGTGATGACCTCAAGTTGAAGAGTGTGCCAATGGTTCCTCCTGGCATCAAGTC
CTTTACCTGAGGAATAACCAAATCGACCATATTGATGAGAAGGCCTTTGAGAACGTCACAGACCTGCAT
GGCTCATTCTTGACCACAACCTTCTAGAAAACTCCAAGATCAAAGGAAAGGTTTTCTCTAAGCTGAAAA
ACTGAAGAAACTGCATATAAACTACAACAACCTGACCGAGTCCGTCGGTCCACTTCCAAAGTCCCTGCA
GACCTACAGCTGACCAATAATAAAATCAGCAAGCTCGGCTCCTTCGACGGGCTGGTCAACTTGACCTTA
TTTATCTTCAACACAACCAGCTCAAAGAGGATGCTGTCTCGGCTTCTCTGAAAGGTCTCAAATCACTAA
GTACCTGGATTTGAGCTTCAATCAGATGAGCAAGCTGCCTGCTGGTCTACCTACATCTCTTCTAACTCC
TACCTAGACAATAATAAGATCAGCAACATTCCGGATGAGTACTTCAAGCGCTTCACTGGGCTGCAATAC
TGCGTTTATCTCACAATGAACTGGCTGATAGTGGGGTACCTGGAAACTCGTTTAATATATCATCCTTGT
CGAGCTTGATCTCTCCTATAATAAGCTTAAGAGTATACCAACAGTTAATGAAAATCTTGAAAATTATTC
CTGGAGGTCAATGAACTTGAAAAGTTTGATGTGAAGAGCTTCTGTAAGATCCTGGGACCACTGTCTTAT
CCAAGATCAAGCATCTGCGCTTGGATGGCAATCCTCTCACTCAGAGCAGTCTGCCTCCTGACATGTATA
GTGTCTACGTGTAGCAAATGAAATCACCGTTAACTAA
Yellow highlights: Primers for qPCR analysis (135bp)
Green highlights: Location of intron 2-3
Accession number: NM_008524Appendix
265
Integrin alpha 10
ATGGAGTCTCTCTCCATCCCTCACCTGCTCCTGCCCCTGGCGTTGCTGACAGGTCTCTGCTCCTCCTTT
AATCTGGATGAACACCACCCACGACTCTTCACAGGGCCACCAGAGGCCGAATTTGGATACAGTGTCTTA
CAGCATGTTGGGGGTGGACAGCGATGGATGCTGGTGGGTGCCCCCTGGGATGGGCCATCAGGTGACCGG
AGAGGGGATGTTTATCGTTGCTCTATAGGGGGATTCCACAGTGCTCCATGTACCAAAGGCCACCTGGGT
GACTATCAACTTGGAAATTCCTCTCAGCCTGCTGTGAATATGCACCTAGGGATGTCTCTACTAGAGACA
GATGCTGATGGGGGATTCATGGCCTGTGCCCCTCTTTGGTCTCGTGCCTGCGGCAGCTCTGTCTTCAGT
TCTGGAATATGTGCCCGTGTGGATGCTTCATTCCGGCCCCAGGGAAGCCTGGCACCCACCGCCCAACGC
TGTCCCACATACATGGATGTCGTCATTGTTTTGGATGGCTCCAACAGTATCTATCCCTGGTCAGAAGTT
CAGACTTTCCTTCGGAGGCTGGTAGGAAGACTGTTCATCGATCCGGAGCAGATACAGGTAGGACTGGTA
CAGTACGGGGAGAACCCTGTGCATGAGTGGTCCCTGGGAGACTTCCGAACAAAGGAAGAAGTTGTGAGA
GCAGCAAGGAACCTAAGTCGGAGGGAAGGGCGAGAAACGAGAACCGCCCAAGCGATCATGGTGGCATGC
ACAGAAGGGTTCAGTCAGTCCCGGGGGGGACGACCAGAGGCCGCTAGGCTGCTGGTAGTTGTCACTGAT
GGAGAGTCCCATGATGGAGAGGAACTTCCAGCAGCGCTAAAGGCCTGTGAGGCTGGCAGAGTGACACGT
TATGGGATTGCGGTCCTTGGTCACTATCTCCGGCGACAGAGAGACCCCAGCTCTTTTCTTCGGGAAATC
AGAGCTATTGCTAGTGATCCAGATGAGCGATTCTTCTTCAATGTCACCGATGAAGCTGCGCTGACAGAC
ATTGTGGATGCACTGGGGGACCGAATTTTTGGTCTTGAAGGGTCCCGTGGAGAAAATGAAAGCTCCTTT
GGGCTAGAAATGTCTGAGATTGGCTTCTCCATCCACCGACTACAGGATGGGATTCTCTTTGGGATGGTG
GGGGCCTATGACTGGGGGGGCTCCGTGCTATGGCTTGAAGAAGGTCGCCGCCTTTTCCCACCACAAGCT
GCCCTGGAAGATGAGTTCCCCCCTGCGTTGCAGAACCATGCGGCCTACCTGGGTTACTCTGTTTCCTCC
ATGCTTCTTCCCGGTGGACGCCGCCTCTTTCTCTCAGGGGCACCGAGGTTTAGACATCGAGGAAAAGTT
ATCGCCTTCCAGCTAAAGAAAGATGGGGTTGTGAGGGTCGCCCAGAGCCTCCAGGGGGATCAGATTGGC
TCATACTTTGGCAGCGAGCTCTGCCCGTTGGATACAGATAAGGACGGAATAACTAATATCTTACTTGTG
GCGGCTCCCATGTTCCTGGGTCCCCAGAACAAGGAGACCGGACGCGTTTATGTGTACATGGTGGGCCAG
CAAAATTTGCTAATGCTCCAAGGAACCCTTCAGCCAGACCGTTCCCAGGATTCTCGGTTTGGCTTTGCC
ATGGCTGCTCTTCCTGATCTGAACCATGATGGTTTCACTGATGTAGCGGTGGGGGCACCCCTGGAGGAT
GGACACCGGGGAGCGTTGTACCTGTATCATGGAACCCAGACTGGAATCAGGCCGCATCCTACCCAGAGG
ATTGCTGCTGTCTCCATGCCACAGGCCCTCCGATACTTCGGCCGAAGTGTGGATGGCCGCTTAGATCTG
GATGGAGATGATCTTGTAGATGTTGCCGTGGGTGCCCACGGGGCAGCCGTTCTGTTCAGCTCCCAGCCC
ATCATCCACCTGATTCCAACCCTGGATGTGATGCCTCCCCACATCAGTGTGGTTCAGAAGGACTGTAAA
AGACGAGGCCAGGAAGCAGCCTGTCTGACCGCAGCCCTTTGCTTCCAAGTAGTGTCTCAAACTCCTGGG
CGTTGGGATAGAAGATTCTACATAAGATTCTCAGCATCACTGGATGAGTGGACCGCTGGGGCACGTGCA
GTATTCGATGGCTCTGGTCAGCGCCTGTCCCCTCGGCAGCTCCAGCTTAGTGTTGGCAATGTCACTTGT
GAACAGCTGCACTTCCATGCACTGGATACATCGGATTACCTCCGGCCAGTGGCCTTGACTGTGACTTTT
GCTTTGGACAACACCACGAAGCCAGGGCCTGTGCTGGCGGAAGGATCCTCTACGACTATACGGAAGCTG
ATCCCCTTCTCAAAGGACTGTGGCCCTGACAATGAATGTGTCACAGACCTGGTGCTTCAAGCTGACATG
GACATCAGAGGCTCCAGGAAGTCCCCATTTGTGGTTCAAGGTGGACGACAGAAAGTGCTGGTGTCTGCG
ACCCTGGAGAACAAGAAGGAGAATGCCTACAACACTAGCCTGAGTCTCAGCTTTTCTAGAAACCTCCAC
CTGGCCAGTCTTACTCCTCAGAAGGCCAAATCAGTGAAGGTGGAGTGCGCAGTCCCTTCCCCCCATACC
CGGCTCTGCACCGTGGGGCATCCGGTCTTCCAGACTGGGGCCAAGGTGAGCTTCCTGTTAGAGTTTGAA
TTTAGCTGCACCTTCCTCCTGAGCCAGGTCTTTGTGAGGCTGACTGCCAGTAGCAGTAGCCTAGAGATG
AATGAGACCCTTCAAGATAACACAGCTCAGACCTCTGCCTACATCCGGTACGAACCTCACCTCGTGTTC
TCCAGTGAGTCCACTCTGCATCGGTATGAGGTTCACCCTTATAGGACTCTCCCAATGGGTCCTGGCCCT
GAATTCAAGACCACTCTTAGGGTTCAGAATCTTGGTTGCCATGTGGTCAGTGGTCTCGTCATCTCCGCC
CTCCTTCCAGCTGTAGCCCATGGGGGTAACTACTTCCTGTCACTATCTCAAGTCATCTCTGGCAATGCA
AGCTGCACGGTGCAGAACCTGACTGAGCCCCCGGGCTTCCCTGTGCACCCAGAGGAGCTTCAGCATGCA
AGCAGACTGAATGGGAGTAACAGTCGATGTCAGGTGGTAAGGTGCCACCTTGGACTGCTGGCAAAGGGG
ACTGAGATCTCTGTCAGGCTGCTGAGGCTGGTTCACAATGAATTCTTTCGGAGGGCCAAGTTCAAGTCT
GTGACAGTGGTCAGCACCTTCAAGTTAGGAACTGAGGAGGGCAGTGTCCTACTACTGAATGAAGCCTCC
CGCTCGAGTGAGAGTCACTTGGAGGTGATTCAGACCCACCCGACCCTCATCTCCCTGTGGATCCTCGTT
GGCAGTGTCCTGGGGGGGCTGCTCCTGCTTGCTCTCCTTGTCTTCTGCCTGTGGAAGCTTGGCTTCTTT
ACCCGTAAGAAAATCCCCAAAGAAGAGAAAGTGAGGAGAAGTTGGAGCAGTGA
Yellow highlights: Primers for qPCR analysis (119bp)
Green highlights: Location of intron 27-28
Accession number: NM_001081053Appendix
266
Dentin Matrix Protein 1
ATGAAGACTGTCATTCTCCTTGTGTTCCTTTGGGGGCTGTCCTGTGCTCTCCCAGTTGCCAGATACCAA
ATACTGAATCTGAAAGCTCTGAAGAGAGGACGGGTGATTTGGCTGGGTCACCACCACCACCCACGAACG
TGAGTCATCAGAAGAAAGTCAAGCTAGCCCAGAGGGACAGGCAAATAGTGACCACACGGACAGCAGTGA
TCTGGAGAGGAGCTGGGCTACGACAGAGGCCAGTACAGACCGGCTGGTGGACTCTCTAAGAGTACGGGA
CCGGCGCCGATAAGGAGGATGATGAAGACGACAGTGGAGATGATACCTTTGGCGATGAGGACAATGATT
AGGGCCCGAAGAAGGACAGTGGGGAGGACCCTCCAAACTGGACAGTGATGAGGACTCCACAGACACCAA
CAGTCCAGTGAAGACAGCACCTCTCAAGAAAACAGTGCCCAAGATACCCCCAGCGACAGCAAAGACCAG
ACAGTGAGGATGAGGCAGACAGCCGGCCTGAGGCAGGCGACTCCACTCAGGACAGTGAGAGTGAGGAAA
GCGGGTGGGAGGTGGCAGCGAGGGGGAGAGTAGCCACGGGGACGGTTCTGAGTTCGATGATGAAGGGAG
CAGAGCGACGACCCCGAGAGTACCAGGAGCGATCGAGGCCACGCCAGAATGAGCAGCGCTGGTATCAGT
CGGAAGAATCTAAAGGGGACCACGAGCCCACGAGCACTCAGGATTCAGATGACAGCCAGTCTGTGGAAT
TTCAAGCAGGAAGTCCTTCAGAAGGTCCCACGTCTCTGAGGAAGACTACAGAGGTGAGCTTACTGACAC
AACAGCAGGGAAACCCAGAGCGACTCCACGGAGGATACGGCCTCCAAGGAGGAAAGCAGGAGCGAGTCC
AGGAGGACACAGCCGAGAGCCAGTCCCAGGAAGATAGCCCAGAGGGGCAAGACCCCAGCAGTGAGTCCG
CGAAGAGGCTGGTGAGCCATCCCAGGAAAGCAGCAGCGAATCTCAGGAAGGGGTGACCAGCGAGTCCAG
GGTGACAACCCAGATAACACAAGTCAGGCAGGAGACCAAGAAGACAGTGAGTCCAGTGAGGAGGACAGC
TGAACACATTCTCCAGCTCAGAAAGCCAGTCCACCGAGGAGCAAGCTGACAGCGAGTCCAACGAGAGCT
CAGCCTCTCCGAGGAGAGTCAGGAGTCGGCCCAGGATGGTGACAGCTCCAGCCAGGAAGGCCTGCAGTC
CAGAGCGCATCCACTGAGAGCAGGAGCCAGGAGAGCCAGTCTGAGCAGGACAGCCGTTCTGAGGAAGAA
GTGACTCTCAGGACAGTAGCCGATCCAAAGAAGAGAGCAACTCCACAGGGAGCGCTTCCAGCAGCGAGA
GGACATCCGTCCCAAGAACATGGAAGCTGACAGTAGGAAACTAATAGTTGATGCTTACCACAACAAACC
ATCGGGGACCAAGATGACAATGACTGTCAGGACGGCTACTAG
Yellow highlights: Primers for qPCR analysis (120bp)
Green highlights: Location of intron 5-6
Accession number: NM_94910
SGCK
ATGACCGTCAAAGCCGAGGCTGCTCGAAGCACCCTTACCTACTCCAGAATGAGGGGAATGGTAGCGATC
TCATCGCTTTTATGAAACAGAGAAGGATGGGCCTGAACGATTTTATTCAGAAGATTGCCAGCAACACCA
TGCATGCAAACACGCTGAAGTTCAGTCCATTTTGAAAATGTCCCATCCTCAGGAGCCGGAGCTTATGAC
GCTAACCCCTCTCCTCCGCCAAGTCCCTCTCAACAAATCAACCTGGGTCCGTCCTCCAACCCTCACGCA
AACCCTCCGACTTTCACTTCTTGAAAGTGATCGGAAAGGGCAGTTTTGGAAAGGTTCTTCTGGCTAGGA
CAAGGCAGAAGAAGTATTCTATGCAGTCAAAGTTTTACAGAAGAAAGCCATCCTGAAGAAGAAAGAGGG
AAGCATATTATGTCAGAGCGGAATGTTCTGTTGAAGAATGTGAAGCACCCTTTCCTGGTGGGCCTTCAT
TCTCATTCCAGACCGCTGACAAGCTCTACTTTGTCCTGGACTACATTAATGGTGGAGAGCTGTTCTACA
TCTCCAGAGGGAGCGCTGCTTCCTGGAACCACGGGCTCGATTCTACGCAGCTGAAATAGCCAGTGCCCG
GGCTATCTGCACTCCCTAAACATCGTTTATAGAGACTTAAAACCTGAGAATATTCTCCTAGACTCCCAG
GGCACATCGTCCTCACTGACTTTGGGCTCTGCAAAGAGAATATTGAGCATAACGGGACAACATCTACCT
CTGTGGCACGCCTGAGTATCTGGCTCCTGAGGTCCTCCATAAGCAGCCGTATGACCGGACGGTGGACTG
TGGTGTCTTGGGGCTGTCCTGTATGAGATGCTCTACGGCCTGCCCCCGTTTTATAGCCGGAACACGGCG
AGATGTACGACAATATTCTGAACAAGCCTCTCCAGTTGAAACCAAATATTACAAACTCGGCAAGGCACT
CCTGGAAGGCCTCCTGCAGAAGGACCGGACCAAGAGGCTGGGTGCCAAGGATGACTTTATGGAGATTAG
AGTCATATTTTCTTCTCTTTAATTAACTGGGATGATCTCATCAATAAGAAGATTACACCCCCATTTAAC
CAAATGTGAGTGGGCCCAGTGACCTTCGGCACTTCGATCCCGAGTTTACCGAGGAGCCGGTCCCCAGCC
CATCGGCAGGTCCCCTGACAGCATCCTTGTCACGGCCAGTGTGAAGGAAGCAGCAGAAGCCTTCCTCGC
TTCTCCTATGCACCTCCTGTGGATTCCTTCCTCTGA
Yellow highlights: Primers for qPCR analysis (129bp)
Green highlights: Location of intron 2-3
Accession number: NM_340062Appendix
267
Collagen type X
ATGCTGCCTCAAATACCCTTTCTGCTGCTAATGTTCTTGACCCTGGTTCATGGGATGTTTTATGCTGAC
GGTACCAAACGCCCACAGGCATAAAGGGCCCACTTGCTAGCCCCAAGACACAATACTTCATCCCATACC
CATAAAGAGTAAAGGGATTCCAGTAAGAGGAGAACAAGGCATTCCTGGTCCACCAGGCCCAACCGGACT
CGAGGACACCCAGGTCCCTCAGGACCGCCAGGCAAGCCAGGCTATGGAAGTCCTGGACTCCAAGGAGAC
CAGGGTTGCCAGGACCACCAGGAATATCAGCCACGGGGAAGCCAGGCCTGCCAGGCCCGCCAGGCAAAC
AGGGGAGAGAGGACCATATGGACACAAAGGAGATATTGGCCCAGCTGGCTTACCCGGACCTCGGGGCCT
CCAGGGCCCCCTGGAATTCCTGGCCCAGCTGGAATTTCTGTGCCAGGAAAACCTGGACAGCAGGGACTA
CAGGTGCCCCAGGACCTAGGGGCTTTCCTGGAGAGAAGGGTGCACAAGGAGCCCCTGGTGTGAATGGGG
GAAAGGGGAAACAGGATATGGCTCTCCTGGCCGTCCAGGTGAGAGGGGTCTTCCAGGCCCTCAAGGTCC
ATAGGACCCCCTGGCCCCTCTGGAGTGGGAAGAAGAGGTGAAAACGGCTTTCCAGGACAGCCGGGCATA
AAGGTGACCGGGGTTTCCCAGGAGAAATGGGACCATCAGGTCCACCAGGTCCCCAAGGTCCTCCCGGGA
GCAAGGACGAGAAGGTATTGGGAAGCCAGGAGCCATTGGATCCCCTGGTCAGCCAGGTATCCCAGGAGA
AAAGGCCACCCAGGGGCTCCAGGAATAGCTGGTCCTCCAGGAGCTCCTGGCTTTGGAAAACAAGGCTTC
CAGGTTTGAGGGGACAAAGGGGACCTGCTGGTCTTCCTGGGGCTCCAGGTGCCAAAGGGGAACGAGGGC
AGCAGGTCATCCTGGAGAACCGGGTCTGCCTGGATCCCCTGGGAATATGGGACCCCAAGGACCTAAAGA
ATCCCAGGGAACCATGGCATTCCAGGCGCTAAAGGTGAGATAGGTCTAGTTGGGCCTGCAGGCCCCCCG
GGGCTAGAGGAGCAAGGGGTCCACCTGGGTTAGATGGAAAAACAGGGTATCCTGGGGAGCCAGGTCTCA
TGGTCCTAAGGGTAACCCAGGGTTACCAGGACAAAAAGGTGATCCTGGAGTGGGAGGAACCCCTGGTCT
CGAGGTCCTGTTGGCCCTGTAGGAGCTAAAGGAGTGCCTGGACACAATGGTGAGGCAGGTCCAAGAGGG
AACCTGGAATACCAGGTACCAGGGGCCCCACTGGGCCACCAGGTGTCCCAGGATTCCCTGGATCTAAGG
TGACCCTGGAAACCCAGGTGCTCCAGGCCCAGCTGGCATAGCAACTAAGGGCCTCAATGGGCCCACTGT
CCTCCAGGCCCTCCTGGTCCAAGAGGCCACAGTGGAGAACCTGGTCTCCCAGGTCCTCCGGGTCCCCCG
GACCCCCCGGCCAAGCAGTCATGCCTGATGGCTTCATAAAGGCAGGCCAGAGGCCCAGGCTTTCTGGGT
GCCGCTTGTCAGTGCTAACCACGGGGTAACAGGTATGCCCGTGTCTGCTTTTACTGTCATTCTCTCTAA
GCTTACCCAGCAGTAGGTGCCCCCATCCCATTTGATGAGATTCTGTACAATAGGCAGCAGCATTACGAC
CAAGATCTGGTATCTTTACCTGTAAGATCCCAGGCATATACTATTTCTCCTACCACGTGCATGTGAAAG
GACTCACGTTTGGGTAGGCCTGTATAAGAACGGCACGCCTACGATGTACACGTATGATGAGTACAGCAA
GGCTACCTGGATCAGGCTTCAGGGAGTGCAATCATGGAGCTCACAGAAAATGACCAGGTATGGCTCCAT
TGCCCAATGCAGAATCAAACGGCCTCTACTCCTCTGAGTACGTCCACTCGTCCTTCTCAGGATTCCTAT
GGCTCCCATGTGA
Yellow highlights: Primers for qPCR analysis (97bp)
Green highlights: Location of intron 1-2
Accession number: NM_84455
p21
ATGTCCAATCCTGGTGATGTCCGACCTGTTCCGCACAGGAGCAAAGTGTGCCGTTGTCTCTTCGGTCCG
TGGACAGTGAGCAGTTGCGCCGTGATTGCGATGCGCTCATGGCGGGCTGTCTCCAGGAGGCCCGAGAAG
GTGGAACTTTGACTTCGTCACGGAGACGCCGCTGGAGGGCAACTTCGTCTGGGAGCGCGTTCGGAGCCT
AGGGCTGCCCAAGGTCTACCTGAGCCCTGGGTCCCGCAGCCGTGACGACCTGGGAGGGGACAAGAGGCC
AGTACTTCCTCTGCCCTGCTGCAGGGGCCAGCTCCGGAGGACCACGTGGCCTTGTCGCTGTCTTGCACC
TGGTGTCTGAGCGGCCTGAAGATTCCCCGGGTGGGCCCGGAACATCTCAGGGCCGAAAACGGAGGCAGC
CAGCCTGACAGATTTCTATCACTCCAAGCGCAGATTGGTCTTCTGCAAGAGAAAACCCTGA
Yellow highlights: Primers for qPCR analysis (113bp)
Green highlights: Location of intron 1-2
Accession number: NM_104556